UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APPLE, INC.,
Petitioner

v.

OMNI MEDSCI INC.,
Patent Owner

Patent No. 10,517,484

Inter Partes Review No. IPR2021-00453

PATENT OWNER'S NOTICE OF APPEAL TO THE U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT

Pursuant to at least 35 U.S.C. §§ 141(c) and 142 and 37 C.F.R. §§ 90.2(a) and 90.3, notice is hereby given that Patent Owner Omni MedSci, Inc. ("Patent Owner") appeals to the United States Court of Appeals for the Federal Circuit from the Final Written Decision on Remand entered February 14, 2025 (Paper 26) ("Remand Decision"), attached as Exhibit A, and from all underlying findings, orders, decisions, rulings, and opinions regarding U.S. Patent No. 10,517,484 ("the '484 patent"), attached as Exhibit B, entered in relation to the Remand Decision in the above-captioned proceeding before the Patent Trial and Appeal Board ("Board").

Pursuant to 37 C.F.R. § 90.3, this Notice of Appeal is timely, having been filed no later than 63 days after the Remand Decision (Paper 26), which is dated February 14, 2025.

For the limited purpose of providing the Director of the United States Patent and Trademark Office with the information requested under 37 C.F.R. § 90.2(a)(3)(ii), Patent Owner submits that the appeal will address aspects of the Board's decision purporting to conclude that Petitioner has demonstrated, by a preponderance of the evidence, that claims 3-6 and 8-14 of the '484 patent are unpatentable. In particular, the issues on appeal may include, but are not limited to:

- Whether claims 3, 4, 8, 9, 10, 11, and 12 of the '484 patent are unpatentable under 35 U.S.C. § 103 in view of Lisogurski (Ex. 1011), Carlson (Ex. 1009),

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

and Tran (Ex. 1064), including any findings or determinations supporting or related to those issues;

- Whether claims 5 and 13 of the '484 patent are unpatentable under 35 U.S.C. § 103 in view of Lisogurski (Ex. 1011), Carlson (Ex. 1009), Tran (Ex. 1064), and Isaacson (Ex. 1063), including any findings or determinations supporting or related to those issues;
- Whether claims 6 and 14 of the '484 patent are unpatentable under 35 U.S.C. § 103 in view of Lisogurski (Ex. 1011), Carlson (Ex. 1009), Tran (Ex. 1064), Isaacson (Ex. 1063), and Valencell-093 (Ex. 1005), including any findings or determinations supporting or related to those issues;
- All other issues decided adversely to Patent Owner.

Pursuant to 35 U.S.C. § 142 and 37 C.F.R. § 90.2(a), this Notice of Appeal is being filed with the Director of the United States Patent and Trademark Office, and a copy of this Notice of Appeal is being concurrently filed with the Board. In addition, pursuant to Federal Circuit Rule 15, a copy of this Notice of Appeal is being concurrently filed with the Clerk of the United States Court of Appeals for the Federal Circuit, along with payment of the required docketing fee. Petitioner is also being served with a copy of this Notice of Appeal.

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

Respectfully submitted,

Dated: April 11, 2025

/ Thomas A. Lewry /
Thomas A. Lewry (Reg. No. 30,770)
John S. LeRoy (Reg. No. 48,158)
John M. Halan (Reg. No. 35,534)
Christopher C. Smith (Reg. No. 59,669)
Andrew B. Turner (Reg. No. 63,121)
BROOKS KUSHMAN P.C.
150 W. Second Street
Suite 400N
Royal Oak, Michigan 48067
(248) 358-4400

Attorneys for Patent Owner

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

CERTIFICATE OF FILING AND SERVICE

The undersigned hereby certifies that on April 11, 2025 a copy of **PATENT OWNER'S NOTICE OF APPEAL** was served by United States Postal Service Priority Express mail to counsel of record as follows:

Jeffrey P. Kushan (Reg. No. 43,401) SIDLEY AUSTIN LLP 1501 K Street NW Washington, DC 20005 (202) 736-8914 IPRnotices@sidley.com Jeffrey P. Kushan jkushan@sidley.com *Counsel for Petitioner, Apple, Inc.*	Ching-Lee Fukuda (Reg. No. 44,334) SIDLEY AUSTIN LLP 787 Seventh Avenue New York, NY 10019 (212) 839-7364 clfukuda@sidley.com Thomas A. Broughan III (Reg. No. 66,001) SIDLEY AUSTIN LLP 1501 K Street NW Washington, DC 20005 (202) 736-8314 tbroughan@sidley.com *Counsel for Petitioner, Apple, Inc.*

In addition, I certify that **PATENT OWNER'S NOTICE OF APPEAL** is being filed on **April 11, 2025** as follows:

- by electronic mail with the Director of the United States Patent and Trademark Office c/o Office of the Solicitor to efileSO@uspto.gov, pursuant to 37 C.F.R. § 90.2(a)(1)(i);
- electronically with the PTAB through the P-TACTS system, pursuant to 37 C.F.R. § 90.2(a)(1)(ii); and
- electronically with the United States Court of Appeals for the Federal

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

Circuit via the CM/ECF system, pursuant to Fed. R. App. Proc. 25(a)(2)(B)(i) and Fed. Cir. R. 25(a)(1)(A).

Respectfully submitted,

/ Thomas A. Lewry /

Thomas A. Lewry (Reg. No. 30,770)
John S. LeRoy (Reg. No. 48,158)
John M. Halan (Reg. No. 35,534)
Christopher C. Smith (Reg. No. 59,669)
Andrew B. Turner (Reg. No. 63,121)
BROOKS KUSHMAN P.C.
150 W. Second Street
Suite 400N
Royal Oak, Michigan 48067
(248) 358-4400

Attorneys for Patent Owner

EXHIBIT A

Trials@uspto.gov
571-272-7822

Paper 26
Date: February 14, 2025

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APPLE, INC.,
Petitioner,

v.

OMNI MEDSCI INC.,
Patent Owner.

IPR2021-00453
Patent 10,517,484 B2

Before GRACE KARAFFA OBERMANN, BRIAN J. McNAMARA, and SHARON FENICK, *Administrative Patent Judges.*

McNAMARA, *Administrative Patent Judge*.

ORDER
Conduct of the Proceeding
Denying Post Remand Briefing
37 C.F. R. § 42.5

JUDGMENT
Final Written Decision on Remand
Determining All Challenged Claims Unpatentable
35 U.S.C. §§ 144, 318(a)

I. BACKGROUND

Apple Inc. ("Petitioner") filed a Petition challenging the patentability of claims 1–23 of U.S. Patent No. 10, 517,484 B2 ("the '484 patent"). Paper 1 ("Petition" or "Pet."). On August 6, 2021, we instituted an *inter partes* review of all claims on all challenge grounds. Paper 7. Omni MedSci, Inc. ("Patent Owner") filed a Patent Owner Response (Paper 10, "PO Resp."), Petitioner filed a Petitioner Reply (Paper 11, "Pet. Reply") and Patent Owner filed a Sur-reply (Paper 13, "PO Sur-reply"). A transcript of an oral hearing held on May 5, 2022 (Paper 20, "Hr'g. Tr.") was entered into the record.

On August 3, 2022, we entered a Final Written Decision (Paper 22, "Final Decision" or "Final Dec.") determining that Petitioner had demonstrated that claims 1, 2, 7, and 15–23 were unpatentable and had not demonstrated that claims 3–6 and 8–14 were unpatentable. Petitioner appealed our determination concerning claims 3–6 and 8–14 to U.S. Court of Appeals for the Federal Circuit. *See* Paper 23, Notice of Appeal. On September 13, 2024, the Federal Circuit affirmed-in-part on claim construction issues, but vacated-in-part and remanded the case to us for further proceedings and consideration of an alternative argument properly raised in Petitioner's Reply under the affirmed construction. *See* Paper 24 ("Mandate"); Paper 25 ("Fed. Cir. Dec.").

On October 29, 2024, we conducted a telephonic hearing with the parties to address their request for additional briefing and to discuss whether additional briefing was appropriate in this case. A transcript of the hearing was entered into the record. Ex. 1068 ("Briefing H'rg. Tr.").

No appeal was taken as to claims 1, 2, 7, and 15–23. Consistent with the Federal Circuit's Mandate, we have reviewed the merits and determine

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

that claims 3–6 and 8–14 are unpatentable. Having determined that claims 3–6 and 8–14 are unpatentable, and recognizing that all other claims have previously been determined to be unpatentable, we determine that claims 1–23 are unpatentable.

II. THE FEDERAL CIRCUIT DECISION

Claim 3 depends from claim 1 and recites that the wearable device of claim 1 "is at least in part configured to identify an object, and to compare a property of at least some of the output signal to a threshold." Ex. 1001, 37:43–46. In relevant part, claim 8 similarly recites that the wearable device is at least in part configured to identify an object. *Id.* at 38:63–67.

In our Final Decision, we determined that the term "identify an object" in claims 3 and 8 is distinguished from the term "detect an object," e.g. as in claim 1. Final Dec. 8–10. The Court affirmed our construction of "identify an object" to mean "to recognize or establish an object as being a particular thing." Fed. Cir. Dec. 10. The Court remanded, however, for further consideration of a "properly raised" argument Petitioner advanced in the Petitioner Reply with respect to our construction, referred to by the Federal Circuit as "the alternative argument.". *Id.* at 2, 13.

III. ADDITIONAL BRIEFING

During the telephonic hearing on additional briefing, Petitioner acknowledged that during the course of the proceeding Petitioner "had raised the alternative reading or basis for why the claims were obvious under the construction that was advanced by [Patent Owner] in the proceeding." Briefing Hr'g Tr. 9:10–13. Petitioner also acknowledged that "it really is the discretion of the Board here to decide how much of a focus they want to get out of the parties on their positions relating to the issue that's disputed." *Id.* at 9:20–23. Petitioner further stated, "we presented our arguments why[,]

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

in this alternative claim construction[,] the evidence did show that the claims were obvious and one of the variables was how the devices identify constituents, specific things in the blood. We believe that was the basis of our position." *Id*. at 16:1–6. As to the subject matter of any additional briefing, Petitioner also stated "it's the same evidence, the same rationale for the argument, the same basis." *Id.* at 16:13–14.

Patent Owner also acknowledged, at least implicitly, that it was provided an opportunity to address the claim construction adopted in our Final Decision and affirmed by the Federal Circuit. *Id.* at 8:16–25 (asking Petitioner "what would necessitate further briefing as to" the remaining arguments to be addressed); 12:10–16 (posing same question to Patent Owner); 12:21–13:7 (Patent Owner's counsel acknowledging that both claim constructions had been "at issue at the time [Patent Owner] filed [its] briefs in the IPR" and requesting briefing only to provide "focused argument" as opposed to the "diluted arguments" in the current record); 14:24–15:11 (Patent Owner's counsel acknowledging that the record did address the claim construction).

Our mandate is to consider the argument the Court determined we did not consider in the Petitioner Reply, which argument, as each party acknowledges, both parties had the opportunity to discuss in the briefs that are in our current record. Under the circumstances, we determine that no additional briefing is required to carry out that mandate.

IV. ANALYSIS

A. Claims 3 and 8

We begin our analysis with claims 3 and 8, as claims 4–6 depend from directly or indirectly from claim 3 and claims 9–14 depend directly or indirectly from claim 8.

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

The arguments in the Petitioner Reply relating to the construction of the claim term "identify an object" as meaning "to recognize or establish an object as being a particular thing" apply equally to claims 3 and 8 and are reproduced below in their entirety.

> Even if [Patent Owner's] construction were accepted, the "identify[ing]" element is taught by both Lisogurski and Tran. Lisogurski and Tran each teach techniques for measuring blood oxygen saturation and other blood constituents. Pet., 58 (stating Tran's monitored information "includes pulse oximetry measurements"), 63 (discussing Lisogurski's "blood oxygen saturation"); Ex.1011, 4:36-41 (describing "calculat[ing]… an amount of a blood constituent (e.g., oxyhemoglobin)"); Ex.1064, 9:38-42, 37:2-12. Measuring blood oxygen saturation requires identifying and quantifying both the oxygenated and deoxygenated hemoglobin in the blood, which Lisogurski and Tran do by measuring reflected light at particular wavelengths known to be associated with each substance. Ex.1003, ¶¶38-39; Ex.1011, 4:42-51; Ex.1064, 37:2-12, 50:10-15. That is the same technique disclosed in the '484 patent. Ex.1001, 11:45-53, 11:59-12:3. Thus, Lisogurski and Tran both teach detecting and identifying blood constituents—oxygenated and deoxygenated hemoglobin—which satisfies Omni's construction.

Pet. Reply 24. At the oral hearing, Petitioner argued that Lisogurski teaches identifying blood constituents. Hr'g. Tr. 21:19–22:21.

The Final Decision states "[a]lthough blood constituents would appear to be objects in the context of claims 3 and 8, . . . it is not clear how one could measure such constituents without identifying them." Final Dec. 51. We determined that "the Petition does not sufficiently articulate support for Petitioner's assertions" and that

> Petitioner's arguments, which concern comparing detected *signals* to a variety of thresholds and providing *parameters for alert generation*, are insufficient to support Petitioner's contention that Lisogurski, Carlson, and Tran disclose the limitation in claims 3 and 8 that the wearable device (claim 3) or

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

> the wearable device, smartphone or tablet (claim 8) is configured to 'identify an object' i.e., 'to recognize or establish an object as being a particular thing.'

Id. at 52 (after discussing arguments found at Pet. 58, 63).

A detailed review of the references cited (if not extensively discussed) in the Petitioner Reply, the portions of the Petition referenced in the Petitioner Reply, and the testimonial evidence provided by Petitioner's expert, Dr. Brian W. Anthony, indicates that Petitioner is correct in its assertion that, at least because Lisogurski discloses calculating an amount of a blood constituent, e.g., oxyhemoglobin, the limitations of claim 3 are taught by the proposed combination of references. In particular, Petitioner notes that Lisogurski and Tran measure deoxygenated hemoglobin by measuring reflected light at particular wavelengths associated with each substance. Pet. Reply 24 (citing Ex.1003 (Anthony Decl.) ¶¶ 38–39; Ex. 1011, 4:42–51; Ex. 1064, 37:2–12, 50:10–15).

Dr. Anthony testifies that, "[b]y measuring how much light is absorbed by the tissue and how the absorption changes over time, a device can calculate parameters that are related to the properties of the tissue and blood." Ex. 1003 ¶ 38. Noting that hemoglobin reflects more red light when oxygenated than when deoxygenated, but reflects the same amount of infrared (IR) light when oxygenated and deoxygenated, Dr. Anthony further testifies that a device that "measures the absorbed red and IR light multiple times per second can determine: (i) the ratio of oxygenated to deoxygenated hemoglobin (oxygen saturation) and (ii) how the volume of blood in the tissue changes, allowing detection of a person's pulse." *Id.* ¶ 39 (citing Ex. 1019 at 769, 771).

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

Lisogurski discloses a similar approach to determining blood saturation stating "[t]he light intensity or the amount of light absorbed may then be used to calculate any of a number of physiological parameters, including an amount of a blood constituent (e.g., oxyhemoglobin) being measured as well as pulse rate and when each individual pulse occurs." *See* Ex. 1011, 4:36–62. As Lisogurski discloses a method of measuring oxygen saturation that uses different wavelengths to distinguish hemoglobin from oxygen carrying hemoglobin, i.e., oxyhemoglobin, Lisogurski teaches identifying an object, i.e., the blood constituent oxyhemoglobin.

Based on the foregoing, we determine that Petitioner demonstrates by a preponderance of the evidence that claims 3 and 8 are unpatentable.

B. Claims 4–6 and 9–14

We structure this Decision to address remaining appealed claims 4–6 and 9–14 based on their dependencies and the challenges asserted in the Petition.

1. *Claims 5 and 13*

The Petition includes a ground asserting that claims 5 and 13 would have been obvious over a combination of Lisogurski, Carlson, Tran, and Isaacson. Pet. 66–72.

Based on our conclusions concerning claims 3 and 8, the substance of Petitioner's additional arguments relating to claims 5 and 13 was not addressed in the Final Decision. Final Dec. 54–55. Similarly, we did not address the substance of Petitioner's additional arguments relating to claims 6 and 14 over a combination including Isaacson, which depend

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

respectively from claims 5 and 13.[1] *Id.* at 59. Therefore, to the extent not addressed in the Final Decision, we address the contentions relating to claims 5 and 13 here, and contentions relating to claims 6 and 14 in the next section of this Decision.

Claim 5, which depends indirectly from claim 3, and claim 13, which depends indirectly from claim 8, both recite details of the location of spatially separated detectors. Petitioner cites Isaacson as disclosing a pulse oximetry system sensor for use on a patient's arm that has two emitters and two detectors separated by varying distances. Pet. 66 (citing Ex. 1063, 1:21–40, 2:57–58, 2:63–66, 3:66–4:3, 3:44–54, 6:32–34). Petitioner notes that Isaacson teaches selecting the distances between the emitters and detectors to allow measuring light that has penetrated different depths of tissue, with greater spacing allowing measuring of greater depth. *Id.* (citing Ex. 1063, 1:41–45, 5:10–15; Ex. 1003 ¶¶ 234–235).

The Patent Owner Response does not address the substance of Isaacson, arguing only that Petitioner fails to show evidence of a motivation to combine the references in the manner claimed. PO Resp. 38–40 (arguing Petitioner applied impermissible hindsight to pick and choose from the references without articulating a reason for the combination). Our analysis of Petitioner's challenge to claims 1–4, 7–12, and 15–22 as unpatentable over Lisogurski, Carlson, and Tran, determined that Petitioner had demonstrated that a person of ordinary skill would have had reason to

[1] Although Petitioner's challenge to claim 23 also ostensibly relied on a combination including Isaacson, because Petitioner's contentions for claim 23 were asserted without reference to Isaacson, our Final Decision determination concerning claim 23, which was not appealed, did not require an analysis of Isaacson or of the propriety of combinations including Isaacson. Final Dec. 59–60.

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

combine the teachings of Lisogurski, Carlson, and Tran. Final Dec. 46–48. As claims 1–2, 7, and 15–22 were found unpatentable and were not the subject of an appeal, we do not revisit the conclusion that a person of ordinary skill would have had reason to combine the teachings of Lisogurski, Tran, and Carlson. *See generally* Final Dec., Fed. Cir. Dec.

As to the further combination with Isaacson, Patent Owner contends only that Petitioner failed to describe a purported motivation to combine the teachings of Isaacson and Lisogurski. PO Resp. 38; Pet. Sur-reply 24–25 (arguing that Petitioner asserted only a motivation to combine each reference with Lisogurski).

Petitioner counterargues that it is not required to show why a person of ordinary skill would have considered every permutation of these references together and that it provided specific reasons for including features of Isaacson into Lisogurski's device. Pet. Sur-reply 24–25. According to Petitioner, a person of ordinary skill would have had reason to incorporate Isaacson's sensor (an arrangement of LEDs and detectors) into Lisogurski's device, which taught that any known sensor layout could be used. *Id.* (citing Ex.1011, 17:39–45; Ex.1003 ¶¶ 239–240). Petitioner further argues that the ordinarily skilled artisan would have looked to Isaacson because it discloses a known arrangement for that the sensor component of Lisogurski's device, and because it also taught solutions to potential problems identified in Lisogurski (e.g., with skin pigmentation). *Id.* (citing Pet. 68–69; Ex.1003 ¶ 243; Ex.1063, 7:59–62, Fig. 1).

In response to similar arguments Patent Owner raised in the context of claim 23 concerning the motivation to combine the teachings of Valencell-093 with those of Lisogurski, Tran, and Carlson, we determined that

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

Petitioner was not required to show why a person of ordinary skill would have considered every permutation of the references. Final Dec. 59.

Based on the arguments and evidence of record, we similarly determine that Petitioner has demonstrated a person of ordinary skill would have recognized that Isaacson is particularly relevant to the wearable devices described by Lisogurski. Having considered the arguments and evidence of record, we determine that Petitioner has demonstrated by a preponderance of the evidence that claims 5 and 13 are unpatentable as obvious in view of the combined teachings of Lisogurski, Tran, Carlson, and Isaacson.

2. *Claims 6 and 14*

Petitioner challenges claims 6 and 14 as unpatentable over the combined teachings of Lisogurski, Carlson, Tran, Isaacson, and Valencell-093. Pet. 72–77. Claim 23, which we found to be unpatentable in a portion of the Final Decision that was not the subject of any appeal, was also challenged on that basis. Final Dec. 59–60 (finding claim 23 unpatentable over the combined teachings of Lisogurski, Carlson, Tran, and Valencell-093, without Isaacson). Patent Owner's counterarguments are limited to contending that Petitioner has not demonstrated adequately a reason to combine the references in the manner claimed. PO Resp. 40–42.

As discussed above, we determine that Petitioner has demonstrated a person of ordinary skill would have had reason to combine the teachings of Isaacson with those of Lisogurski, Tran, and Carlson, for reasons similar to those applicable to the combination of Lisogurski, Carlson, and Tran with the teachings of Valencell-093. Again, we rely on the same reasoning to determine that Petitioner has demonstrated that a person of ordinary skill in the art would have had reason to combine the teachings of Isaacson with those of Lisogurski, Tran, Carlson, and Valencell-093.

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

Like claim 23, claims 6 and 14 recite that the wearable device further comprises a reflective surface positioned to reflect at least a portion of the lens output light reflected from the tissue. Ex. 1001, 38:4–7, 39:34–37, 40:53–55. Having determined elsewhere in this Decision that claims 3–5 and 8–13 from which claims 6 and 14 depend are unpatentable, we determine that Petitioner has demonstrated by a preponderance of the evidence that claims 6 and 14 are unpatentable for the same reasons claim 23 is unpatentable. *See* Final Dec. 59–60.

3. *Claims 4 and 9–12*

Claim 9 depends from claim 8 and recites limitations similar to those of claim 17 that recite coupling spatially separated detectors to an amplifier having a gain adjusted to improve detection sensitivity. Claim 17 was found unpatentable and was not the subject of an appeal. *See* Final Dec. 45, 54. Having determined that claim 8 and claim 17 are unpatentable, we determine for the same reasons that Petitioner has demonstrated claim 9 is unpatentable.

Claim 10 depends from claim 9 and recites limitations similar to the artificial intelligence limitations recited in claim 18. Claim 18 was found unpatentable and was not the subject of an appeal. *See* Final Dec. 48–49. Having determined that claims 9 and 18 are unpatentable, we determine for the same reasons that Petitioner has demonstrated claim 10, which depends from claim 9, is unpatentable.

Claims 4 and 11 depend from claims 3 and 10, respectively, and recite limitations similar to the pattern matching limitations of claim 19, which was found unpatentable and was not the subject of an appeal. *See* Final Dec. 53. Having determined that claims 3, 10, and 19 are unpatentable, we

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

determine for the same reasons that Petitioner has demonstrated claims 4 and 11 are unpatentable.

Claim 12 depends from claim 10 and recites limitations similar to the pattern identification and classification limitations of claim 21. Claim 21 was found unpatentable and was not the subject of an appeal. *See* Final Dec. 53. Having determined that claims 10 and 21 are unpatentable, we determine for the same reasons that Petitioner has demonstrated claim 12 is unpatentable.

V. CONCLUSION

As a result of the above determinations, we modify our Final Decision to determine that all challenged claims are unpatentable.

In summary:

Claim(s)	35 U.S.C. §	Basis/ Reference(s)	Claim(s) Shown Unpatentable	Claim(s) Not shown Unpatentable
1, 7, 15, 17	103	Lisogurski, Carlson	1, 7, 15, 17	
1–4, 7–12, 15–22	103	Lisogurski, Carlson, Tran	1–4, 7–12, 15–22	
5, 13	103	Lisogurski, Carlson, Tran, Isaacson	5, 13	
6, 14, 23	103	Lisogurski, Carlson, Tran, Isaacson, Valencell-093	6, 14, 23	
Overall Outcome			1–23	

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

VI. ORDER

In consideration of the above it is:

ORDERED that no additional briefing is authorized; and

FURTHER ORDERED that claims 1–23 are unpatentable.

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

FOR PETITIONER:

Jeffrey Kushan
Ching-Lee Fukuda
Thomas Broughan
SIDLEY AUSTIN LLP
jkushan@sidley.com
clfukuda@sidley.com
tbroughan@sidley.com

FOR PATENT OWNER:

Thomas Lewry
John LeRoy
John Halan
Christopher Smith
Andrew Turner
BROOKS KUSHMAN P.C.
tlewry@brookskushman.com
jleroy@brookskushman.com
jhalan@brookskushman.com
csmith@brookskushman.com
aturner@brookskushman.com

Omni MedSci Ex. 2012
Samsung Electronics Co. Ltd., et al., v. Omni MedSci - IPR2025-01253

EXHIBIT B

US010517484B2

(12) **United States Patent**
Islam

(10) **Patent No.: US 10,517,484 B2**
(45) **Date of Patent: *Dec. 31, 2019**

(54) **SEMICONDUCTOR DIODES-BASED PHYSIOLOGICAL MEASUREMENT DEVICE WITH IMPROVED SIGNAL-TO-NOISE RATIO**

(71) Applicant: **Omni Medsci, Inc.**, Ann Arbor, MI (US)

(72) Inventor: **Mohammed N. Islam**, Ann Arbor, MI (US)

(73) Assignee: **Omni Medsci, Inc.**, Ann Arbor, MI (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **16/506,885**

(22) Filed: **Jul. 9, 2019**

(65) **Prior Publication Data**

US 2019/0328235 A1 Oct. 31, 2019

Related U.S. Application Data

(60) Continuation of application No. 16/272,069, filed on Feb. 11, 2019, which is a continuation of application

(Continued)

(51) **Int. Cl.**
G01J 5/02 (2006.01)
A61B 5/00 (2006.01)

(Continued)

(52) **U.S. Cl.**
CPC ***A61B 5/0088*** (2013.01); ***A61B 5/0013*** (2013.01); ***A61B 5/0022*** (2013.01);

(Continued)

(58) **Field of Classification Search**
CPC G01N 21/3581; G01N 21/3563; G01N 21/35; G01N 21/4738; G01N 21/55;

(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,063,106 A 12/1977 Ashkin et al.
4,158,750 A 6/1979 Sakoe et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA 2 458 123 5/2012
CN 101849821 B 7/2013

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 61/350,673; titled: Opticoustic Sensor; Inventor: Massi Joe E. Kiani; filed Jun. 2, 2010.

(Continued)

Primary Examiner — Md M Rahman
(74) *Attorney, Agent, or Firm* — Brooks Kushman P.C.

(57) **ABSTRACT**

A wearable device includes a measurement device to measure a physiological parameter adapted to be placed on a wrist or an ear of a user. A plurality of semiconductor light sources such as light emitting diodes generate corresponding output light having an initial light intensity. A receiver includes spatially separated detectors receiving reflected light from the output lights and coupled to analog to digital converters. The receiver is configured to synchronize to the semiconductor source(s). The measurement device improves signal-to-noise ratio of the output signal by increasing light intensity relative to the initial light intensity and by increasing a pulse rate. Further improvement in signal-to-noise ratio is achieved by using change detection, where the receiver compares the signals with light on and with light off.

23 Claims, 34 Drawing Sheets



Related U.S. Application Data

No. 16/029,611, filed on Jul. 8, 2018, now Pat. No. 10,201,283, which is a continuation of application No. 15/888,052, filed on Feb. 4, 2018, now Pat. No. 10,136,819, which is a continuation of application No. 15/212,549, filed on Jul. 18, 2016, now Pat. No. 9,885,698, which is a continuation of application No. 14/650,897, filed as application No. PCT/US2013/075700 on Dec. 17, 2013, now Pat. No. 9,494,567, application No. 16/506,885, which is a continuation of application No. 16/004,359, filed on Jun. 9, 2018, which is a continuation of application No. 14/109,007, filed on Dec. 17, 2013, now Pat. No. 9,993,159, application No. 16/506,885, which is a continuation of application No. 16/188,194, filed on Nov. 12, 2018, now Pat. No. 10,386,230, which is a continuation of application No. 16/004,154, filed on Jun. 8, 2018, now Pat. No. 10,126,283, which is a continuation of application No. 15/855,201, filed on Dec. 27, 2017, now Pat. No. 9,995,722, which is a continuation of application No. 15/711,907, filed on Sep. 21, 2017, now Pat. No. 9,897,584, which is a division of application No. 15/357,225, filed on Nov. 21, 2016, now Pat. No. 9,797,876, which is a continuation of application No. 14/650,981, filed as application No. PCT/US2013/075767 on Dec. 17, 2013, now Pat. No. 9,500,634, application No. 16/506,885, which is a continuation of application No. 16/241,628, filed on Jan. 7, 2019, now Pat. No. 10,441,176, which is a continuation of application No. 16/015,737, filed on Jun. 22, 2018, now Pat. No. 10,172,523, which is a continuation of application No. 15/594,053, filed on May 12, 2017, now Pat. No. 10,188,299, which is a continuation of application No. 14/875,709, filed on Oct. 6, 2015, now Pat. No. 9,651,533, which is a continuation of application No. 14/108,986, filed on Dec. 17, 2013, now Pat. No. 9,164,032, application No. 16/506,885, which is a continuation of application No. 16/284,514, filed on Feb. 15, 2019, which is a continuation of application No. 16/016,649, filed on Jun. 24, 2018, now Pat. No. 10,213,113, which is a continuation of application No. 15/860,065, filed on Jan. 2, 2018, now Pat. No. 10,098,546, which is a continuation of application No. 15/686,198, filed on Aug. 25, 2017, now Pat. No. 9,861,286, which is a continuation of application No. 15/357,136, filed on Nov. 21, 2016, now Pat. No. 9,757,040, which is a continuation of application No. 14/651,367, filed as application No. PCT/US2013/075736 on Dec. 17, 2013, now Pat. No. 9,500,635.

(60) Provisional application No. 61/747,472, filed on Dec. 31, 2012, provisional application No. 61/747,553, filed on Dec. 31, 2012, provisional application No. 61/747,485, filed on Dec. 31, 2012, provisional application No. 61/747,487, filed on Dec. 31, 2012, provisional application No. 61/747,477, filed on Dec. 31, 2012, provisional application No. 61/754,698, filed on Jan. 21, 2013.

(51) **Int. Cl.**

G01N 21/3563	(2014.01)
G01N 33/02	(2006.01)
G01N 33/15	(2006.01)
G01N 33/44	(2006.01)
G01N 33/49	(2006.01)
A61B 5/145	(2006.01)
A61B 5/1455	(2006.01)
G01J 3/02	(2006.01)
G01J 3/10	(2006.01)
G01J 3/14	(2006.01)
G01J 3/28	(2006.01)
G01J 3/42	(2006.01)
G01J 3/453	(2006.01)
G01N 21/35	(2014.01)
G01N 21/359	(2014.01)
G01N 21/39	(2006.01)
G01N 21/88	(2006.01)
G01N 21/85	(2006.01)
H01S 3/067	(2006.01)
G01N 21/95	(2006.01)
H01S 3/30	(2006.01)
G01J 3/12	(2006.01)
G01M 3/38	(2006.01)
G01J 3/18	(2006.01)
H01S 3/00	(2006.01)

(52) **U.S. Cl.**

CPC ***A61B 5/0075*** (2013.01); ***A61B 5/0086*** (2013.01); ***A61B 5/1455*** (2013.01); ***A61B 5/14532*** (2013.01); ***A61B 5/14546*** (2013.01); ***A61B 5/4547*** (2013.01); ***A61B 5/6801*** (2013.01); ***A61B 5/7257*** (2013.01); ***A61B 5/742*** (2013.01); ***A61B 5/7405*** (2013.01); ***G01J 3/0218*** (2013.01); ***G01J 3/108*** (2013.01); ***G01J 3/14*** (2013.01); ***G01J 3/28*** (2013.01); ***G01J 3/2823*** (2013.01); ***G01J 3/42*** (2013.01); ***G01J 3/453*** (2013.01); ***G01N 21/35*** (2013.01); ***G01N 21/359*** (2013.01); ***G01N 21/3563*** (2013.01); ***G01N 21/39*** (2013.01); ***G01N 21/88*** (2013.01); ***G01N 33/02*** (2013.01); ***G01N 33/025*** (2013.01); ***G01N 33/15*** (2013.01); ***G01N 33/442*** (2013.01); ***G01N 33/49*** (2013.01); *A61B 2562/0233* (2013.01); *A61B 2562/0238* (2013.01); *A61B 2562/146* (2013.01); *A61B 2576/02* (2013.01); *G01J 3/1838* (2013.01); *G01J 2003/104* (2013.01); *G01J 2003/1208* (2013.01); *G01J 2003/2826* (2013.01); *G01M 3/38* (2013.01); *G01N 21/85* (2013.01); *G01N 21/9508* (2013.01); *G01N 2021/3595* (2013.01); *G01N 2021/399* (2013.01); *G01N 2201/061* (2013.01); *G01N 2201/062* (2013.01); *G01N 2201/06113* (2013.01); *G01N 2201/08* (2013.01); *G01N 2201/12* (2013.01); *G01N 2201/129* (2013.01); *H01S 3/0092* (2013.01); *H01S 3/06758* (2013.01); *H01S 3/302* (2013.01)

(58) **Field of Classification Search**

CPC G01N 21/31; G01N 21/552; G01J 3/02; G01J 3/28; G01J 3/42

USPC 356/300

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,221,997	A	9/1980	Flemming
4,275,266	A	6/1981	Lasar
4,374,618	A	2/1983	Howard
4,403,605	A	9/1983	Tanikawa

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,462,080 A 7/1984 Johnstone et al.
4,516,207 A 5/1985 Moriyama et al.
4,523,884 A 6/1985 Clement et al.
4,605,080 A 8/1986 Lemelson
4,641,292 A 2/1987 Tunnell et al.
4,704,696 A 11/1987 Reimer et al.
4,728,974 A 3/1988 Nio et al.
4,762,455 A 8/1988 Coughlan et al.
4,776,016 A 10/1988 Hansen
4,958,910 A 9/1990 Taylor et al.
4,972,331 A 11/1990 Chance
4,989,253 A 1/1991 Liang et al.
5,078,140 A 1/1992 Kwoh
5,084,880 A 1/1992 Esterowitz et al.
5,086,401 A 2/1992 Glassman et al.
5,134,620 A 7/1992 Huber
5,142,930 A 9/1992 Allen et al.
5,180,378 A 1/1993 Kung et al.
5,191,628 A 3/1993 Byron
5,218,655 A 6/1993 Mizrahi
5,230,023 A 7/1993 Nakano
5,246,004 A 9/1993 Clarke et al.
5,267,152 A 11/1993 Yang et al.
5,267,256 A 11/1993 Saruwatari et al.
5,267,323 A 11/1993 Kimura
5,300,097 A 4/1994 Lemer et al.
5,303,148 A 4/1994 Mattson et al.
5,305,427 A 4/1994 Nagata
5,313,306 A 5/1994 Kuban et al.
5,323,404 A 6/1994 Grubb
5,345,538 A 9/1994 Narayannan et al.
5,368,224 A 11/1994 Richardson et al.
5,400,165 A 3/1995 Gnauck et al.
5,408,409 A 4/1995 Glassman et al.
5,458,122 A 10/1995 Hethuin
5,544,654 A 8/1996 Murphy et al.
5,572,999 A 11/1996 Funda et al.
5,617,871 A 4/1997 Burrows
5,631,758 A 5/1997 Knox et al.
5,687,734 A 11/1997 Dempsey et al.
5,695,493 A 12/1997 Nakajima et al.
5,696,778 A 12/1997 MacPherson
5,704,351 A 1/1998 Mortara et al.
5,718,234 A 2/1998 Warden et al.
5,746,206 A 5/1998 Mannheimer
5,747,806 A 5/1998 Khalil
5,748,103 A 5/1998 Flach et al.
5,774,213 A 6/1998 Trebino et al.
5,792,204 A 8/1998 Snell
5,795,300 A 8/1998 Bryars
5,812,978 A 9/1998 Nolan
5,855,550 A 1/1999 Lai et al.
5,862,803 A 1/1999 Besson et al.
5,867,305 A 2/1999 Waarts et al.
5,912,749 A 6/1999 Harstead et al.
5,919,134 A 7/1999 Diab
5,944,659 A 8/1999 Flach et al.
5,950,629 A 9/1999 Taylor et al.
5,957,854 A 9/1999 Besson et al.
5,970,457 A 10/1999 Brant et al.
6,014,249 A 1/2000 Fermann et al.
6,031,603 A 2/2000 Fine et al.
6,043,927 A 3/2000 Islam
6,044,283 A 3/2000 Fein et al.
6,115,673 A 9/2000 Malin
6,181,414 B1 1/2001 Raz et al.
6,185,535 B1 2/2001 Hedin et al.
6,200,309 B1 3/2001 Rice et al.
6,212,310 B1 4/2001 Waarts et al.
6,224,542 B1 5/2001 Chang et al.
6,246,707 B1 6/2001 Yin et al.
6,246,896 B1 6/2001 Dumoulin
6,273,858 B1 8/2001 Fox et al.
6,278,975 B1 8/2001 Brant et al.
6,281,471 B1 8/2001 Smart
6,285,897 B1 9/2001 Kilcoyne
6,289,238 B1 9/2001 Besson et al.
6,301,271 B1 10/2001 Sanders et al.
6,301,273 B1 10/2001 Sanders et al.
6,325,978 B1 12/2001 Labuda et al.
6,333,803 B1 12/2001 Kurotori et al.
6,337,462 B1 1/2002 Smart
6,340,806 B1 1/2002 Smart et al.
6,350,261 B1 2/2002 Domankevitz et al.
6,364,834 B1 4/2002 Reuss et al.
6,374,006 B1 4/2002 Islam et al.
6,381,391 B1 4/2002 Islam et al.
6,402,691 B1 6/2002 Peddicord et al.
6,407,853 B1 6/2002 Samson et al.
6,436,107 B1 8/2002 Wang et al.
6,441,747 B1 8/2002 Khair et al.
6,442,430 B1 8/2002 Ferek-Petric
6,443,890 B1 9/2002 Schulze et al.
6,450,172 B1 9/2002 Hartlaub et al.
6,453,201 B1 9/2002 Daum et al.
6,454,705 B1 9/2002 Cosentino et al.
6,458,120 B1 10/2002 Shen et al.
6,462,500 B1 10/2002 L'Hegarat et al.
6,463,361 B1 10/2002 Wang et al.
6,480,656 B1 11/2002 Islam et al.
6,505,133 B1 1/2003 Hanna et al.
6,509,566 B1 1/2003 Wamsley et al.
6,512,936 B1 1/2003 Monfre et al.
6,534,012 B1 3/2003 Hazen et al.
6,549,702 B2 4/2003 Islam et al.
6,567,431 B2 5/2003 Tabirian et al.
6,587,702 B1 7/2003 Ruchti
6,603,910 B2 8/2003 Islam et al.
6,605,080 B1 8/2003 Altshuler et al.
6,611,643 B2 8/2003 Birk
6,619,835 B2 9/2003 Kita
6,625,180 B2 9/2003 Bufetov et al.
6,631,025 B2 10/2003 Islam et al.
6,640,117 B2 10/2003 Makarewicz
6,659,947 B1 12/2003 Carter et al.
6,659,999 B1 12/2003 Anderson et al.
6,701,170 B2 3/2004 Stetson
6,708,048 B1 3/2004 Chance
6,731,967 B1 5/2004 Turcott
6,738,652 B2 5/2004 Mattu
6,760,148 B2 7/2004 Islam
6,773,922 B2 8/2004 Jeng
6,788,965 B2 9/2004 Ruchti
6,802,811 B1 10/2004 Slepian
6,816,241 B2 11/2004 Grubisic
6,847,336 B1 1/2005 Lemelson
6,864,978 B1 3/2005 Hazen
6,885,498 B2 4/2005 Islam
6,885,683 B1 4/2005 Fermann et al.
6,898,451 B2 5/2005 Wuori
6,916,096 B2 7/2005 Eberl et al.
6,943,936 B2 9/2005 Islam et al.
6,990,364 B2 1/2006 Ruchti
7,010,336 B2 3/2006 Lorenz
7,027,467 B2 4/2006 Baev et al.
7,060,061 B2 6/2006 Altshuler et al.
7,105,823 B2 9/2006 Abrahamsson et al.
7,133,710 B2 11/2006 Acosta
7,167,300 B2 1/2007 Fermann et al.
7,184,148 B2 2/2007 Alphonse
7,209,657 B1 4/2007 Islam
7,233,816 B2 6/2007 Blank
7,259,906 B1 8/2007 Islam
7,263,288 B1 8/2007 Islam
7,278,966 B2 10/2007 Hjelt et al.
7,294,105 B1 11/2007 Islam
7,299,080 B2 11/2007 Acosta
7,317,938 B2 1/2008 Lorenz
7,318,909 B2 1/2008 Lehmann et al.
7,332,784 B2 2/2008 Mills et al.
7,356,364 B1 4/2008 Bullock et al.
7,395,158 B2 7/2008 Monfre
7,433,116 B1 10/2008 Islam
7,468,036 B1 12/2008 Rulkov et al.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,519,253	B2	4/2009	Islam
7,519,406	B2	4/2009	Blank
7,620,674	B2	11/2009	Ruchti
7,648,463	B1	1/2010	Elhag et al.
7,697,966	B2	4/2010	Monfre
7,771,320	B2	8/2010	Riley et al.
7,787,503	B2	8/2010	Wadsworth
7,787,924	B2	8/2010	Acosta
7,800,818	B2	9/2010	Mattsson
7,807,718	B2	10/2010	Hashim
7,848,605	B2	12/2010	Ridder et al.
7,890,158	B2	2/2011	Rowe et al.
7,969,558	B2	6/2011	Hall
8,000,574	B2	8/2011	Buchter
8,145,286	B2	3/2012	Arai
8,157,730	B2	4/2012	LeBoeuf et al.
8,158,175	B2	4/2012	Bourg, Jr.
8,158,493	B2	4/2012	Shah et al.
8,172,761	B1	5/2012	Rulkov et al.
8,180,422	B2	5/2012	Rebec
8,180,591	B2	5/2012	Yuen et al.
8,198,589	B2	6/2012	Tolton et al.
8,213,007	B2	7/2012	Wang et al.
8,310,336	B2	11/2012	Muhsin et al.
8,315,682	B2	11/2012	Such et al.
8,430,310	B1	4/2013	Ho et al.
8,463,576	B2	6/2013	Yuen et al.
8,472,108	B2	6/2013	Islam
8,475,367	B1	7/2013	Yuen et al.
8,509,882	B2	8/2013	Albert et al.
RE44,875	E	4/2014	Kiani et al.
8,755,871	B2	6/2014	Weng et al.
8,767,190	B2	7/2014	Hall
8,788,002	B2	7/2014	LeBoeuf et al.
8,945,017	B2	2/2015	Venkatraman et al.
8,948,832	B2	2/2015	Hong et al.
8,954,135	B2	2/2015	Yuen et al.
9,142,117	B2	9/2015	Muhsin et al.
9,164,032	B2	10/2015	Islam
9,179,876	B2	11/2015	Ochs et al.
9,192,329	B2	11/2015	Al-Ali
9,207,121	B2	12/2015	Adler
9,241,676	B2	1/2016	Lisogurski et al.
9,326,712	B1	5/2016	Kiani
9,596,990	B2	3/2017	Park et al.
9,651,533	B2	5/2017	Islam
9,675,250	B2	6/2017	Tverskoy
9,757,040	B2	9/2017	Islam
9,820,658	B2	11/2017	Tran
9,861,286	B1	1/2018	Islam
9,885,698	B2	2/2018	Islam
2002/0013518	A1	1/2002	West et al.
2002/0019584	A1	2/2002	Schulze et al.
2002/0032468	A1	3/2002	Hill et al.
2002/0082612	A1	6/2002	Moll et al.
2002/0109621	A1	8/2002	Khair et al.
2002/0115914	A1	8/2002	Russ
2002/0128846	A1	9/2002	Miller
2002/0178003	A1	11/2002	Gehrke et al.
2003/0022126	A1	1/2003	Buchalla
2003/0107739	A1	6/2003	Lehmann et al.
2003/0109055	A1	6/2003	Lehmann et al.
2003/0152307	A1	8/2003	Drasek et al.
2004/0174914	A1	9/2004	Fukatsu
2004/0240037	A1	12/2004	Harter
2005/0049468	A1	3/2005	Carlson et al.
2005/0111500	A1	5/2005	Harter et al.
2005/0133691	A1	6/2005	Doppke et al.
2005/0209516	A1	9/2005	Fraden
2006/0058683	A1	3/2006	Chance
2006/0198397	A1	9/2006	Korolev et al.
2006/0223032	A1	10/2006	Fried
2006/0245461	A1	11/2006	Islam
2006/0268393	A1	11/2006	Islam
2006/0281982	A1	12/2006	Grata et al.
2006/0283931	A1	12/2006	Polli et al.
2007/0021670	A1	1/2007	Mandelis et al.
2007/0078348	A1	4/2007	Holman
2008/0086318	A1	4/2008	Gilley et al.
2008/0105665	A1	5/2008	Kondo
2008/0240502	A1	10/2008	Freedman et al.
2009/0028193	A1	1/2009	Islam
2009/0105605	A1	4/2009	Abreu
2009/0156932	A1	6/2009	Zharov
2009/0185274	A1	7/2009	Shpunt
2009/0204110	A1	8/2009	Islam
2009/0244288	A1	10/2009	Fujimoto et al.
2009/0287067	A1	11/2009	Dorogusker et al.
2010/0007717	A1	1/2010	Spektor et al.
2010/0046067	A1	2/2010	Fermann et al.
2010/0118123	A1	5/2010	Freedman et al.
2010/0160794	A1	6/2010	Banet et al.
2010/0160798	A1	6/2010	Banet et al.
2010/0217099	A1	8/2010	LeBoeuf et al.
2010/0217102	A1	8/2010	LeBoeuf et al.
2010/0284082	A1	11/2010	Shpunt et al.
2010/0322490	A1	12/2010	Pan
2010/0331637	A1	12/2010	Ting
2011/0040197	A1	2/2011	Welch et al.
2011/0143364	A1	6/2011	Kim
2011/0188054	A1	8/2011	Petronius et al.
2011/0208015	A1	8/2011	Welch et al.
2011/0237911	A1	9/2011	Lamego et al.
2011/0267688	A1	11/2011	Kleppe et al.
2011/0282167	A1	11/2011	Ridder et al.
2011/0292376	A1	12/2011	Kukushkin et al.
2012/0013722	A1	1/2012	Wong
2012/0041767	A1	2/2012	Hoffman et al.
2012/0197093	A1	8/2012	LeBoeuf et al.
2012/0203077	A1	8/2012	He et al.
2012/0239013	A1	9/2012	Islam
2012/0245439	A1	9/2012	Andre et al.
2012/0310062	A1	12/2012	Li et al.
2012/0316455	A1	12/2012	Rahman et al.
2013/0274569	A1	10/2013	Islam
2013/0281795	A1	10/2013	Varadan
2013/0303921	A1	11/2013	Chu et al.
2013/0327966	A1	12/2013	Fidler et al.
2014/0078510	A1	3/2014	Rubio Guivernau et al.
2014/0081100	A1	3/2014	Muhsin et al.
2014/0236021	A1	8/2014	Islam
2014/0249427	A1	9/2014	Liu
2014/0275852	A1	9/2014	Hong et al.
2014/0275854	A1	9/2014	Venkatraman et al.
2015/0011851	A1	1/2015	Mehta et al.
2016/0045118	A1	2/2016	Kiani
2016/0327476	A1	11/2016	Islam
2018/0231373	A1	8/2018	Pesach et al.

FOREIGN PATENT DOCUMENTS

DE	102010012987	A1	10/2010
EP	1148666		10/2001
JP	2005270544	A	10/2005
WO	09715240		5/1997
WO	WO09715240		5/1997
WO	97049340		12/1997
WO	WO97049340		12/1997
WO	01150959		7/2001
WO	WO01150959		7/2001
WO	200189362		11/2001
WO	200227640		4/2002
WO	200228123		4/2002
WO	2005013843	A2	2/2005
WO	2007061772	A2	5/2007
WO	2008120217	A2	10/2008
WO	2009130464	A1	10/2009
WO	2012135952	A1	10/2012
WO	2013012938		1/2013
WO	WO2013012938	A1	1/2013

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO	2015084376	6/2015
WO	WO2015084376 A1	6/2015

OTHER PUBLICATIONS

Non-Final Office Action for U.S. Appl. No. 14/875,709 dated May 26, 2016.
Segtnan, Vegard H., et al. "Screening of acrylamide contents in potato crisps using process variable settings and near-infrared spectroscopy." Molecular nutrition & food research 50.9 (2006): 811-817.
Shiroma, Cecilia, and Luis Rodriguez-Saona. "Application of NIR and MIR spectroscopy in quality control of potato chips." Journal of Food Composition and Analysis 22.6 (2009): 596-605.
Pedreschi, F., V. H. Segtnan, and S. H. Knutsen. "On-line monitoring of fat, dry matter and acrylamide contents in potato chips using near infrared interactance and visual reflectance imaging." Food Chemistry 121.2 (2010): 616-620.
Kays, Sandra E., William R. Windham, and Franklin E. Barton. "Prediction of total dietary fiber in cereal products using near-infrared reflectance spectroscopy." Journal of Agricultural and food chemistry 44.8 (1996): 2266-2271.
Williams, Phil. "Near-Infrared Spectroscopy of Cereals." Handbook of vibrational spectroscopy (2006).
Ng, Choo Lum, Randy L. Wehling, and Susan L. Cuppett. "Method for determining frying oil degradation by near-infrared spectroscopy." Journal of agricultural and food chemistry 55.3 (2007): 593-597.
"Analysis of Edible Oils Using FT—NIR Spectroscopy." Bruker Optics, www.azom.com/article.aspx?ArticleID=5981, Mar. 10, 2012.
Shiroma, Cecilia. "Rapid quality control of potato chips using near and mid-infrared spectroscopy." (2007).
Ni, Yongnian, Minghua Mei, and Serge Kokot. "Analysis of complex, processed substances with the use of NIR spectroscopy and chemometrics: Classification and prediction of properties—The potato crisps example." Chemometrics and Intelligent Laboratory Systems 105.2 (2011): 147-156.
Hartmann, R., and H. Büning-Pfaue. "NIR determination of potato constituents." Potato research 41.4 (1998): 327-334.
Thybo, Anette Kistrup, et al. "Prediction of sensory texture of cooked potatoes using uniaxial compression, near infrared spectroscopy and low field1H NMR spectroscopy." LWT-Food Science and Technology 33.2 (2000): 103-111.
Büning-Pfaue, Hans. "Analysis of water in food by near infrared spectroscopy." Food Chemistry 82.1 (2003): 107-115.
Haase, Norbert U. "Prediction of potato processing quality by near infrared reflectance spectroscopy of ground raw tubers" Journal of Near Infrared Spectroscopy 19.1 (2011): 37-45.
September, Danwille Jacqwin Franco. Detection and quantification of spice adulteration by near infrared hyperspectral imaging. Diss. Stellenbosch: University of Stellenbosch, 2011.
Galvis-Sánchez, Andrea C., et al. "Fourier transform near-infrared spectroscopy application for sea salt quality evaluation." Journal of agricultural and food chemistry 59.20 (2011): 11109-11116.
Rein, Alan, and Luis Rodriguez-Saona. "Measurement of Acrylamide in Potato Chips by Portable FTIR Analyzers." (2013).
Ayvaz, Huseyin, et al. "Application of infrared microspectroscopy and chemometric analysis for screening the acrylamide content in potato chips." Analytical Methods 5.8 (2013): 2020-2027.
Istepanian, Robert H., "The Comparative Performance of Mobile Telemedical Systems based on the IS-54 and GSM Cellular Telephone Standards"; Journal of Telemedicine and Telecare 1999; pp. 97-104.
Aris, Ishak Bin, "An Internet-Based Blood Pressure Monitoring System for Patients"; Journal of Telemedicine and Telecare 2001; pp. 51-53.
Sun, Y., C.F. Booker, S. Kumari, R.N. Day, M. Davidson, A. Periasamy, "Characterization of an orange acceptor fluorescent protein for sensitized spectral fluorescence resonant energy transfer microscopy using a white-light laser," Journal of Biomedical Optics, vol. 14, No. 5, paper 054009 (2009).
Borlinghaus, R., "Colours Count: how the challenge of fluorescence was solved in confocal microscopy," in Modern Research and Educational Topics in Microscopy, A. Mendez-Vilas and J. Diaz, eds, pp. 890-899, Formatex (2007).
Borlinghaus, R., "The White Confocal: Continuous Spectral Tuning in Excitation and Emission," in Optical Fluorescence Microscopy, A. Diaspro (Ed), Chapter 2, pp. 37-54, ISBN 978-3-642-15174-3, Springer-Verlag, Berlin (2011).
Borlinghaus, R.T., L. Kuschel, "White Light Laser: The Ultimate Source for Confocal Microscopy," http://www.leica-microsystems.com/science-lab/white-light-laser (Jun. 27, 2012).
Ziegler, U., A.G. Bittermann, M. Hoechli, "Introduction to Confocal Laser Scanning Microscopy (LEICA)," www.zmb.unizh.ch, May 29, 2013.
"Application Brief the role of infrared microprobe analysis in forensic drug analysis," www.smithsdetection.com, Jun. 27, 2005.
Jasco Application Note No. 200DR0188-E, "Rapid Identification of illegal drug using NIR (identification of MDMA tablet)", Sep. 4, 2008.
Palou, A. J. Cruz, M. Blanco, J. Tomas, J. De Los Rios, M. Alcala, "Determination of drug, excipients and coating distribution in pharmaceutical tablets using NIR-CI," Journal of Pharmaceutical Analysis, vol. 2, No. 2, pp. 90-97 (2012).
Arnold, T., M. De Biasio, R. Leitner, "Near-Infrared Imaging Spectroscopy for Counterfeit Drug Detection," Next Generation Spectroscopic Technologies IV, edited by M. A. Druy, R.A. Crocombe, Proceedings of SPIE, vol. 8032, 80320Y-1 to 7, (2011).
Wedding, B.B., C. Wright, S. Grauf, R.D. White, "The application of near infrared spectroscopy for the assessment of avocado quality attributes," Infrared Spectroscopy—Life and Biomedical Sciences, pp. 211-230 (2011).
Michaels, C.A., T. Masiello, P.M. Chu, "Fourier transform spectrometry with a near infrared supercontinuum source," Optical Society of America, CLEO/IQEC Conference, paper CMDD6 (2009).
Michaels, C.A., T. Masiello, P.M. Chu, "Fourier transform spectrometry with a near-infrared supercontinuum source," Applied Spectroscopy, vol. 63, No. 5, pp. 538-543 (2009).
Moros,J., J. Kuligowski, G. Quintas, S. Garrigues, M. DeLa Guardia, "New cut-off criterion for uninformative variable elimination in multivariate calibration of near-infrared spectra for the determination of heroin in illicit street drugs," Analytica Chimica Acta, vol. 630, pp. 150-160 (2008).
Moros, J. N. Gallpienso, R. Vilches, S. Garrigues, M. DeLa Guardia, "Nondestructive direct determination of heroin in seized illicit street drugs by diffuse reflectance near-infrared spectroscopy," Analytical chemistry, vol. 80, No. 19, pp. 7257-7265 (Oct. 1, 2008).
Roggo, Y. P. Chalus, L. Maurer, C. Lema-Martinez, A. Edmond, N. Jent, "A review of near infrared spectroscopy and chemometrics in pharmaceutical technologies," Journal of Pharmaceutical and Biomedical Analysis, vol. 44, pp. 683-700 (2007).
Pojic, M. J. Mastilovic, N. Majcen, "The application of near infrared spectroscopy in wheat quality control," Infrared Spectroscopy—Life and Biomedical Sciences, pp. 167-184 (2012).
Reich, G. "Near-infrared spectroscopy and imaging: basic principles and pharmaceutical applications," Advanced Drug Delivery Reviews, vol. 57, pp. 1109-1143 (2005).
Rodionova, O.Y., L.P. Houmoller, A.L. Pomerantsev, P. Geladi, J. Burger, V.L. Dorofeyev, A.P. Arzamastsev, "NIR spectrometry for counterfeit drug detection: a feasibility study," Analytica Chimica Acta, vol. 549, pp. 151-158 (2005).
Schneider, R.C., K.A. Kovar, "Analysis of ecstasy tablets: comparison of reflectance and transmittance near infrared spectroscopy," Forensic Science International, vol. 134, pp. 187-195 (2003).
Olsen, B.A., M.W. Borer, F.M. Perry, R.A. Forbes, "Screening for counterfeit drugs using near-infrared spectroscopy," Pharmaceutical Technology, pp. 62-71 (Jun. 2002).
Scafi, S.H.F., C. Pasquini, "Identification of counterfeit drugs using near-infrared spectroscopy," Analyst, vol. 126, pp. 2218-2224 (2001).

(56) **References Cited**

OTHER PUBLICATIONS

Sondermann, N., K.A. Kovar, "Identification of ecstasy in complex matrices using near-infrared spectroscopy," Forensic Science International, vol. 102, pp. 133-147 (1999).
Rambla, F.J., S. Garrigues, M. DeLa Guardia, "PLS-NIR determination of total sugar, glucose, fructose and sucrose in aqueous solutions of fruit juices," Analytica Chimica Acta, vol. 344, pp. 41-53 (1997).
Bizheva, K, et al., "Compact, broad-bandwidth fiberlaserforsub-2-pm axial resolution optical coherence tomography in the 1300-nm wavelength region," Optics Letters, vol. 28, No. 9, May 1, 2003, pp. 707-709.
Wang, Yimin, et al., "Ultrahigh-resolution optical coherence tomography by broadband continuum generation from a photonic crystal fiber", Optics Letters, vol. 28, No. 3, Feb. 1, 2003, pp. 182-184.
Seefeldt, Michael, et al., "Compact white-light source with an average output power of 2.4 Wand 900 nm spectral bandwidth", Optics Communications 216, pp. 199-202.
Xie, T.-Q., et al., "Detection of tumorigenesis in urinary bladder with optical coherence tomography: optical characterization of morphological changes", Optics Express, vol. 10, No. 24, Dec. 2, 2002, 2003, pp. 1431-1443.
Povazay, B., et al., "Submicrometer axial resolution optical coherence tomography", Optics Letters, vol. 27, No. 20, Oct. 15, 2002, pp. 1800-1802.
Kowalevicz, Andrew M., et al., "Ultrahigh resolution optical coherence tomography using a superluminescent light source" Optics Express 349, vol. 10, No. 7, Apr. 8, 2002, pp. 349-353.
Oughstun, Kurt E., "Influence of precursor fields on ultrashort pulse autocorrelation measurements and pulse width evolution", Optics Express, vol. 8, No. 8, Apr. 9, 2001, pp. 481-491.
Li, Xingde, et al., "Imaging needle for optical coherence tomography", Optics Letters, vol. 25, No. 20, Oct. 15, 2000, pp. 1520-1522.
D'Amico, Anthony V., et al., "Optical Coherence Tomography as a Method for Identifying Benign and Malignant Microscopic Structures in the Prostate Gland", Basic Science, Urology 55 (5), 2000, pp. 783-787.
Rollins, Andrew M., et al., "Real-time in vivo imaging of human gastrointestinal ultrastructure by use of endoscopic optical coherence tomography with a novel efficient interferometer design", Optics Letters, vol. 24, No. 19, Oct. 1, 1999, pp. 1358-1360.
De Boer, Johannes F., el al., "Determination of the depth-resolved Stokes parameters of light backscattered from turbid media by use of polarization-sensitive optical coherence tomography", Optics Letters, vol. 24, No. 5; Mar. 1, 1999, pp. 300-302.
Roggan, Andre, et al., "Optical Properties of Circulating Human Blood in the Wavelength Range 400-2500 NM", Journal of Biomedical Optics, vol. 4, No. 1, Jan. 1999, pp. 36-46.
De Boer, Johannes F., et al., "Imaging thermally damaged tissue by polarization sensitive optical coherence tomography", Optics Express 212, vol. 3, No. 6, Sep. 14, 1998, pp. 212-218.
Tearney, Guillermo J., et al., "In vivo Endoscopic Optical Biopsy with Optical Coherence Tomography", Science, New Series, vol. 276, Jun. 27, 1997, pp. 2037-2039.
Soppart, Stephen A., et al., "Noninvasive assessment of the developing Xenopus cardiovascular system using optical coherence tomography", Prec. Natl. Acad. Sci. USA, vol. 94, Apr. 1997, pp. 4256-4261.
Boppart, Stephen A., et al., "Imaging developing neural morphology using optical coherence tomography", Journal of Neuroscience Methods 70, 1996, pp. 65-72.
Aaviksoo, J., et al., "Observation of optical precursors at pulse propagation in GaAs", Physical Review A, vol. 44, No. 9, Nov. 1, 1991, pp. R5353-R5356.
Harrington, James A., "Infrared Fiber Optics", OSA Handbook, vol. III, white paper, to be published by McGraw Hill, Undated, 13 pages.
Fedotova, O., et al., "Supercontinuum generation in planar rib waveguides enabled by anomalous dispersion", Optics Express, vol. 14, No. 4, Feb. 20, 2006, pp. 1512-1517.
Moon, Sucbei, et al., "Generation of octave-spanning supercontinuum with I550-nm amplified diode-laser pulses and a dispersion-shifted fiber", Optics Express, vol. 14, No. 1, Jan. 9, 2006, pp. 270-278.
Hagen, C. L., et al., "Generation of a Continuum Extending to the Midinfrared by Pumping ZBLAN Fiber With an Ultrafast 1550-nm Source", IEEE Photonics Technology Letters, vol. 18, No. 1, Jan. 1, 2006, pp. 91-93.
Travers, J. C., et al., "Extended blue supercontinuum generation in cascaded holey fibers", Optics Letters, vol. 30, No. 23, Dec. 1, 2005, pp. 3132-3134.
Schreiber, T., et al., "Supercontinuum generation by femtosecond single and dual wavelength pumping in photonic crystal fibers with two zero dispersion wavelengths", Optics Express, vol. 13, No. 23, Nov. 14, 2005, pp. 9556-9569.
Genty, G., et al., "Supercontinuum generation in large mode-area microstructured fibers", Optics Express, vol. 13, No. 21, Oct. 17, 2005, pp. 8625-8633.
Lee, Ju Han, et al., "Continuous-wave supercontinuum laser based on an erbium-doped fiber ring cavity incorporating a highly nonlinear optical fiber", Optics Letters, vol. 30, No. 19, Oct. 1, 2005, pp. 2599-2601.
International Search Report and Written Opinion for International Application No. PCT/US2013/075700 dated Apr. 24, 2014.
International Preliminary Report on Patentability for International Application No. PCT/US2013/075700 dated Jul. 9, 2015.
Ooi ET, Zhang XQ, Chen JH, Soh PH, Ng K, Yeo JH, "Non-invasive glucose measurement using multiple laser diodes," Optical Diagnostic and Sensing VII, edited by Gerard L. Cote, Alexander V. Priezzhev, Proc. of SPIE vol. 6445, 64450K , (2007).
Schulz, I., J. Putzger, A. Niklas, M. Brandt, A. Jager, A. Hardt, S. Knorzer, K.A. Hiller, S. Loftier, G. Schmalz, S.N. Danilov, S. Giglberger, M. Hirmer, S.D. Ganichev, G. Monkman, "PPG signal acquisition and analysis on in vitro tooth model for dental pulp vitality assessment," ARC Submission 16, (2012).
Drexler, C., Hirmer, M., Danilov, S., Giglberger, S., Putzger, J., Niklas, A., Jager, K, Hiller, K., Loftier, S., Schmalz, G., Redlich, B., Schulz, I., Monkman, G., Ganichev, S. "Infrared spectroscopy for clinical diagnosis of dental pulp vitality." Infrared, Millimeter, and Terahertz Waves (IRMMW-THz), 2012 37th International Conference on. IEEE (2012).
Hirmer, Marion, Danilov, Sergey, Giglberger, Stephan, Putzger, Jurgen, Niklas, Andreas, Jager, Andreas, Hiller, Karl-Anton, Loftier, Susanne, Schmalz, Gottfried, Redlich, Britta, Schulz, Irene, Monkman, Gareth, Ganichev, Sergey. "Spectroscopic Study of Human Teeth and Blood from Visible to Terahertz Frequencies for Clinical Diagnosis of Denta Pulp Vitality." Journal of Infrared, Millimeter, and Terahertz Waves 33.3 (2012): 366-375.
Na, J, J.H. Baek, S.Y. Ryu, C. Lee, B.H. Lee, "Tomographic imaging of incipient dental-caries using optical coherence tomography and comparison with various modalities," Optical Review, vol. 16, No. 4, pp. 426-431 (2009).
Pan, Yingtian, et al., "Hand-held arthroscopic optical coherence tomography for in vivo high-resolution imaging of articular cartilage", Journal of Biomedical Optics 8(4), Oct. 2003, pp. 648-654.
Xie, Tuqiang, et al., "Endoscopic optical coherence tomography with a modified microelectromechanical systems mirror for detection of bladder cancers", Applied Optics, vol. 42, No. 31, Nov. 1, 2003, pp. 6422-6426.
Dubois, A., et al., "Three-dimensional cellular-level imaging using full-field optical coherence tomography", Physics in Medicine and Biology, Phys. Med. Biol. 49, 2004, pp. 1227-1234.
Park, Jesung, et al., "Analysis of birefringent image in the retinal nerve fiber layer by polarization sensitive optical coherence tomography", Ophthalmic Technologies XIV, Proceedings of SPIE, vol. 5314, 2004, pp. 188-194.
Unterhuber, A., et al., "Advances in broad bandwidth light sources for ultrahigh resolution optical coherence tomography", Physics in Medicine and Biology, Phys. Med. Biol. 49, 2004, pp. 1235-1246.
Drexler, Wolfgang, "Ultrahigh-resolution optical coherence tomography", Journal of Biomedical Optics, vol. 9, No. 1, Jan./Feb. 2004, pp. 47-74.

(56) **References Cited**

OTHER PUBLICATIONS

Schmitt, Joseph, et al., "Intravascular Optical Coherence Tomography Opens a Window Onto Coronary Artery Disease", Optics & Photonics News, Feb. 2004, pp. 20-25.
Nassif, N.A, et al., "In vivo high-resolution video-rate spectral-domain optical coherence tomography of the human retina and optic nerve", Optics Express, vol. 12, No. 3, Feb. 9, 2004, pp. 367-376.
Choi, Seung-Ho, et al., "Observation of Optical Precursors in Water", Physical Review Letters, vol. 92, No. 19, May 14, 2004, pp. 193903-1-193903-.3.
Pierce, Mark C., et al., "Advances in Optical Coherence Tomography imaging for Dermatology", Optical Coherence Tomography Advances, The Journal of Investigative Dermatology, Sep. 3, 2004, pp. 458-463.
"State-Specific Trends in Chronic Kidney Failure—United States, 1990-2001", Morbidity and Mortality Weekly Report, Department of Health and Human Services Centers for Disease Control and Prevention, vol. 53, No. 39, copied from intemet: file:// C:\Documents and Settings\eturlo\Desktop\State-Specific Trends in Chronic Kidney . . . Feb. 12, 2010, Oct. 8, 2004, pp. 918-920.
I.B. Ads, A.A.E. Wagie, N.B. Mariun, A.B.E. Jammal, "An Internet-based blood pressure monitoring system for patients," Journal of Telemedicine and Telecare, 2001, pp. 51-53.
R.H. Istepanian, B. Woodward, P.A. Bales, S. Chen, B. Luk, "The comparative performance of mobile telemediCal systems based on the IS-54 and GSM cellular telephone standards," Journal of Telemedicine and Telecare, 1999, pp. 97-104.
Shaw, et al, IR Supercontinuum Generation in As—Se Photonic Crystal Fiber, Optical Society of America, Copyright 2005, 3 pages.
PCT/US06/44451, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, Nov. 29, 2007, 12 pages.
G.S. Edwards et al., "Free-electron-laser-based biophysical and biomedical Instrumentation," American Institute of Physics, vol. 74, No. 7, Jul. 2003, pp. 3207-3245.
Computer Motion, Inc., "501(k) Summary—ZEUS® MicroWrist™ Surgical System and Accessories," Sep. 24, 2002, 6 pages.
Computer Motion, Inc. "HERMES™ O.R. Control Center—510(k) Summary of Safety and Effectiveness," Oct. 11, 2002, 5 pages.
K.M. Joos, et al. "Optic Nerve Sheath Fenestration with a Novel Wavelength Produced by the Free Electron Laser (FEL)," Lasers in Surgery and Medicine, 27: 2000,191-205.
J. Sanghera, I. Aggarwal, "IR Fiber Optics at NRL," undated, 10 pages.
J. Sanghera, L.B. Shaw, I.D. Aggarwal, "Applications of chalcogenide glass optical fibers," Academic of Science, 2003, pp. 1-11.
B. Rigas, P.T.T. Wong, "Human Colon Adenocarcinoma Cell Lines Display Infrared Spectroscopic Features," Cancer Research, Jan. 1, 1992, pp. 84-88.
G. Edwards, et al., "Comparison of OPA and Mark-III FEL for Tissue Ablation at 6.45 Microns," Department of Physics and Free Electron Laser Laboratory, Duke University, 2002, 7 pages.
Glenn Edwards, "Biomedical and potential clinical applications for pulsed lasers operating near 6.45 um," Society of Photo-Optical Instrumentation Engineers, 1995, 2 pages.
PASSAT, "Solid-State Lasers and Optical Components," Jul. 14, 2003, 5 pages.
P.A. Thielen and L.B. Shaw, et al., "Small-core As—Se fiber for Raman amplification," Optics Leti-ers, vol. 28, No. 16, Aug. 15, 2003, 3 pages.
R.Rox Anderson, et al., "Selective Photothermolysis: Precise Microsurgery by Selective Absorption of Pulsed Radiation," Department of Dermatology, Harvard Medical School, Science, vol. 220, Apr. 29, 1983, 4 pages.
U.S. Appl. No. 10/652,276, "System and Method for Voice Control of Medical devices," by Mohammed N. Islam, filed Aug. 29, 2003.
U.S. Appl. No. 10/757,341, "System and Method for Voice Control of Medical devices," by Mohammed N. Islam, filed Jan. 13, 2004.
U.S. Appl. No. 12/206,432, "System and Method for Voice Control of Medical Devices," by Mohammed N. Islam, filed Sep. 8, 2008.
U.S. Patent and Trademark Office, Office Action for U.S. Appl. No. 12/206,432, filed Sep. 8, 2008, Mohammed N, Islam, Date filed: Mar. 12, 2009
U.S. Patent and Trademark Office, Notice of Allowance and Fee(s) Due for U.S. Appl. No. 12/206,432, filed Sep. 8, 2008, Mohammed N. Islam, Date filed: Aug. 28, 2009
Declaration of Brian W. Anthony, PhD regarding U.S. Pat. No. 9,651,533 filed in IPR2019-00913 & IPR2019-00916 (Apr. 10, 2019).
Declaration of Brian W. Anthony, PhD regarding U.S. Pat. No. 9,757,040 filed in IPR2019-00910 & IPR2019-00917 (Apr. 10, 2019).
Declaration of Brian W. Anthony, PhD regarding U.S. Pat. No. 9,861,286 filed in IPR2019-00911 & IPR2019-00914 (Apr. 10, 2019).
Declaration of Brian W. Anthony, PhD regarding U.S. Pat. No. 9,885,698 filed in IPR2019-00912 & IPR2019-00915 (Apr. 10, 2019).
Proof of Service of Summons in *Omni MedSci, Inc.* v. *Apple Inc.*, No. 2:18-cv-134 (E.D. Tex.) (Dkt. #12) (Apr. 13, 2018).
U.S. Appl. No. 61/747,487, filed Dec. 31, 2012.
U.S. Appl. No. 61/747,472, filed Dec. 31, 2012.
U.S. Appl. No. 61/747,477, filed Dec. 31, 2012.
U.S. Appl. No. 61/754,698, filed Jan. 21, 2013.
Joseph D. Bronzino; "The Biomedical Engineering Handbook", (1995).
M. Krantz, et al., The mobile fitness coach: Towards individualized skill assessment using personalized mobile devices, Pervasive and Mobile Computing (Jun. 2012).
S. Patel, et al., A review of wearable sensors and systems with application rehabilitation, Journal of Neuroengineering & Rehabilitation 2012 9:21.
ScienceDirect Report on M. Krantz, et al., The mobile fitness coach: Towards individualized skill assessment using personalized mobile devices, Pervasive and Mobile Computing (2012), available at https://www.sciencedirect.com/science/article/pii/S1574119212000673?via%3Dihub (2018 Elsevier B.V.).
Rauf Adil, "The Usage of Tablets in the HealthCare Industry," available at https://www.healthcareitnews.com/blog/usage-tablets-healthcare-industry (Aug. 2, 2012).
A. Omre, Bluetooth Low Energy: Wireless Connectivity for Medical Monitoring, Journal of Diabetes Science & Technology , vol. 4, Issue 2 (Mar. 2010).
"Absorption Coefficient and Penetration Depth," The Science of Solar, available at https://photon.libretexts.org/The_Science_of_Solar/Solar_Basics/C._Semiconductors_and_Solarinteractions/III._Absorption_of_Light_and_Generation/1._Absorption_Coefficient_and_Penetration_Depth (Last Updated Nov. 3, 2018).
F. Buttussi, et al., MOPET: A context-aware and user-adaptive wearable system for fitness training, Artificial Intelligence in Medicine (2008) 42, 153-163.
P. Baum et al., Strategic Intelligence Monitor on Personal Health Systems, Phase 2: Market Developments—Remote Patient Monitoring and Treatment, Telecare, Fitness/Wellness and mHealth, JRC Scientific and Policy Reports of European Commission (2013).
"Compendium of Chemical Terminology Gold Book," International Union of Pure and Applied Chemistry, Version 2.3.3 (Feb. 24, 2014).
M. Swan, Sensor Mania! The Internet of Things, Wearable Computing, Objective Metrics, and the Quantified Self 2.0, Journal of Sensor and Actuator Networks (2012).
Excerpts from Merriam-Webster's Collegiate Dictionary Eleventh Edition (2011).
T. Lister et al., Optical properties of human skin, Journal of Biomedical Optics (Sep. 2012).
A. Bashkatov et al., Optical properties of human skin, subcutaneous and mucous tissues in the wavelength range from 400 to 2000 nm, Journal of Physics D: Applied Physics 38 (2005) 2543-2555.
E.F. Schubert, Light-Emitting Diodes (Cambridge Univ. Press, 2nd ed. Reprinted 2014).
Barolet, Daniel, Light-Emitting Diodes (LEDs) in Dermatology, Seminars in Cutaneous Medicine and Surgery 27:227-238 (2008).

(56) **References Cited**

OTHER PUBLICATIONS

Omni MedSci Inc.'s Opening Claim Construction Brief filed in Case No. 2:18-cv-134-RWS (Dkt. #85) (Dec. 20, 2018).
Apple Inc.'s Preliminary Claim Constructions and Extrinsic Evidence Pursuant to Patent Local Rule 4-2 served in Case No. 2:18-cv-134-RWS (Nov. 1, 2018).
Excerpts from the American Heritage Dictionary, 5th Edition (Jul. 2012).
Curriculum Vitae of Brian W. Anthony, PhD (Nov. 18, 2018).
Amended Joint Claim Construction and Prehearing Statement filed in Case No. 2:18-cv-134-RWS (Dkt. #102) (Jan. 11, 2019).
Excerpt from Claim Construction Markman Hearing Transcript filed in Case No. 2:18-cv-134-RWS (Feb. 6, 2019) vol. 1, pp. 1, 2, 21, 22.
Dr. Mohammed Islam, Faculty Profile, University of Michigan, College of Engineering (available at https://islam.engin.umich.edu) (2019 The Regents of the University of Michigan).
Technology Transfer Policy, Office of Technology Transfer—University of Michigan (available at https://techtransfer.umich.edu/for-inventors/policies/technology-transfer-policy/) (revision effective Jun. 1, 2009).
The Bylaws of the University of Michigan Board of Regents, (available at http://www.regents.umich.edu/bylaws/bylawsrevised_09-18.pdf) (last updated Sep. 20, 2018).
District Court Preliminary Claim Constructions in Case No. 2:18-cv-134-RWS (received Feb. 6, 2019) from Court at Markman hearing.
File History for U.S. Pat. No. 9,651,533 issued May 16, 2017.
File History for U.S. Pat. No. 9,757,040 issued Sep. 12, 2017.
File History for U.S. Pat. No. 9,861,286 issued Jan. 9, 2018.
File History for U.S. Pat. No. 9,885,698 issued Feb. 6, 2018.
Extended European Search Report for European Application No. 17155541.0 dated May 24, 2017.
Robert S. Jones et al.; Near-Infrared Transillumination at 1310-nm for the Imaging of Early Dental Decay; vol. 11, No. 18; Optics Express 2259; Sep. 8, 2003.
Extended European Search Report for European Application No. 13867892.5 dated Jul. 22, 2016.
Extended European Search Report for European Application No. 13867874.3 dated Jul. 15, 2016.
Vinay V. Alexander et al.; Modulation Instability High Power All-Fiber Supercontinuum Lasers and Their Applications; Optical Fiber Technology 18; 2012; pp. 349-374.
Final Office Action dated Oct. 21, 2016 for U.S. Appl. No. 14/875,709.
Hori, Takashi, et al., "Flatly broadened, wideband and low noise supercontinuum generation in highly nonlinear hybrid fiber", Optics Express, vol. 12, No. 2, Jan. 26, 2004, pp. 317-324.
Wadsworth, W. J., et al., "Supercontinuum and four-wave mixing with Q-switched pulses in endlessly single-mode photonic crystal fibres", Optics Express, vol. 12, No. 2, Jan. 26, 2004, pp. 299-309.
Hilligsoe, Karen Marie, et al., "Supercontinuum generation in a photonic crystal fiber with two zero dispersion wavelengths", Optics Express, vol. 12, No. 6, Mar. 22, 2004, pp. 1045-1054.
Venugopalan, V., "Optical Society of America Biomed Topical Meeting Tutorial on Tissue Optics", Apr. 27, 2004, pp. 1-32.
Slusher, Richart E., et al., "Large Raman gain and nonlinear phase shifts in high-purity As2So3 chalcogenide fibers", J. Opt. Soc. Am. B, vol. 21, No. 6, Jun. 2004, pp. 1146-1155.
Leon-Saval, S. G., et al., "Supercontinuum generation in submicron fibre waveguides", Optics Express, vol. 12, No. 13, Jun. 28, 2004, pp. 2864-2869.
Nicholson, J. W., et al., "High power, single mode, all-fiber source of femtosecond pulses at 1550 nm and its use in supercontinuum generation", Optics Express, vol. 12, No. 13, Jun. 28, 2004, pp. 3025-3034.
Genty, G., et al., "Enhanced bandwidth of supercontinuum generated m microstructured fibers", Optics Express, vol. 12, No. 15, Jul. 26, 2004, pp. 3471-3480.
Champert, Pierre-Alain, et al., "White-light supercontinuum generation in normally dispersive optical fiber using original multi-wavelength pumping system", Optics Express, vol. 12, No. 19, Sep. 20, 2004, pp. 4366-4371.
Nicholson, J. W., "Supercontinuum generation in ultraviolet-irradiated fibers", Optics Letters, vol. 29, No. 20, Oct. 15, 2004, pp. 2363-2365.
Hori, Takashi, et al., "Experimental and numerical analysis of widely broadened supercontinuum generation in highly nonlinear dispersion-shifted fiber with a femtosecond pulse", J. Opt. Soc. Am. B, vol. 21, No. 11, Nov. 2004, pp. 1969-1980.
Demircan, Ayhan, et al., "Supercontinuum generation by the modulation instability", Optics Communications 244, 2005, pp. 181-185.
Papemyi, S. B., et al., "Sixth-Order Cascaded Raman Amplification", OFC/NFOEC, 2005, 3 pages.
Tanaka, Keiji, "Optical nonlinearity in photonic glasses", Journal of Materials Science: Materials in Electronics 16, 2005, pp. 633-643.
Westbrook, Paul S., "Improved Supercontinuum Generation Through UV Processing of Highly Nonlinear Fibers", Journal of Lightwave Technology, vol. 23, No. 1, Jan. 2005, pp. 13-18.
Abeeluck, Akheelesh K., et al., "Continuous-wave pumping in the anomalous- and normal dispersion regimes of nonlinear fibers for supercontinuum generatfon", Optics Letters, vol. 30, No. 1, Jan. 1, 2005, pp. 61-63.
Kutz, J. Nathan, et al., "Enhanced Supercontinuum Generation through Dispersion-Management", Optics Express, vol. 13, No. 11, May 30, 2005, pp. 3989-3998.
Lee, Ju Han, et al., "Experimental performance comparison for various continuous-wave supercontinuum schemes: ring cavity and single pass structures", Optics Express, vol. 13, No. 13, Jun. 27, 2005, pp. 4848-4853.
Saliminia, A., et al., "Ultra-broad and coherent white light generation in silica glass by focused femtosecond pulses at 1.5pm", Optics Express, vol. 13, No. 15, Jul. 25, 2005, pp. 5731-5738.
Takushima, Yuichi, High average power, depolarized supercontinuum generation using a 1.55-um ASE noise source, Optics Express, vol. 13, No. 15, Jul. 25, 2005, pp. 5871.-5877.
Travers, J. C., et al., "Extended continuous-wave supercontinuum generation in a low-water-loss holey fiber", Optics Letters, vol. 30, No. 15, Aug. 1, 2005, pp. 1938-1940.
Kobtsev, Serguei M., et al., "Modelling of high-power supercontinuum generation in highly nonlinear, dispersion shifted fibers at CW pump", Optics Express, vol. 13, No. 18, Sep. 5, 2005, pp. 6912-6918.
Falk, Peter, et al., "Supercontinuum generation in a photonic crystal fiber with two zero-dispersion wavelengths tapered to normal dispersion at all wavelengths", Optics Express, vol. 13, No. 19, Sep. 19, 2005, pp. 7535-7540.
Tombelaine, Vincent, et al., "Ultra wide band supercontinuum generation in air-silica holey fibers by SHG-induced modulation instabilities", Optics Express, vol. 13, No. 19, Sep. 19, 2005, pp. 7399-7404.
Boppart, Stephen A., el al., "Noninvasive assessment of the developing Xenopus cardiovascular system using optical coherence tomography", Prec. Natl. Acad. Sci. USA, vol. 94, Apr. 1997, pp. 4256-4261.
International Search Report and Written Opinion for International Application No. PCT/US2013/075767 dated Oct. 14, 2014.
International Preliminary Report on Patentability for International Application No. PCT/US2013/07567 dated Jul. 9, 2015.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit A), 66 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit B), 73 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit C), 85 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit D), 38 pps.

(56) **References Cited**

OTHER PUBLICATIONS

Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit E), 120 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit F), 40 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit G), 66 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit H), 74 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit I), 102 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit J), 64 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit K), 77 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit L), 64 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit M), 119 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit N), 50 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit O), 63 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit P), 78 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit Q), 69 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit R), 61 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit S), 50 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit T), 174 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit U), 334 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit V), 137 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit W), 384 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit X), 291 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit Y), 120 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit Z), 53 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit AA), 75 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit BB), 65 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit CC), 320 pps.
Omni Medsci, Inc. v. *Apple Inc.*; Case No. 2:18-cv-134-RWS (E.D. Tex.); Defendant's Invalidity Contentions, Aug. 28, 2018 (Exhibit DD), 240 pps.
Rhee et al., Artifact-Resistant Power-Efficient Design of Finger-Ring Plethysmographic Sensors, IEEE Transactions on Biomedical Engineering (Jul. 2001), vol. 48, No. 7, Cambridge, MA, 11 pages.
Branche et al., Signal Quality and Power Consumption of a New Prototype Reflectance Pulse Oximeter Sensor, Proceedings of the IEEE 31st Annual Northeast Bioengineering Conference (2005), Hoboken, NJ, 2 pages.
Peláez, LED Power Reduction Trade-Offs for Ambulatory Pulse Oximetry, Conference Proceedings of the 29th Annual International Conference of the IEEE EMBS (Aug. 2007) Lyon, France, 4 pages.
Luo et al., A Non-Invasive Dual-Channel Oximeter Based on Near-Infrared Spectroscopy (NIRS), Biophotonics Lab, Center of Advanced Research in Photonics (2007), The Chinese University of Hong Kong, China, 2 pages.
Asada et al., The MIT Ring: History, Technology, and Challenges of Wearable Health Monitoring, MIT Industrial Liaison Program (2010) R&D Conference, MA, 72 pages.
Asada et al., Mobile Monitoring with Wearable Photoplethysmographic Biosensors, Technical and Clinical Aspects of a Ring Sensor for Ambulatory, Telemetric, Continuous Health Monitoring in the Field, in the Hospital, and in the Home, IEEE Engineering in Medicine and Biology Magazine, (May/Jun. 2003) 13 pages.
Schreiner et al., Blood Oxygen Level Measurement with a Chest-Based Pulse Oximetry Prototype System, Computing in Cardiology (2010) NIBEC, University of Ulster, Newtownabbey, Northern Ireland, 4 pages.
GE Healthcare, TuffSat User's Guide and Service Manual Electromagnetic Compatibility (EMC), (Mar. 2005) Helsinki, Finland, 43 pages.
Kurylyak et al., Smartphone-Based Photoplethysmogram Measurement, Department of Electronics, Computer and System Sciences, (2012) River Publishers, University of Calabria, Italy, 30 pages.
Patterson et al., Ratiometric Artifact Reduction in Low Power Reflective Photoplethysmography, (Aug. 2011) IEEE Transactions on Biomedical Circuits and Systems, vol. 5, No. 4, 9 pages.
Cai et al., Implementation of a Wireless Pulse Oximeter Based on Wrist Band Sensor, College of Biological Science and Medical Engineering Southeast University, (2010) 3rd International Conference on Biomedical Engineering and Informatics, Nanjing, China, 4 pages.
Yamaha, BODiBEAT, Body, Music, In Sync., BF-1 Quick Guide, Player/Heart Rate Monitor: Quick Manual, 120 pages.
GE Healthcare, GE Ohmeda TufSat Oximeter for Clinicians on the go, (2012), A General Electric Co., www.gehealthcare.com, GE, Finland, 4 pages.
Wang et al., Multichannel Reflective PPG Earpiece Sensor with Passive Motion Cancellation, (Dec. 2007) IEEE Transactions on Biomedical Circuits and Systems, vol. 1, No. 4, 7 pages.
Webster, Design of Pulse Oximeters, Medical Science Series (1997), Department of Electrical and Computer Engineering, University of Wisconsin-Madison, Institute of Physics Publishing, Bristol and Philadelphia, 267 pages.
Taos, Inc., Infrared Light-to-Voltage Optical Sensors, (2006) Texas Advanced Optoelectronic Solutions Inc., The Lumenology Company, TX, 14 pages.
Jung et al., Design of a Low-Power Consumption Wearable Reflectance Pulse Oximetry for Ubiquitous Healthcare System, International Conference on Control, Automation and Systems (Oct. 2008), in COEX, Seoul, Korea, 4 pages.
Embedded-Lab, Introducing Easy Pulse: A DIY Photoplethysmographic Sensor for Measuring Hearth Rate, posted on www.Embedded-Lab.com Sep. 12, 2012, by R-B, 10 pages.
Asare et al., Analysis of Multi-Spectral Photoplethysmograph Biosensors, Proc. SPIE 8801, Novel Biophotonic Techniques and Appli-

(56) **References Cited**

OTHER PUBLICATIONS

cations II, 880106 (Jun. 2013), European Conferences on Biomedical Optics, Munich, Germany, 7 pages.
Morón et al, A Wireless Monitoring System for Pulse-Oximetry Sensors, (2005) Electronic Technology Department, University of Málaga, Spain, 6 pages.
Roggan, A., M. Friebel, K. Doschel, A. Hahn, G. Muller, "Optical properties of circulating human blood in the wavelength range 400-2500nm," Journal of Biomedical Optics, vol. 4, No. 1, pp. 36-46, (Jan. 1999).
Taroni, P., "Diffuse optical imaging and spectroscopy of the breast: a brief outline of history and perspectives," Photochemical Photobiological Science, vol. 11, pp. 241-250 (2012).
Herranz, M., A. Ruibal, "Optical imaging in breast cancer diagnosis: the next evolution," Journal of Oncology, vol. 2012, article ID 863747, 10 pages, (2012).
Walsh, M.J., R.K. Reddy, R. Bhargava, "Label-free biomedical imaging with mid-IR spectroscopy," IEEE Journal of Selected Topics in Quantum Electronics, article identifier 10.1109/JSTQE.2011.2182635, 12 pages, (2011).
Evers, D.J., B.H.W. Hendriks, G.W. Lucassen, T.J.M. Ruers, "Optical spectroscopy: current advances and future applications in cancer diagnosis and therapy," Future Oncology, vol. 8, No. 3, pp. 307-320 (2012).
Evers, D.J., R. Nachabe, H.M. Klomp, J.W. van Sandick, M.W. Wouters, G.W. Lucassen, B.H.W. Hendriks, J. Wesseling, T.J.M. Ruers, "Diffuse reflectance spectroscopy: a new guidance tool for improvement of biopsy procedures in lung malignancies," Clinical Lung Cancer, article identifier 10.1016/j.clc.2012.02.001, 8 pages, (2012).
Bellisola, G. C. Sorio, "Infrared spectroscopy and microscopy in cancer research and diagnosis," American Journal of Cancer Research, vol. 2, No. 1, pp. 1-21 (2012).
Noreen, R., C.C. Chien, M. Delugin, S. Yao, R. Pineau, Y. Hwu, M. Moenner, C. Petibois, "Detection of collagens in brain tumors based on FTIR imaging and chemometrics," Annals of Bioanalytic Chemistry, vol. 401, pp. 345-852 (2011).
Nachabe, R., D.J. Evers, B.H.W. Hendriks, G.W. Lucassen, M.van der Voort, E.J. Rutgers, M.J.V. Peeters, J.A. Van der Hage, H.S. Oldenburg, J. Wesseling, T.J.M. Ruers, "Diagnosis of breast cancer using diffuse optical spectroscopy from 500 to 1600nm: comparison of classification methods," Journal of Biomedical Optics, vol. 16, No. 8, article 087010, 12 pages (Aug. 2011).
Fantini, S. A. Sassaroli, "Near-infrared optical mammography for breast cancer detection with intrinsic contrast," Annals of Biomedical Engineering, vol. 40, No. 2, pp. 398-407 (Feb. 2012).
Akbari, H. K. Uto, Y. Kosugi, K. Kojima, N. Tanaka, "Cancer detection using infrared hyperspectral imaging," Cancer Science, vol. 102, No. 4, pp. 852-857 (Apr. 2011).
Parawira, S. "Classification of hyperspectral breast images for cancer detection," Dec. 4, 2009, downloaded from WWW, 5 pages.
Leff, D.R., O.J. Warren, L.C. Enfield, A. Gibson, T. Athanasion, D.K. Patten, J. Hebden, G.Z. Yang, A. Darzi, "Diffuse optical imaging of the healthy and diseased breast: a systematic review," Breast Cancer Research Treatment, vol. 108, pp. 9-22 (2008).
Konderpati, V.R., H.M. Heise, J. Backhaus, "Recent applications of near-infrared spectroscopy in cancer diagnosis and therapy," Annals of Bioanalytic Chemistry, vol. 390, pp. 125-139 (2008).
Taroni, P. D. Cornelli, A. Giusto, A. Pifferi, N. Shah, L. Spinelli, A. Torricelli, R. Cubeddu, "Assessment of collagen absorption and related potential diagnostic applications," Diffuse Optical Imaging of Tissue, edited by B.W. Pogue, R. Cubeddu, Proceedings of SPIE-OSA Biomedical Optics, SPIE vol. 6629, paper 66290D, 5 pages, (2007).
Mehrotra, R. A. Gupta, A. Kaushik, N. Prakash, H. Kandpal, "Infrared spectroscopic analysis of tumor pathology," Indian Journal of Experimental Biology, vol. 45, pp. 71-76 (Jan. 2007).
Urbas, A., M.W. Manning, A. Daugherty, L.A. Cassis, R.A. Lodder, "Near-infrared spectrometry of abdominal aortic aneurysm in the ApoE Mouse," Analytical Chemistry, vol. 75, No. 15, pp. 3650-3655 (Jul. 15, 2003).
Hirosawa, N. Y. Sakamoto, H. Katayama, S. Tonooka, K. Yano, "In vivo investigation of progressive alternations in rat mammary gland tumors by near-infrared spectroscopy," Analytical Biochemistry, vol. 305, pp. 156-165 (2002).
Notice of Allowance for U.S. Appl. No. 14/875,709 dated Jan. 10, 2017.
Watari, M., H. Migashiyama, N. Mitsui, M. Tomo, Y. Ozaki, "On-line monitoring of the density of linear low-density polyethylene in a real plant by near-infrared spectroscopy and chemometrics," Applied Spectroscopy, vol. 58, No. 2, pp. 248-255 (2004).
Tolton, B.T., "A concept for a gas-filter correlation radiometer to remotely sense the atmospheric carbon dioxide column from space," Notes and Correspondence, Journal of Atmospheric and Oceanic Technology, vol. 21, pp. 837-852, (May 2004).
Nunnally, W.C., S.K. Holland, G. Laufer, "Wide field of view solar occultation gas filter correlation radiometer for stratospheric methane measurements from a sounding rocket," Thermosense XXV, K.E. Elliot, X.P. Maldague, Editors, Proceedings of SPIE, vol. 5073, pp. 122-130 (2003).
Xiao, J. Q. Tian, Y. Lu, L. Wang, X. Qi, B. Wen, "Extraction of hydrocarbon content information by using hyperspectral image at Liaodong Bay, China," downloaded from world wide web on Apr. 6, 2012.
McCoy, R.M., J.G. Blake, K.L. Andrews, "Detecting hydrocarbon microseepage," Oil and Gas Journal, pp. 40-45 (May 28, 2001).
Van Der Meer, F. P. Van Dijk, H. Van Der Werff, H. Yang, "Remote sensing and petroleum seepage: a review and case study," Terra Nova, vol. 14, No. 1, pp. 1-17 (2002).
Van Der Meer, F., P. Van Dijk, S. Kroonenberg, Y. Hong, H. Lang, "Hyperspectral hydrocarbon microseepage detection and monitoring: potentials and limitations," Second EARSEI workshop on imaging spectroscopy, pp. 1-9 (2000).
Andreoli, G. B. Bulgarelli, B. Hosgood, D. Tarchi, "Hyperspectral analysis of oil and oil-impacted soils for remote sensing purposes," Institute for the Protection and Security of the Citizen, European Commission Joint Research Centre, EUR 22739 EN (Mar. 2007).
S.D. Khan, S. Jacobson, "Remote sensing and geochemistry for detecting hydrocarbon microseepages," GSA Bulletin, vol. 120, No. 1/2, pp. 96-105 (Jan./Feb. 2008).
F. Kuhn, K. Oppermann, B. Horig, "Hydrocarbon Index—and algorithm for hyperspectral detection of hydrocarbons," International Journal of Remote Sensing, vol. 25, No. 12, pp. 2467-2473 (Jun. 20, 2004).
Shu-Fang, T. C. Jian-Ping, Z. Mi, "The information of oil and gas micro-seepage in Dongsheng Region of Inner Mongolia extraction based on the airborne hyperspectral remote sensing image," Remote Sensing of the Environment, 16th National Symposium on Remote Sensing of China, edited by Q. Tong, Proceedings of SPIE, vol. 7123, 71230K-1 to 8, (2008).
Xu, D., G. Ni, T. Jiang, L. Jiang, M. Chi, "Integration of field work and hyperspectral data for oil and gas exploration," IEEE 1-4244-1212-9/07, pp. 3194-3197 (2007).
Xu, D-Q, G-Q Ni, L-L Jiang, Y-T Shen, T. Li, S-L Ge, X-B Shu, "Exploring for natural gas using reflectance spectra of surface soils," Advances in Space Research, vol. 41, pp. 1800-1817 (2008).
M. Kumar, M.N. Islam, F.L. Terry, M.J. Freeman, A. Chan, M. Neelakandan, T. Manzur, "Stand-off detection of solid targets with diffuse reflection spectroscopy using a high-power mid-infrared supercontinuum source," Applied Optics, vol. 51, No. 15, pp. 2794-2807 (May 20, 2012).
Clark, R.N., J.M. Curchin, T. M. Hoefen, G.A. Swayze, "Reflectance Spectroscopy of organic compounds: 1. Alkanes," Journal of Geophysical Research, vol. 114, pp. EO3001 1 to 19, (2009).
Inter Partes Review No. IPR2019-00910; Petition for Inter Partes Review of U.S. Pat. No. 9,757,040; *Apple Inc.* v. *Omni Medsci, Inc.*; pp. 1-96; dated Apr. 10, 2019.
Inter Partes Review No. IPR2019-00911; Petition for Inter Partes Review of U.S. Pat. No. 9,861,286; *Apple Inc.* v. *Omni Medsci, Inc.*; pp. 1-83; dated Apr. 10, 2019.

(56) **References Cited**

OTHER PUBLICATIONS

Inter Partes Review No. IPR2019-00912; Petition for Inter Partes Review of U.S. Pat. No. 9,885,698; *Apple Inc.* v. *Omni Medsci, Inc.*; pp. 1-94; dated Apr. 10, 2019.
Inter Partes Review No. IPR2019-00913; Petition for Inter Partes Review of U.S. Pat. No. 9,651,533; *Apple Inc.* v. *Omni Medsci, Inc.*; pp. 1-96; dated Apr. 10, 2019.
Inter Partes Review No. IPR2019-00914; Petition for Inter Partes Review of U.S. Pat. No. 9,861,286; *Apple Inc.* v. *Omni Medsci, Inc.*; pp. 1-90; dated Apr. 10, 2019.
Inter Partes Review No. IPR2019-00915; Petition for Inter Partes Review of U.S. Pat. No. 9,885,698; *Apple Inc.* v. *Omni Medsci, Inc.*; pp. 1-91; dated Apr. 10, 2019.
Inter Partes Review No. IPR2019-00916; Petition for Inter Partes Review of U.S. Pat. No. 9,651,533; *Apple Inc.* v. *Omni Medsci, Inc.*; pp. 1-90; dated Apr. 10, 2019.
Inter Partes Review No. IPR2019-00917; Petition for Inter Partes Review of U.S. Pat. No. 9,757,040; *Apple Inc.* v. *Omni Medsci, Inc.*; pp. 1-93; dated Apr. 10, 2019.
"Application Brief AB-070: The role of infrared microprobe analysis in forensic drug analysis," www.smithsdetection.com, Jun. 27, 2005.
Arnold, T., M. De Biasio, R. Leitner, "Near-Infrared Imaging Spectroscopy for Counterfeit Drug Detection," Next Generation Spectroscopic Technologies IV, edited by M. A. Daly, R.A. Crocombe, Proceedings of SPIE, vol. 8032, 80320Y-1 to 7, (2011).
J.G. Webster; Design of Pulse Oximeters; Medical Science Series; Taylor & Francis Group; CRC Press; Oct. 23, 1997; 260 pps.
H. Harry Asada et al.; Mobile Monitoring With Wearable Photoplethysmographic Biosensors; IEEE Engineering in Medicine and Biology Magazine, Jun. 2003; 13 pps.
United States District Court Eastern District of Texas Marshall Division; Defendant and Counter Claimant Apple Inc.'s Amended Answer, Affirmative Defenses, and Counterclaims to Complaint of Plaintiff and Counter Defendant Omni Medsci, Inc.; Document 38; Jul. 19, 2018; 32 pps.
Extended European Search Report for European Application No. 17156625.0 dated Mar. 20, 2017.
Vassif, N.A., et al., "In vivo high-resolution video-rate spectral-domain optical coherence tomography of the human retina and optic nerve", Optics Express, vol. 12, No. 3, Feb. 9, 2004, pp. 367-376.
U.S. Patent and Trademark Office, Office Action for U.S. Appl. No. 12/206,432, filed Sep. 8, 2008, Mohammed N, Islam, filed Mar. 12, 2009.
U.S. Patent and Trademark Office, Notice of Allowance and Fee(s) Due for U.S. Appl. No. 12/206,432, filed Sep. 8, 2008, Mohammed N. Islam, filed Aug. 28, 2009.
International Search Report and Written Opinion for International Application No. PCT/US2013/075736 dated Apr. 7, 2014.
International Preliminary Report on Patentability for International Application No. PCT/US2013/075736 dated Jul. 9, 2015.
Hazen, K.H., M.A. Arnold, G.W. Small, "Measurement of glucose and other analytes in undiluted human serum with near-infrared transmission spectroscopy," Analytica Chimica Acta, vol, 371, pp. 255-267 (1998).
Malin, S.F., T.L. Ruchti, T.B. Blank, S.N. Thennadil, S.L. Monfre, "Noninvasive prediction of glucose by near-infrared diffuse reflectance spectroscopy," Clinical Chemistry, vol. 45, No. 9, pp. 1651-1658 (1999).
Thennadil, S.N., J.L. Rennert, B.J. Wenzel, K.H. Hazen, T.L. Ruchti, M.B. Block, "Comparison of glucose concentration in interstitial fluid, and capillary and venous blood during rapid changes in blood glucose levels," Diabetes Technology & Therapeutics, vol. 3, No. 3, pp. 357-365 (2001).
Troy, T.L., S.N. Thennadil, "Optical properties of human skin in the near infrared wavelength range of 1000 to 2200nm," Journal of Biomedical Optics, vol. 6, No. 2, pp. 167-176, (2001).
Blank, T.B., T.L. Ruchti, A.D. Lorenz, S.L. Monfre, M.R. Makarewicz, M. Mattu, K.H. Hazen, "Clinical results from a non-invasive blood glucose monitor," Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring II, A.V. Priezzhev and G.L. Cote, Editors, Proceedings of SPIE, vol. 4624, pp. 1019 (2002).
Yeh, S-J, C.F. Hanna, O.S. Khalil, "Monitoring blood glucose changes in cutaneous tissue by temperature-modulated localized reflectance measurements," Clinical Chemistry, vol. 49, No. 6, pp. 924-934 (2003).
Marbach, R., T. Koschinsky, F.A. Gries, H.M. Heise, "Noninvasive blood glucose assay by near-infrared diffuse reflectance spectroscopy of the human inner lip," Applied Spectroscopy, vol. 47, No. 7, pp. 875-881 (1993).
Enejder, A.M.K., T.G. Scecina, J. Oh, M. Hunter, W.C. Shih, S. Sasic, G.L. Horowitz, M.S. Feld, "Raman spectroscopy for noninvasive glucose measurements," Journal of Biomedical Optics, vol. 10, No. 3, 031114 (2005).
Olesberg, J.T., L. Liu, V.V. Zee, M.A. Arnold, "In vivo near-infrared spectroscopy of rat skin tissue with varying blood glucose levels," Analytic Chemistry, vol. 78, No. 1, pp. 215-223 (2006).
Olesberg, J.T., M.A. Arnold, C. Mermelstein, J. Schmitz, J. Wagner, "Tunable laser diode system for noninvasive blood glucose measurements," Applied Spectroscopy, vol. 59, No. 12, pp. 1480-1484 (2005).
Harman-Boehm, I. A. Gal, A.M. Raykhman, J.D. Zahn, E. Naidis, Y. Mayzel, "Noninvasive glucose monitoring: a novel approach," Journal of Diabetes Science and Technology, vol. 3, No. 2 pp. 253-260 (2009).
Kim-K.D., G.S. Son, S.S. Lim, S.S. Lee, "Measurement of glucose level exploiting a relative optical absorption at discrete probe wavelengths," Japanese Journal of Applied Physics, vol. 48, 077001 (2009).
Smith, J.L., "The Pursuit of Noninvasive Glucose: Hunting the Deceitful Turkey," 2nd Edition, pp. 1-141 (2011).
Pezzaniti, J.L., T.W. Jeng, L. McDowell, G.M. Oosta, "Preliminary investigation of near-infrared spectroscopic measurements of urea, creatinine, glucose, protein and ketone in urine," Clinical Biochemistry, vol. 34, pp. 239-246 (2001).
Lussi, A., R. Hibst, R. Paulus, "Diagnodent: An optical method for caries detection," Journal of Dental Research, vol. 83, special issue C, pp. C80-C83 (2004).
Reese, E.L, E.E. Fisher, D.A. Horowitz, "Photoelectric densitometry of the circulation of the human dental pulp," The Journal of the Baltimore College of Dental Surgery, vol. 26, No. 1, pp. 6-18 (1971).
Zakian, C., I. Pretty, R. Ellwood, "Near-infrared hyperspectral imaging of teeth for dental caries detection," Journal of Biomedical Optics, vol. 16, No. 6, 064047 (2009).
Belikov, A.V., A.V. Skripnik, K.V. Shatilova, "Study of the dynamics of the absorption spectra of human tooth enamel and dentine under heating and ablation by submillisecond pulse radiation of an erbium laser with a generation wavelength of 2.79 um," Optics and Spectroscopy, vol. 109, No. 2, pp. 211-216 (2010).
Karlsson, L. "Caries detection methods based on changes in optical properties between healthy and carious tissue," International Journal of Dentistry, vol. 2010, Article ID 270729, 9 pages (2010).
Fried, D. M. Staninec, C.L. Darling, "Near-infrared imaging of dental decay at 1310nm," Journal of Laser Dentistry, vol. 18, No. 1, pp. 8-16 (2010).
Burmen, M. P. Usenik, A. Fidler, F. Pernus, B. Likar, "A construction of standardized near infrared hyper-spectral teeth database—a first step in the development of reliable diagnostic tool for quantification and early detection of caries," Lasers in Dentistry XVII, edited by P. Rechmann, D. Fried, Proceedings of SPIE, vol. 7884, Paper 78840E (2011).
Maia, A., L. Karlsson, W. Margulis, A. Gomes, "Evaluation of two imaging techniques: near-infrared transillumination and dental radiographs for the detection of early approximal enamel caries," Dentomaxillofacial Radiology, vol. 40, pp. 429-433 (2011).
Chung, S., D. Fried, M. Staninec, C.L. Darling, "Multispectral near-IR reflectance and transillumination imaging of teeth," Biomedical Optics Express, vol. 2, No. 10, pp. 2804-2814 (2011).

(56) **References Cited**

OTHER PUBLICATIONS

Chung, S., D. Fried, M. Staninec, C.L. Darling, "Near infrared imaging of teeth at wavelengths between 1200 and 1600nm," Proceedings of the Society of Photo Optical Instrument Engineering, paper 7884 (2011).
Staninec, M., S.M. Douglas, C.L. Darling, K. Chan, H. Kang, R. C. Lee, D. Fried, "Nondestructive clinical assessment of occlusal caries lesions using near-IR imaging methods," Lasers in Surgery and Medicine, vol. 43, No. 10, pp. 951-959 (2011).
Nishizawa, N., "Generation and application of high-quality supercontinuum sources," Optical Fiber Technology, vol. 18, pp. 394-402 (2012).
Slusher, Richart E., et al., "Large Raman gain and nonlinear phase shills in high-purity As2So3 chalcogenide fibers", J. Opt. Soc. Am. B, vol. 21, No. 6, Jun. 2004, pp. 1146-1155.
Malin, S.F ., T. L. Ruchti, T.B. Blank, S.N. Thennadil, S.L. Monfre, "Noninvasive prediction of glucose by near-infrared diffuse reflectance spectroscopy," Clincal Chemistry, vol. 45, No. 9, pp. 1651-1658 (1999).
Lussi, A., R. Hibst, R. Paulus, "Diagnodent: An optical method for caries detection," Journal of Dental Research, vol. 33, special issue C, pp. C80-C83 (2004).
Wang, Lohong V., Multiscale photoacoustic microscopy and computed tomography, Sep. 2009, Nature Photonics, vol. 3, pp. 503-509.
Drexler, C., Hirmer, M., Danilov, S., Giglberger, S., Putzger, J., Niklas, A., Jager, A., Hiller, K., Loftier, S., Schmalz, G., Redlich, B., Schulz, I., Monkman, G., Ganichev, S. "Infrared spectroscopy for clinical diagnosis of dental pulp vitality." Infrared, Millimeter, and Terahertz Waves (IRMMW-THz), 2012 37th International Conference on. IEEE (2012).
Hirmer, Marion, Danilov, Sergey, Giglberger, Stephan, Putzger, Jurgen, Niklas, Andreas, Jager, Andreas, Hiller, Karl-Anton, Loftier, Susanne, Schmalz, Gottfried, Redlich, Britta, Schulz, Irene, Monkman, Gareth, Ganichev, Sergey. "Spectroscopic Study of Human Teeth and Blood from Visible to Terahertz Frequencies for Clinical Diagnosis of Dental Pulp Vitality." Journal of Infrared, Millimeter, and Terahertz Waves 33.3 (2012): 366-375.
Li et al, A Wireless Reflective Pulse Oximeter with Digital Baseline Control for Unfiltered Photoplethysmograms, (Jun. 2012) IEEE Transactions on Biomedical Circuits and Systems, vol. 6, No. 3, 10 pages.
Humphreys et al., Noncontact Simultaneous Dual Wavelength Photoplethysmography: A Further Step Toward Noncontact Pulse Oximetry, (2007) Review of Scientific Instruments 78, 044304, American Institute of Physics, 6 pages.
Mendelson et al., A Wearable Reflectance Pulse Oximeter for Remote Physiological Monitoring, (Aug./Sep. 2006) Proceedings of the 28th IEEE EMBS Annual International Conference New York City, NY, 4 pages.
United States District Court Eastern District of Texas Marshall Division; *Omni Medsci, Inc.* vs. *Apple Inc.*; Civil Action No. 2:18-cv-00134 Jury Trial Demanded; Defendant's Invalidity Contentions; Aug. 28, 2018; 33 pps.
Islam, M. N., et al., "Broad bandwidths from frequency-shifting solitons in fibers", Optics Letters, vol. 14, No. 7, Apr. 1, 1989, pp. 370-372.
Islam, M. N., et al., "Femtosecond distributed soliton spectrum in fibers", J. Opt. Soc. Am. B, vol. 6, No. 6, Jun. 1989, pp. 1149-1158.
Busse, Lynda E., et al., "Design Parameters for Fluoride Multimode Fibers", Journal of Lightwave Technology, vol. 9, No. 7, Jul. 1991, pp. 828-831.
Wuthrich, Stefan, et al., "Optical damage thresholds at 2.94 um in fluoride glass fibers", Appled Optics, vol. 31, No. 27, Sep. 20, 1992, pp. 5833-5837.
Inoue, H., et al., "Computer simulation of the vibrational spectra and properties of fluoride glasses based on ZrF4", Journal of Non-Crystalline Solids, vol. 161, 1993, pp. 118-122.
Mizunami, Toru, et al., "Gain saturation characteristics of Raman amplification in silica and fluoride glass optical fibers", Optics Communications 97, 1993, pp. 74-78.
Desthieux, B., et al., "111 kW (0. 5 mJ) pulse amplification at 1.5 um using a gated cascade of three erbium-doped fiber amplifiers," Appl. Phys. Lett. vol. 63, Aug. 2, 1993, pp. 586-588.
Edwards, Glenn, et al., "Tissue ablation by a free-electron laser tuned to the amide II band", Nature, vol. 371, Sep. 29, 1994, pp. 416-419.
Borrelli, N. F., et al., "Resonant and non-resonant effects in photonic glasses", Journal of Non-Crystalline Solids 185, 1995, pp. 109-122.
Asobe, Masaki, et al., "Third-order nonlinear spectroscopy in As2S3 chalcogenide glass fibers", J. Appl. Phys. 77 (11), Jun. 1, 1995, pp. 5518-5523.
Jarman, Richard H., "Novel optical fiber lasers", Current Opinion in Solid State and Materials Science, 1996, pp. 199-203.
Iatridis, James C., et al., "Is the Nucleus Pulposus a Solid or a Fluid? Mechanical Behaviors of the Nucleus Pulposus of the Human Intervertebral Disc", Spine, vol. 21(10), May 15, 1996, pp. 1174-1184.
Asobe, Masaki, "Nonlinear Optical Properties of Chalcogenide Glass Fibers and Their Application to All-Optical Switching", Optical Fiber Technology, vol. 3, Article No. OF970214, 1997, pp. 142-148.
Smektala, F., et al., "Chalcogenide glasses with large non-linear refractive indices", Journal of Non-Crystalline Solids 239, 1998, pp. 139-142.
Hamilton, James D., et al., "High Frequency Ultrasound Imaging with Optical Arrays", IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol. 45, No. 1, Jan. 1998, pp. 216-235.
Hamilton, James D., et al., "High Frequency Ultrasound Imaging Using an Active Optical Detector", IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol. 45, No. 3, May 1998, pp. 719-727.
Nowak, G. A., et al., "Low-power high-efficiency wavelength conversion based on modulational instability in high-nonlinearity fiber," Optics Letters, vol. 23, No. 12, Jun. 15, 1998, pp. 936-938.
Cardinal, T., et al., "Non-linear optical properties of chalcogenide glasses in the system As—S—Se", Journal of Non-Crystalline Solids 256 & 257, 1999, pp. 353-360.
Lucas, Jacques, "Infrared glasses", Current Opinion in Solid State & Materials Science 4, 1999. pp. 181-187.
Sanghera, J. S., et al., Active and passive chalcogenide glass optical fibers for IR applications: a review, Journal of Non-Crystalline Solids 256 & 257, 1999, pp. 6-16.
Nishida, Yoshiki, et al., "Reliability of Fluoride Fiber Module for Optical Amplifier Use", IEEE Photonics Technology Letters, vol. 11, No. 12, Dec. 1999, pp. 1596-1598.
Nowak, George A., et al., "Stable supercontinuum generation in short lengths of conventional dispersion-shifted fiber", Applied Optics, vol. 38, No. 36, Dec. 20, 1999, pp. 7364-7369.
Urban, J. P. G., et al., "The Nucleus of the Intervertebral Disc from Development to Degeneration" Amer. Zool., vol. 40, 2000, pp. 53-61.
Hamilton, James D., et al., "High Frequency Optoacoustic Arrays Using Etalon Detection", IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol. 47, No. 1, Jan. 2000, pp. 160-169.
Ranka, Jinendra K., et al., "Visible continuum generation in air-silica microstructure optical fibers with anomalous dispersion at 800 nm", Optics Letters, vol. 25, No. 1, Jan. 1, 2000, pp. 25-27.
Boult, Maggi, et al., "Systematic Review of Percutaneous Endoscopic Laser Discectomy: Update and Re-appraisal", Australian Safety and Efficacy Register of New Interventional Procedures—Surgical Report No. 5, Feb. 2000, 49 pages.
Boult, Maggi, et aL, "Percutaneous Endoscopic Laser Discectomy", Systematic Review, Aust. N.Z.J. Surg., vol. 70, Apr. 7, 2000, pp. 475-479.
Camacho, Nancy P., et al., "FTIR Microscopic Imaging of Collagen and Proteoglycan in Bovine Cartilage," Biopolymers (Biospectroscopy), vol. 62, 2001, pp. 1-8.

(56) **References Cited**

OTHER PUBLICATIONS

Choi, Joon Y., et al, "Thermal, Mechanical, Optical, and Morphologic Changes in Bovine Nucleus Pulposus Induced by Nd:YAG (λ=1.32 um) Laser Irradiation", Lasers in Surgery and Medicine, vol. 28, 2001, pp. 248-254.
Hafez, M. I., et al., "The Effect of Irrigation on Peak Temperatures in Nerve Root, Dura, and Intervertebral Disc During Laser-Assisted Foraminoplasty", Lasers in Surgery and Medicine, vol. 29, 2001, pp. 33-37.
Jackson, Stuart D., et al., "Theory and numerical simulation of nth-order cascaded Raman fiber lasers", J. Opt. Soc. Am. B, vol. 18, No. 9, Sep. 2001, pp. 1297-1306.
Werle, Peter, et al., "Near- and mid-infrared laser-optical sensors for gas analysis", Optics and Lasers in Engineering 37, 2002, pp. 101-114.
Beck, Mattias, et al., "Continuous Wave Operation of a Mid-Infrared Semiconductor Laser at Room Temperature," Science vol. 295, www.sciencemag.org, Jan. 11, 2002, pp. 301-305.
Harbold, J. M., et al., "Highly nonlinear As—S—Se glasses for all-optical switching", Optics Letters, vol. 27, No. 2, Jan. 15, 2002, pp. 119-121.
Coen, Stephane, et al., "Supercontinuum generation by stimulated Raman scattering and parametric four-wave mixing in photonic crystal fibers", J. Opt. Soc. Am. B, vol. 19, No. 4, Apr. 2002, pp. 753-764.
Dudley, John M., et al., "Supercontinuum generation in air-silica microstructured fibers with nanosecond and femtosecond pulse pumping", J. Opt. Soc. Am. B, vol. 19, No. 4, Apr. 2002, pp. 765-771.
Harbold, Jeffrey M., et al., "Highly Nonlinear Ge—As—Se and. Ge—As—S—Se Glasses for All-Optical Switching", IEEE Photonics Technology Letters, vol. 14, No. 6, Jun. 2002, pp. 822-824.
Husakou, Anton V., et al, "Supercontinuum generation, four-wave mixing, and fission of higher-order solitons in photonic-crystal fibers", J. Opt. Soc. Am. B, vol. 19, No. 9, Sep. 2002, pp. 2171-2182.
Wadsworth, William J., et al., "Supercontinuum generation in photonic crystal fibers and optical fiber tapers: a novel light source", J. Opt. Soc. Am. B, vol. 19, No. 9, Sep. 2002, pp. 2148-2155.
Kumar, V.V. Ravi Kanth, et al, "Extruded soft glass photonic crystal fiber for ultrabroad supercontinuum generation", Optics Express, vol. 10, No. 25, Dec. 16, 2002, pp. 1520-1525.
Edwards, Glenn 8., el al., "Advantage of the Mark-III FEL for biophysical research and biomedical applications", J. Synchrotron Rad. vol. 10, 2003, pp. 354-357.
Nicholson, J. W., et al., "Pulsed and continuous-wave supercontinuum generation in highly nonlinear, dispersion-shifted fibers", Applied Physics B 77, 2003, pp. 211-218.
Sobol, Emil, et al., "Time-resolved, light scattering measurements of cartilage and comea denaturation due to free electron laser radiation", Journal of Biomedical Optics, vol. 8, No. 2, Apr. 2003, pp. 216-222.
Nicholson, J. W., et al., "All-fiber, octave-spanning supercontinuum", Optics Letters, vol. 28, No. 8, Apr. 15, 2003, pp. 643-645.
Faralli, S., et al., "Impact of Double Rayleigh Scattering Noise in Distributed Higher Order Raman Pumping Schemes", IEEE Photonics Technology Letters, vol. 15, No. 6, Jun. 2003, pp. 804-806.
"New and Emerging Techniques—Surgical, Rapid Review, Laser Discectomy", Australian Safety and Efficacy Register of New Interventional Procedures—Surgical, Jun. 2003, 12 pages.
Avdokhin, A. V., et al, "Continuous-wave, high-power, Raman continuum generation in holey fibers", Optics Letters, vol. 28, No. 15, Aug. 1, 2003, pp. 1353-1355.
Mussot, Amaud, el al., "Generation of a broadband single-mode supercontinuum in a conventional dispersion-shifted fiber by use of a subnanosecond microchip laser", Optics Letters, vol. 28, No. 19, Oct. 1, 2003, pp. 1820-1822.
Slusher, Richard, et al., "Highly nonlinear composite chalcogenide/polymer fibers", OSA 2004, 1 page.
Thongtrangan, Issada, et al., "Minimally invasive spinal surgery: a historical perspective", Neurosurg. Focus, vol. 16, Aricle 13, Jan. 2004, pp. 1-10.
Valery V. Tuchin et al.; Finger Tissue Model and Blood Perfused Skin Tissue Phantom; Proc. of SPIE vol. 7898; 2011; pp. 1-11.
Zenzo Miwa et al.; Pulpal Blood Flow in Vital and Nonvital Young Permanent Teeth Measured by Transmitted-Light Photoplethysmography: A Pilot Study; Pediatric Dentistry 2002; pp. 1-5.
Hirmer, Marion, Danilov, Sergey, Giglberger, Stephan, Putzger, Jurgen, Niklas, Andreas, Jager, Andreas, Hiller, Karl-Anton, Loffler, Susanne, Schmalz, Gottfried, Redlich, Britta, Schulz, Irene, Monkman, Gareth, Ganichev, Sergey. "Spectroscopic Study of Human Teeth and Blood from Visible to Terahertz Frequencies for Clinical Diagnosis of Dental Pulp Vitality." Journal of Infrared, Millimeter, and Terahertz Waves 33.3 (2012): 366-375.


WAVELENGTH (μm)
2.7
3.33
4.0
5.0
10
0.8
0.6
0.4
0.2
TRANSMITTANCE
100
3000
2000
1000
WAVENUMBER (cm-1)

FIG. 1


200
201
202
203
1587
1750
2120
2270
2320
ABSORBANCE
0.06
0.05
0.04
0.03
0.02
0.01
0.00
-0.01
-0.02
1500
1600
1700
1800
1900
2000
2100
2200
2300
2400
WAVELENGTH (nm)

FIG. 2


300
301
302
NORMALIZED ABSORBANCE
1.0
0.8
0.6
0.4
0.2
0.0
1500
1600
1700
1800
1900
2000
2100
2200
2300
2400
2500
WAVELENGTH (nm)

FIG. 3A


350
06
05
04
03
02
01
0
OPTICAL DENSITY UNITS
351
353
352
700
800
900
1000
1100
1200
1300
WAVELENGTH (nm)

FIG. 3B


401
25 mg/ml
50 mg/ml
75 mg/ml
100 mg/ml
125 mg/ml
~2.12 µm
~2.27 µm
~2.32 µm
0.08
0.06
0.04
0.02
0.00
-0.02
-0.04
ABSORBANCE
2100
2200
2300
2400
WAVELENGTH (nm)

FIG. 4A


402
2.5mg/ml
5 mg/ml
250 mg/dl
500mg/dl
25 mg/ml
50 mg/ml
75 mg/ml
100 mg/ml
125 mg/ml
~1587 nm
~1750 nm
0.30
0.25
0.20
0.15
0.10
0.05
0.00
-0.05
ABSORBANCE
1550
1600
1650
1700
1750
1800
WAVELENGTH (nm)

FIG. 4B


500
501
502
503
504
505
506
507
200
100
0
-100
-200
EXTINCTION (μAU mM⁻¹ mm⁻¹)
2.05
2.10
2.15
2.20
2.25
2.30
2.35
2.40
WAVELENGTH (μm)

FIG. 5


REGION OF INTEREST
2-2.5 μm
600
0.8
0.6
0.4
0.2
TRANSMITTANCE
16
12
8
4
WAVELENGTH (μm)

FIG. 6


0.05
0.04
0.03
0.02
0.01
0.00
-0.01
-0.02
DIFFERENCE ABSORBANCE, (mm⁻¹)
2100
2200
2300
2400
WAVELENGTH (nm)
701
702
703
704
705
706

FIG. 7


800
0.003
0.002
0.001
-0.001
-0.002
-0.003
DIFFERENCE DERIVATIVE (mm-1)
801
803
2100
2200
2300
2400
WAVELENGTH (nm)
0.006
0.004
0.002
0.000
-0.002
-0.004
-0.006
DIFFERENCE DERIVATIVE (mm-1)
804
802
805
2100
2200
2300
2400
WAVELENGTH (nm)

FIG. 8A


2nd C-H
1st C-H
825
O
O
O
O
O
C
H
ABSORBANCE
0.9
0.8
0.7
0.6
0.5
0.4
1000
1500
2000
2500
WAVELENGTH (nm)

FIG. 8B



FIG. 8C


875
880
879
876
877
878
0.8
0.6
0.4
0.2
0
REFLECTANCE
1,500
2,000
2,500
WAVELENGTH (nm)

FIG. 8D



FIG. 9


1000
ABSORPTION COEFFICIENT (cm⁻¹)
100
10
1
0.1
WAVELENGTH (nm)
1000
1200
1400
1600
1800
2000
2200
2400
2600
1587
1750
2120
2270
2320
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1210 nm
1720 nm

FIG. 10



FIG. 11



FIG. 12


1320
LIGHT INPUT
1327
1326 LENS/MIRROR ASSEMBLY
CLAMP/ MOUNT
1323
1325 MULTIPLE LENS ARRAY AND/OR CYLINDRICAL LENS WINDOW
COOLING FLUID IN
1324
COOLING FLUID OUT
1321
1322 SAPHENOUS VEIN
SAPHENO-FEMORAL JUNCTION

FIG. 13A



FIG. 13B


1400
ATTENUATION COEFFICIENT [mm-1]
3.0
2.5
2.0
1.5
1.0
S4(C)
S5(A)
S3(A)
S6(B)
S2(B)
S7(D)
S4(C)
S3(A)
S2(B)
S6(B)
S5(A)
S7(D)
1402
1404
1.0
1.5
2.0
2.5
1403
1405
1406
1401
ABSORBANCE
0.02
0.015
0.01
0.005
0
-0.005
-0.01
-0.015
-0.02
5g/dL
1g/dL
5g/dL
1g/dL
1.5
1.7
1.9
2.1
2.3
2.5
WAVELENGTH [μm]
ABSORBANCE OF GLUCOSE (d=0.75mm)

FIG. 14


1500
1511
LIGHT SOURCE
1513
REFLECTANCE SPECTROMETER / RECEIVER / CAMERA
1503
1504
1505
1501
1506
1512
TRANSMISSION SPECTROMETER / RECEIVER / CAMERA
1507
1502
1508
1509
1510

FIG. 15


1600
EXTINCTION (cm^{-1})
180
160
140
120
100
80
60
40
20
0
600
800
1000
1200
1400
1600
1800
2000
2200
2400
2600
WAVELENGTH (nm)
1601
ATTENUATION COEFFICIENT OF ENAMEL
WATER ABSORPTION
1602

FIG. 16A


1650
600
500
400
300
1652
1651
K_{p2} cm^{-1}
1.2
1.6
2.0
2.4
WAVELENGTH (μm)

FIG. 16B


1700
1704
1701
1702
1703
0.6
0.5
0.4
0.3
0.2
0.1
0
REFLECTANCE
1000
1500
2000
2500
WAVELENGTH (nm)

FIG. 17


1806
LIGHT INPUT
DETECTOR OUTPUT
1807
1800
1804
1805
1801
1802
1803
1808

FIG. 18A


1850
1851
1852
1852
1852
1853
1853
1853
1854
1854
1854
1855
1855
1855
1856
1858
1857
1859
LIGHT INPUT
DETECTOR OUTPUT

FIG. 18B


1900
1901
FAC+SAC
1902
SPATIAL INTERLEAVING OR COMBINING
1903
POLARIZATION BEAM COMBINING
1904
MODULAR MULTI-PURPOSE LASER-HEAD
CUSTOM BEAM SHAPING MODULE
1905
FIBER COUPLING
1907
DIRECT DIODE APPLICATION
1906

FIG. 19


2000
SEED LASER
FIBER AMPLIFIER
SC GENERATION
2002
2007
PULSE ELECTRONICS
2001
2003
2004
2005
2006
2008
2009

FIG. 20


2100
2105
2104
2101
2103
2107
2108
2109
2110
2111
2113
2112
2114
2115
PRE-AMP
2102
POWER-AMP
2106

FIG. 21


2200
60
55
50
45
40
35
1400
1600
1800
2000
2200
2400
2600
WAVELENGTH (nm)
RELATIVE INTENSITY (dB)

FIG. 22


2300
PULSE ELECTRONICS
2301
2302
2305
2306
2303
2307
2308
2304
2309
2310
2350
PULSE ELECTRONICS
2351
2352
2355
2356
2353
2357
2358
2354
2359
2360

FIG. 23


2400
2401
2402
2403
2404
BAN
OR
PAN
2405
2406
WIRELESS TRANSMISSION
(E.G. WIFI,
CELLULAR
NETWORK)
2407
"CLOUD"
-RECEIVE
-BUFFER/STORE
-PROCESS
-STORE RESULTS
-TRANSMIT
2408
RETURN DATA
2409
HEALTHCARE
PROVIDER
2410
OTHER
DESIGNATED
RECIPIENTS

FIG. 24


2500
2501
SC SOURCE
CHOPPER
2503
2502
5 m
1204
SAMPLE
2506
INPUT SLIT
MONOCHROMATOR
OUTPUT SLIT
2507
InSb DETECTOR +
PRE-AMP
2508
LOCK-IN
AMPLIFIER
2505

FIG. 25


2600
CONTROL FUNCTION
ON-LINE MONITORING OF PROCESS PARAMETERS
2606
PROCESS OUTPUT
2603
CLOSED LOOP CONTROL (PROCESS PARAMETERS ONLY)
2605
TEMPERATURE
TIME
PRESSURE
ETC.
MANUFACTURING PROCESS
2601
PROCESS CONTROL
2604
PROCESS FEED
2602

FIG. 26

SEMICONDUCTOR DIODES-BASED PHYSIOLOGICAL MEASUREMENT DEVICE WITH IMPROVED SIGNAL-TO-NOISE RATIO

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 16/272,069 filed Feb. 11, 2019, which is a continuation of U.S. application Ser. No. 16/029,611 filed Jul. 8, 2018 (now U.S. Pat. No. 10,201,283), which is a continuation of U.S. application Ser. No. 15/888,052 filed Feb. 4, 2018 (now U.S. Pat. No. 10,136,819), which is a continuation of U.S. application Ser. No. 15/212,549 filed Jul. 18, 2016 (now U.S. Pat. No. 9,885,698), which is a continuation of U.S. application Ser. No. 14/650,897 filed Jun. 10, 2015 (now U.S. Pat. No. 9,494,567), which is a U.S. National Phase of PCT/US2013/075700 filed Dec. 17, 2013, which claims the benefit of U.S. provisional application Ser. No. 61/747,472 filed Dec. 31, 2012, the disclosures of all of which are hereby incorporated in their entirety by reference herein.

This application is also a continuation of U.S. application Ser. No. 16/004,359 filed Jun. 9, 2018, which is a continuation of U.S. application Ser. No. 14/109,007 filed Dec. 17, 2013 (now U.S. Pat. No. 9,993,159), which claims the benefit of U.S. provisional application Ser. No. 61/747,553 filed Dec. 31, 2012, the disclosures of all of which are hereby incorporated in their entirety by reference herein.

This application is also a continuation of U.S. application Ser. No. 16/188,194 filed Nov. 12, 2018, which is a continuation of U.S. application Ser. No. 16/004,154 filed Jun. 8, 2018 (now U.S. Pat. No. 10,126,283), which is a continuation of U.S. application Ser. No. 15/855,201 filed Dec. 27, 2017 (now U.S. Pat. No. 9,995,722), which is a continuation of U.S. application Ser. No. 15/711,907 filed Sep. 21, 2017 (now U.S. Pat. No. 9,897,584), which is a divisional of U.S. application Ser. No. 15/357,225 filed Nov. 21, 2016 (now U.S. Pat. No. 9,797,876), which is a continuation of U.S. application Ser. No. 14/650,981 filed Jun. 10, 2015 (now U.S. Pat. No. 9,500,634), which is the U.S. national phase of PCT Application No. PCT/US2013/075767 filed Dec. 17, 2013, which claims the benefit of U.S. provisional application Ser. No. 61/747,485 filed Dec. 31, 2012, the disclosures of all of which are hereby incorporated by reference in their entirety.

This application is also a continuation of U.S. application Ser. No. 16/241,628 filed Jan. 7, 2019, which is a continuation of U.S. Ser. No. 16/015,737 filed Jun. 22, 2018 (now U.S. Pat. No. 10,172,523), which is a continuation of U.S. Ser. No. 15/594,053 filed May 12, 2017 (now U.S. Pat. No. 10,188,299), which is a continuation of U.S. application Ser. No. 14/875,709 filed Oct. 6, 2015 (now U.S. Pat. No. 9,651,533), which is a continuation of U.S. application Ser. No. 14/108,986 filed Dec. 17, 2013 (now U.S. Pat. No. 9,164,032), which claims the benefit of U.S. provisional application Ser. No. 61/747,487 filed Dec. 31, 2012, the disclosures of all of which are hereby incorporated in their entirety by reference herein.

This application is also a continuation of U.S. application Ser. No. 16/284,514 filed Feb. 25, 2019, which is a continuation of U.S. application Ser. No. 16/016,649 filed Jun. 24, 2018 (now U.S. Pat. No. 10,213,113), which is a continuation of U.S. application Ser. No. 15/860,065 filed Jan. 2, 2018 (now U.S. Pat. No. 10,098,546), which is a Continuation of U.S. application Ser. No. 15/686,198 filed Aug. 25, 2017 (now U.S. Pat. No. 9,861,286), which is a continuation of U.S. application Ser. No. 15/357,136 filed Nov. 21, 2016 (now U.S. Pat. No. 9,757,040), which is a continuation of U.S. application Ser. No. 14/651,367 filed Jun. 11, 2015 (now U.S. Pat. No. 9,500,635), which is the U.S. national phase of PCT Application No. PCT/US2013/075736 filed Dec. 17, 2013, which claims the benefit of U.S. provisional application Ser. No. 61/747,477 filed Dec. 31, 2012 and U.S. provisional application Ser. No. 61/754,698 filed Jan. 21, 2013, the disclosures of all of which are hereby incorporated by reference in their entirety.

This application is related to U.S. provisional application Ser. No. 61/747,477 filed Dec. 31, 2012; Ser. No. 61/747,481 filed Dec. 31, 2012; Ser. No. 61/747,485 filed Dec. 31, 2012; Ser. No. 61/747,487 filed Dec. 31, 2012; Ser. No. 61/747,492 filed Dec. 31, 2012; Ser. No. 61/747,553 filed Dec. 31, 2012; and Set. No. 61/754,698 filed Jan. 21, 2013, the disclosures of all of which are hereby incorporated in their entirety by reference herein.

This application is also related to International Application PCT/US2013/075736 entitled Short-Wave Infrared Super-Continuum Lasers For Early Detection Of Dental Caries; U.S. application Ser. No. 14/108,995 filed Dec. 17, 2013 entitled Focused Near-Infrared Lasers For Non-Invasive Vasectomy And Other Thermal Coagulation Or Occlusion Procedures (U.S. Pat. App. Pub. No. US2014/0188092A1); International Application PCT/US2013/075767 entitled Short-Wave Infrared Super-Continuum Lasers For Natural Gas Leak Detection, Exploration, And Other Active Remote Sensing Applications; U.S. application Ser. No. 14/108,986 filed Dec. 17, 2013 entitled Short-Wave Infrared Super-Continuum Lasers For Detecting Counterfeit Or Illicit Drugs And Pharmaceutical Process Control (now U.S. Pat. No. 9,164,032); U.S. application Ser. No. 14/108,974 filed Dec. 17, 2013 entitled Non-Invasive Treatment Of Varicose Veins (U.S. Pat. App. Pub. No. US2014/018894A1); and U.S. application Ser. No. 14/109,007 filed Dec. 17, 2013 entitled Near-Infrared Super-Continuum Lasers For Early Detection Of Breast And Other Cancers (now U.S. Pat. No. 9,993,159), the disclosures of all of which are hereby incorporated in their entirety by reference herein.

BACKGROUND

With the growing obesity epidemic, the number of individuals with diabetes is also increasing dramatically. For example, there are over 200 million people who have diabetes. Diabetes control requires monitoring of the glucose level, and most glucose measuring systems available commercially require drawing of blood. Depending on the severity of the diabetes, a patient may have to draw blood and measure glucose four to six times a day. This may be extremely painful and inconvenient for many people. In addition, for some groups, such as soldiers in the battlefield, it may be dangerous to have to measure periodically their glucose level with finger pricks.

Thus, there is an unmet need for non-invasive glucose monitoring (e.g., monitoring glucose without drawing blood). The challenge has been that a non-invasive system requires adequate sensitivity and selectivity, along with repeatability of the results. Yet, this is a very large market, with an estimated annual market of over $10B in 2011 for self-monitoring of glucose levels.

One approach to non-invasive monitoring of blood constituents or blood analytes is to use near-infrared spectroscopy, such as absorption spectroscopy or near-infrared diffuse reflection or transmission spectroscopy. Some attempts

have been made to use broadband light sources, such as tungsten lamps, to perform the spectroscopy. However, several challenges have arisen in these efforts. First, many other constituents in the blood also have signatures in the near-infrared, so spectroscopy and pattern matching, often called spectral fingerprinting, is required to distinguish the glucose with sufficient confidence. Second, the non-invasive procedures have often transmitted or reflected light through the skin, but skin has many spectral artifacts in the near-infrared that may mask the glucose signatures. Moreover, the skin may have significant water and blood content. These difficulties become particularly complicated when a weak light source is used, such as a lamp. More light intensity can help to increase the signal levels, and, hence, the signal-to-noise ratio.

As described in this disclosure, by using brighter light sources, such as fiber-based supercontinuum lasers, superluminescent laser diodes, light-emitting diodes or a number of laser diodes, the near-infrared signal level from blood constituents may be increased. By shining light through the teeth, which have fewer spectral artifacts than skin in the near-infrared, the blood constituents may be measured with less interfering artifacts. Also, by using pattern matching in spectral fingerprinting and various software techniques, the signatures from different constituents in the blood may be identified. Moreover, value-add services may be provided by wirelessly communicating the monitored data to a handheld device such as a smart phone, and then wirelessly communicating the processed data to the cloud for storing, processing, and transmitting to several locations.

SUMMARY OF EXAMPLE EMBODIMENTS

In one embodiment, a smart phone or tablet comprises one or more laser diodes configured to be pulsed and to generate light having one or more optical wavelengths, wherein at least a portion of the one or more optical wavelengths is a near-infrared wavelength between 700 nanometers and 2500 nanometers. A first one or more lenses is configured to receive a portion of the light from the one or more laser diodes and to direct at least some portion of the received light to tissue. An array of laser diodes is configured to be pulsed and to generate light having one or more optical wavelengths, wherein at least a portion of the one or more optical wavelengths is a near-infrared wavelength between 700 nanometers and 2500 nanometers. A second one or more lenses is configured to receive a portion of the light from the array of laser diodes, the array of laser diodes and the second one or more lenses configured to form the light into a plurality of spots and to direct at least some of the spots to tissue. An infrared camera is configured to be synchronized to the at least one of the one or more laser diodes to receive at least a portion of light reflected from the tissue from at least one of the one or more laser diodes, wherein the infrared camera generates data based at least in part on the received light. The infrared camera is further configured to be synchronized to the array of laser diodes to receive light from at least a portion of the plurality of spots reflected from the tissue, and wherein the infrared camera generates additional data based at least in part on the received light. The infrared camera is further configured to: receive light while the one or more laser diodes and the array of laser diodes are off and convert the received light into a first signal; and receive light while at least some of the one or more laser diodes or some of the array of laser diodes are on, and convert the received light into a second signal, the received light including at least a part of the portion of the light from the at least one of the one or more laser diodes reflected from the tissue, or at least a part of the portion of the light from the array of laser diodes reflected from the tissue. The smart phone or tablet is configured to generate a two-dimensional or three-dimensional image using a difference between the first signal and the second signal, and using at least part of the data or at least part of the additional data from the infrared camera. The smart phone or tablet further comprises a wireless receiver, a wireless transmitter, a display, a voice input module, and a speaker.

Embodiments may include a smart phone or tablet comprising one or more laser diodes configured to be pulsed and to generate light having one or more optical wavelengths, wherein at least a portion of the one or more optical wavelengths is a near-infrared wavelength between 700 nanometers and 2500 nanometers. A first one or more lenses is configured to receive a portion of the light from the one or more laser diodes and to direct at least some portion of the received light to tissue. An array of laser diodes is configured to be pulsed and to generate light having one or more optical wavelengths, wherein at least a portion of the one or more optical wavelengths is a near-infrared wavelength between 700 nanometers and 2500 nanometers. A second one or more lenses is configured to receive a portion of the light from the array of laser diodes, the array of laser diodes and the second one or more lenses configured to form the light into a plurality of spots and to direct at least some of the spots to tissue. An infrared camera is configured to be synchronized to the at least one of the one or more laser diodes to receive at least a portion of light reflected from the tissue from at least one of the one or more laser diodes, and wherein the infrared camera generates data based at least in part on the received light. The infrared camera is further configured to be synchronized to the array of laser diodes to receive light from at least a portion of the plurality of spots reflected from the tissue, wherein the infrared camera generates additional data based at least in part on the received light. The smart phone or tablet is configured to generate a two-dimensional or three-dimensional image using at least part of the data or part of the additional data from the infrared camera. The smart phone or tablet further comprises a wireless receiver, a wireless transmitter, a display, a voice input module, and a speaker.

In one embodiment, a smart phone or tablet comprises one or more laser diodes configured to be pulsed and to generate light having one or more optical wavelengths, wherein at least a portion of the one or more optical wavelengths is a near-infrared wavelength between 700 nanometers and 2500 nanometers. A first one or more lenses is configured to receive a portion of the light from the one or more laser diodes and to direct at least some portion of the received light to tissue. An array of laser diodes is configured to be pulsed and to generate light having one or more optical wavelengths, wherein at least a portion of the one or more optical wavelengths is a near-infrared wavelength between 700 nanometers and 2500 nanometers. A second one or more lenses is configured to receive a portion of the light from the array of laser diodes, the array of laser diodes and the second one or more lenses configured to form the light into a plurality of spots and to direct at least some of the spots to tissue, wherein the plurality of spots are also formed at least in part by using an assembly in front of the array of laser diodes. An infrared camera is configured to be synchronized to the at least one of the one or more laser diodes to receive at least a portion of light reflected from the tissue from at least one of the one or more laser diodes, wherein the infrared camera generates data based at least in part on the

received light. The infrared camera is further configured to be synchronized to the array of laser diodes to receive light from at least a portion of the plurality of spots reflected from the tissue, wherein the infrared camera generates additional data based at least in part on the received light. The smart phone or tablet is configured to generate a two-dimensional or three-dimensional image using at least part of the data or part of the additional data from the infrared camera. The smart phone or tablet further comprises a wireless receiver, a wireless transmitter, a display, a voice input module, and a speaker.

BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding of the present disclosure, and for further features and advantages thereof, reference is now made to the following description taken in conjunction with the accompanying drawings, in which:

FIG. **1** plots the transmittance versus wavenumber for glucose in the mid-wave and long-wave infrared wavelengths between approximately 2.7 to 12 microns.

FIG. **2** illustrates measurements of the absorbance of different blood constituents, such as glucose, hemoglobin, and hemoglobin A1c. The measurements are done using an FTIR spectrometer in samples with a 1 mm path length.

FIG. **3**A shows the normalized absorbance of water and glucose (not drawn to scale). Water shows transmission windows between about 1500-1850 nm and 2050-2500 nm.

FIG. **3**B illustrates the absorbance of hemoglobin and oxygenated hemoglobin overlapped with water.

FIG. **4**A shows measured absorbance in different concentrations of glucose solution over the wavelength range of about 2000 to 2400 nm. This data is collected using a SWIR super-continuum laser with the sample path length of about 1.1 mm.

FIG. **4**B illustrates measured absorbance in different concentrations of glucose solution over the wavelength range of about 1550 to 1800 nm. The data is collected using a SWIR super-continuum laser with a sample path length of about 10 mm.

FIG. **5** illustrates the spectrum for different blood constituents in the wavelength range of about 2 to 2.45 microns (2000 to 2450 nm).

FIG. **6** shows the transmittance versus wavelength in microns for the ketone 3-hydroxybutyrate. The wavelength range is approximately 2 to 16 microns.

FIG. **7** illustrates the optical absorbance for ketones as well as some other blood constituents in the wavelength range of about 2100 to 2400 nm.

FIG. **8**A shows the first derivative spectra of ketone and protein at concentrations of 10 g/L (left). In addition, the first derivative spectra of urea, creatinine, and glucose are shown on the right at concentrations of 10 g/L.

FIG. **8**B illustrates the near infrared absorbance for triglyceride.

FIG. **8**C shows the near-infrared reflectance spectrum for cholesterol.

FIG. **8**D illustrates the near-infrared reflectance versus wavelength for various blood constituents, including cholesterol, glucose, albumin, uric acid, and urea.

FIG. **9** shows a schematic of the human skin. In particular, the dermis may comprise significant amounts of collagen, elastin, lipids, and water.

FIG. **10** illustrates the absorption coefficients for water (including scattering), adipose, collagen, and elastin.

FIG. **11** shows the dorsal of the hand, where a differential measurement may be made to at least partially compensate for or subtract out the skin interference.

FIG. **12** shows the dorsal of the foot, where a differential measurement may be made to at least partially compensate for or subtract out the skin interference.

FIG. **13**A shows an embodiment that may comprise multiple collimated or focused light beams.

FIG. **13**B illustrates a typical human nail tissue structure and the capillary vessels below it.

FIG. **14** shows the attenuation coefficient for seven nail samples that are allowed to stand in an environment with a humidity level of 14%. These coefficients are measured using an FTIR spectrometer over the near-infrared wavelength range of approximately 1 to 2.5 microns. Below is also included the spectrum of glucose.

FIG. **15** illustrates the structure of a tooth.

FIG. **16**A shows the attenuation coefficient for dental enamel and water versus wavelength from approximately 600 nm to 2600 nm.

FIG. **16**B illustrates the absorption spectrum of intact enamel and dentine in the wavelength range of approximately 1.2 to 2.4 microns.

FIG. **17** shows the near infrared spectral reflectance over the wavelength range of approximately 800 nm to 2500 nm from an occlusal tooth surface. The black diamonds correspond to the reflectance from a sound, intact tooth section. The asterisks correspond to a tooth section with an enamel lesion. The circles correspond to a tooth section with a dentine lesion.

FIG. **18**A illustrates a clamp design of a human interface to cap over one or more teeth and perform a non-invasive measurement of blood constituents.

FIG. **18**B shows a mouth guard design of a human interface to perform a non-invasive measurement of blood constituents.

FIG. **19** illustrates a block diagram or building blocks for constructing high power laser diode assemblies.

FIG. **20** shows a platform architecture for different wavelength ranges for an all-fiber-integrated, high powered, super-continuum light source.

FIG. **21** illustrates one embodiment of a short-wave infrared (SWIR) super-continuum (SC) light source.

FIG. **22** shows the output spectrum from the SWIR SC laser of FIG. **21** when about 10 m length of fiber for SC generation is used. This fiber is a single-mode, non-dispersion shifted fiber that is optimized for operation near 1550 nm.

FIG. **23** illustrates high power SWIR-SC lasers that may generate light between approximately 1.4-1.8 microns (top) or approximately 2-2.5 microns (bottom).

FIG. **24** schematically shows that the medical measurement device can be part of a personal or body area network that communicates with another device (e.g., smart phone or tablet) that communicates with the cloud. The cloud may in turn communicate information with the user, healthcare providers, or other designated recipients.

FIG. **25** shows the experimental set-up for a reflection-spectroscopy based stand-off detection system.

FIG. **26** shows what might be an eventual flow-chart of a smart manufacturing process.

DETAILED DESCRIPTION

As required, detailed embodiments of the present disclosure are disclosed herein; however, it is to be understood that the disclosed embodiments are merely exemplary of the

disclosure that may be embodied in various and alternative forms. The figures are not necessarily to scale; some features may be exaggerated or minimized to show details of particular components. Therefore, specific structural and functional details disclosed herein are not to be interpreted as limiting, but merely as a representative basis for teaching one skilled in the art to variously employ the present disclosure.

Various ailments or diseases may require measurement of the concentration of one or more blood constituents. For example, diabetes may require measurement of the blood glucose and HbA1c levels. On the other hand, diseases or disorders characterized by impaired glucose metabolism may require the measurement of ketone bodies in the blood. Examples of impaired glucose metabolism diseases include Alzheimer's, Parkinson's, Huntington's, and Lou Gehrig's or amyotrophic lateral sclerosis (ALS). Techniques related to near-infrared spectroscopy or hyper-spectral imaging may be particularly advantageous for non-invasive monitoring of some of these blood constituents.

Hyper-spectral images may provide spectral information to identify and distinguish between spectrally similar materials, providing the ability to make proper distinctions among materials with only subtle signature differences. In the SWIR wavelength range, numerous gases, liquids and solids have unique chemical signatures, particularly materials comprising hydro-carbon bonds, O—H bonds, N—H bonds, etc. Therefore, spectroscopy in the SWIR may be attractive for stand-off or remote sensing of materials based on their chemical signature, which may complement other imaging information.

One embodiment of remote sensing that is used to identify and classify various materials is so-called "hyper-spectral imaging." Hyper-spectral sensors may collect information as a set of images, where each image represents a range of wavelengths over a spectral band. Hyper-spectral imaging may deal with imaging narrow spectral bands over an approximately continuous spectral range. As an example, in hyper-spectral imaging the sun may be used as the illumination source, and the daytime illumination may comprise direct solar illumination as well as scattered solar (skylight), which is caused by the presence of the atmosphere. However, the sun illumination changes with time of day, clouds or inclement weather may block the sun light, and the sun light is not accessible in the night time. Therefore, it would be advantageous to have a broadband light source covering the SWIR that may be used in place of the sun to identify or classify materials in remote sensing or stand-off detection applications.

In one embodiment, a SWIR camera or infrared camera system may be used to capture the images. The camera may include one or more lenses on the input, which may be adjustable. The focal plane assemblies may be made from mercury cadmium telluride material (HgCdTe), and the detectors may also include thermo-electric coolers. Alternately, the image sensors may be made from indium gallium arsenide (InGaAs), and CMOS transistors may be connected to each pixel of the InGaAs photodiode array. The camera may interface wirelessly or with a cable (e.g., USB, Ethernet cable, or fiber optics cable) to a computer or tablet or smart phone, where the images may be captured and processed. These are a few examples of infrared cameras, but other SWIR or infrared cameras may be used and are intended to be covered by this disclosure.

Described herein are just some examples of the beneficial use of near-infrared or SWIR lasers for active remote sensing or hyper-spectral imaging. However, many other spectroscopy and identification procedures can use the near-infrared or SWIR light consistent with this disclosure and are intended to be covered by the disclosure. As one example, the fiber-based super-continuum lasers may have a pulsed output with pulse durations of approximately 0.5-2 nsec and pulse repetition rates of several Megahertz. Therefore, the active remote sensing or hyper-spectral imaging applications may also be combined with LIDAR-type applications. Namely, the distance or time axis can be added to the information based on time-of-flight measurements. For this type of information to be used, the detection system would also have to be time-gated to be able to measure the time difference between the pulses sent and the pulses received. By calculating the round-trip time for the signal, the distance of the object may be judged. In another embodiment, GPS (global positioning system) information may be added, so the active remote sensing or hyper-spectral imagery would also have a location tag on the data. Moreover, the active remote sensing or hyper-spectral imaging information could also be combined with two-dimensional or three-dimensional images to provide a physical picture as well as a chemical composition identification of the materials. These are just some modifications of the active remote sensing or hyper-spectral imaging system described in this disclosure, but other techniques may also be added or combinations of these techniques may be added, and these are also intended to be covered by this disclosure.

Described herein are just some examples of the beneficial use of near-infrared or SWIR lasers for active remote sensing or hyper-spectral imaging. However, many other spectroscopy and identification procedures can use the near-infrared or SWIR light consistent with this disclosure and are intended to be covered by the disclosure. As one example, the fiber-based super-continuum lasers may have a pulsed output with pulse durations of approximately 0.5-2 nsec and pulse repetition rates of several Megahertz. Therefore, the active remote sensing or hyper-spectral imaging applications may also be combined with LIDAR-type applications. Namely, the distance or time axis can be added to the information based on time-of-flight measurements. For this type of information to be used, the detection system would also have to be time-gated to be able to measure the time difference between the pulses sent and the pulses received. By calculating the round-trip time for the signal, the distance of the object may be judged. In another embodiment, GPS (global positioning system) information may be added, so the active remote sensing or hyper-spectral imagery would also have a location tag on the data. Moreover, the active remote sensing or hyper-spectral imaging information could also be combined with two-dimensional or three-dimensional images to provide a physical picture as well as a chemical composition identification of the materials. These are just some modifications of the active remote sensing or hyper-spectral imaging system described in this disclosure, but other techniques may also be added or combinations of these techniques may be added, and these are also intended to be covered by this disclosure.

In some instances, it may be desirable to create multiple locations of focused light on the varicose vein. For example, the speed of the treatment may be increased by causing thermal coagulation or occlusion at multiple locations. Multiple collimated or focused light beams may be created in one assembly. In this embodiment, optionally a surface cooling apparatus may be used, where a cooling fluid may be flowed either touching or in close proximity to the skin. Also, in this particular embodiment a cylindrical assembly may optionally be used, where the cylindrical length may be

several millimeters in length and defined by a clamp or mount placed on or near the leg. In one embodiment, a window and/or lenslet array is also shown on the cylindrical surface for permitting the light to be incident on the skin and varicose vein at multiple spots. The lenslet array may comprise circular, spherical or cylindrical lenses, depending on the type of spots desired. As before, one advantage of placing the lenslet array in close proximity to the skin and varicose vein may be that a high NA, lens may be used. Also, the input from the lens and/or mirror assembly to the lenslet array may be single large beam, or a plurality of smaller beams. In one embodiment, a plurality of spots may be created by the lenslet array to cause a plurality of locations of thermal coagulation in the varicose vein. Any number of spots may be used and are intended to be covered by this disclosure.

In a non-limiting example, a plurality of spots may be used, or what might be called a fractionated beam. The fractionated laser beam may be added to the laser delivery assembly or delivery head in a number of ways. In one embodiment, a screen-like spatial filter may be placed in the pathway of the beam to be delivered to the biological tissue. The screen-like spatial filter can have opaque regions to block the light and holes or transparent regions, through which the laser beam may pass to the tissue sample. The ratio of opaque to transparent regions may be varied, depending on the application of the laser. In another embodiment, a lenslet array can be used at or near the output interface where the light emerges. In yet another embodiment, at least a part of the delivery fiber from the infrared laser system to the delivery head may be a bundle of fibers, which may comprise a plurality of fiber cores surrounded by cladding regions. The fiber cores can then correspond to the exposed regions, and the cladding areas can approximate the opaque areas not to be exposed to the laser light. As an example, a bundle of fibers may be excited by at least a part of the laser system output, and then the fiber bundle can be fused together and perhaps pulled down to a desired diameter to expose to the tissue sample near the delivery head. In yet another embodiment, a photonic crystal fiber may be used to create the fractionated laser beam. In one non-limiting example, the photonic crystal fiber can be coupled to at least a part of the laser system output at one end, and the other end can be coupled to the delivery head. In a further example, the fractionated laser beam may be generated by a heavily multi-mode fiber, where the speckle pattern at the output may create the high intensity and low intensity spatial pattern at the output. Although several exemplary techniques are provided for creating a fractionated laser beam, other techniques that can be compatible with optical fibers are also intended to be included by this disclosure.

Although the output from a fiber laser may be from a single or multi-mode fiber, different spatial spot sizes or spatial profiles may be beneficial for different applications. For example, in some instances it may be desirable to have a series of spots or a fractionated beam with a grid of spots. In one embodiment, a bundle of fibers or a light pipe with a plurality of guiding cores may be used. In another embodiment, one or more fiber cores may be followed by a lenslet array to create a plurality of collimated or focused beams. In yet another embodiment, a delivery light pipe may be followed by a grid-like structure to divide up the beam into a plurality of spots. These are specific examples of beam shaping, and other apparatuses and methods may also be used and are consistent with this disclosure.

As used throughout this document, the term "couple" and or "coupled" refers to any direct or indirect communication between two or more elements, whether or not those elements are physically connected to one another. As used throughout this disclosure, the term "spectroscopy" means that a tissue or sample is inspected by comparing different features, such as wavelength (or frequency), spatial location, transmission, absorption, reflectivity, scattering, refractive index, or opacity. In one embodiment, "spectroscopy" may mean that the wavelength of the light source is varied, and the transmission, absorption or reflectivity of the tissue or sample is measured as a function of wavelength. In another embodiment, "spectroscopy" may mean that the wavelength dependence of the transmission, absorption or reflectivity is compared between different spatial locations on a tissue or sample. As an illustration, the "spectroscopy" may be performed by varying the wavelength of the light source, or by using a broadband light source and analyzing the signal using a spectrometer, wavemeter, or optical spectrum analyzer.

As used throughout this document, the term. "fiber laser" refers to a laser or oscillator that has as an output light or an optical beam, wherein at least a part of the laser comprises an optical fiber. For instance, the fiber in the "fiber laser" may comprise one of or a combination of a single mode fiber, a multi-mode fiber, a mid-infrared fiber, a photonic crystal fiber, a doped fiber, a gain fiber, or, more generally, an approximately cylindrically shaped waveguide or light-pipe. In one embodiment, the gain fiber may be doped with rare earth material, such as ytterbium, erbium, and/or thulium. In another embodiment, the mid-infrared fiber may comprise one or a combination of fluoride fiber, ZBLAN fiber, chalcogenide fiber, tellurite fiber, or germanium doped fiber. In yet another embodiment, the single mode fiber may include standard single-mode fiber, dispersion shifted fiber, non-zero dispersion shifted fiber, high-nonlinearity fiber, and small core size fibers.

As used throughout this disclosure, the term "pump laser" refers to a laser or oscillator that has as an output light or an optical beam, wherein the output light or optical beam is coupled to a gain medium to excite the gain medium, which in turn may amplify another input optical signal or beam. In one particular example, the gain medium may be a doped fiber, such as a fiber doped with ytterbium, erbium or thulium. In one embodiment, the "pump laser" may be a fiber laser, a solid state laser, a laser involving a nonlinear crystal, an optical parametric oscillator, a semiconductor laser, or a plurality of semiconductor lasers that may be multiplexed together. In another embodiment, the "pump laser" may be coupled to the gain medium by using a fiber coupler, a dichroic mirror, a multiplexer, a wavelength division multiplexer, a grating, or a fused fiber coupler.

As used throughout this document, the term "super-continuum" and or "supercontinuum" and or "SC" refers to a broadband light beam or output that comprises a plurality of wavelengths. In a particular example, the plurality of wavelengths may be adjacent to one-another, so that the spectrum of the light beam or output appears as a continuous band when measured with a spectrometer. In one embodiment, the broadband light beam may have a bandwidth of at least 10 nm. In another embodiment, the "super-continuum" may be generated through nonlinear optical interactions in a medium, such as an optical fiber or nonlinear crystal. For example, the "super-continuum" may be generated through one or a combination of nonlinear activities such as four-wave mixing, the Raman effect, modulational instability, and self-phase modulation.

As used throughout this disclosure, the terms "optical light" and or "optical beam" and or "light beam" refer to

photons or light transmitted to a particular location in space. The "optical light" and or "optical beam" and or "light beam" may be modulated or unmodulated. In one embodiment, the "optical light" and or "optical beam" and or "light beam" may originate from a fiber, a fiber laser, a laser, a light emitting diode, a lamp, a pump laser, or a light source. In general, the "near-infrared (NIR)" region of the electromagnetic spectrum covers between approximately 0.7 microns (700 nm) to about 2.5 microns (2500 nm). However, it may also be advantageous to use just the short-wave infrared between approximately 1.4 microns (1400 nm) and about 2.5 microns (2500 nm). One reason for preferring the SWIR over the entire NIR may be to operate in the so-called "eye-safe" window, which corresponds to wavelengths longer than about 1400 nm. Therefore, for the remainder of the disclosure the SWIR will be used for illustrative purposes. However, it should be clear that the discussion that follows could also apply to using the NIR wavelength range, or other wavelength bands.

Spectrum for Glucose

One molecule of interest is glucose. The glucose molecule has the chemical formula $C_6H_{12}O_6$, so it has a number of hydro-carbon bonds. An example of the infrared transmittance of glucose **100** is illustrated in FIG. **1**. The vibrational spectroscopy shows that the strongest lines for bending and stretching modes of C—H and O—H bonds lie in the wavelength range of approximately 6-12 microns. However, light sources and detectors are more difficult in the mid-wave infrared and long-wave infrared, and there is also strongly increasing water absorption in the human body beyond about 2.5 microns. Although weaker, there are also non-linear combinations of stretching and bending modes between about 2 to 2.5 microns, and first overtone of C—H stretching modes between approximately 1.5-1.8 microns. These signatures may fall in valleys of water absorption, permitting non-invasive detection through the body. In addition, there are yet weaker features from the second overtones and higher-order combinations between about 0.8-1.2 microns; in addition to being weaker, these features may also be masked by absorption in the hemoglobin. Hence, the short-wave infrared (SWIR) wavelength range of approximately 1.4 to 2.5 microns may be an attractive window for near-infrared spectroscopy of blood constituents.

As an example, measurements of the optical absorbance **200** of hemoglobin, glucose and HbA1c have been performed using a Fourier-Transform Infrared Spectrometer-FTIR. As FIG. **2** shows, in the SWIR wavelength range hemoglobin is nearly flat in spectrum **201** (the noise at the edges is due to the weaker light signal in the measurements). On the other hand, the glucose absorbance **202** has at least five distinct peaks near 1587 nm, 1750 nm, 2120 nm, 2270 nm and 2320 nm.

FIG. **3**A overlaps **300** the normalized absorbance of glucose **301** with the absorbance of water **302** (not drawn to scale). It may be seen that water has an absorbance feature between approximately 1850 nm and 2050 nm, but water **302** also has a nice transmission window between approximately 1500-1850 nm and 2050 to 2500 nm. For wavelengths less than about 1100 nm, the absorption of hemoglobin **351** and oxygenated hemoglobin **352** in FIG. **3**B has a number of features **350**, which may make it more difficult to measure blood constituents. Also, beyond 2500 nm the water absorption becomes considerably stronger over a wide wavelength range. Therefore, an advantageous window for measuring glucose and other blood constituents may be in the SWIR between 1500 and 1850 nm and 2050 to 2500 nm. These are exemplary wavelength ranges, and other ranges can be used that would still fall within the scope of this disclosure.

One further consideration in choosing the laser wavelength is known as the "eye safe" window for wavelengths longer than about 1400 nm. In particular, wavelengths in the eye safe window may not transmit down to the retina of the eye, and therefore, these wavelengths may be less likely to create permanent eye damage. The near-infrared wavelengths have the potential to be dangerous, because the eye cannot see the wavelengths (as it can in the visible), yet they can penetrate and cause damage to the eye. Even if a practitioner is not looking directly at the laser beam, the practitioner's eyes may receive stray light from a reflection or scattering from some surface. Hence, it can always be a good practice to use eye protection when working around lasers. Since wavelengths longer than about 1400 nm are substantially not transmitted to the retina or substantially absorbed in the retina, this wavelength range is known as the eye safe window. For wavelengths longer than 1400 nm, in general only the cornea of the eye may receive or absorb the light radiation.

Beyond measuring blood constituents such as glucose using FTIR spectrometers, measurements have also been conducted in another embodiment using super-continuum lasers, which will be described later in this disclosure. In this particular embodiment, some of the exemplary preliminary data for glucose absorbance are illustrated in FIGS. **4**A and **4**B. The optical spectra **401** in FIG. **4**A for different levels of glucose concentration in the wavelength range between 2000 and 2400 nm show the three absorption peaks near 2120 nm (2.12 μm), 2270 nm (2.27 μm) and 2320 nm (2.32 μm). Moreover, the optical spectra **402** in FIG. **4**B for different levels of glucose concentration in the wavelength range between 1500 and 1800 nm show the two broader absorption peaks near 1587 nm and 1750 nm. It should be appreciated that although data measured with FTIR spectrometers or super-continuum lasers have been illustrated, other light sources can also be used to obtain the data, such as super-luminescent laser diodes, light emitting diodes, a plurality of laser diodes, or even bright lamp sources that generate adequate light in the SWIR.

Although glucose has a distinctive signature in the SWIR wavelength range, one problem of non-invasive glucose monitoring is that many other blood constituents also have hydro-carbon bonds. Consequently, there can be interfering signals from other constituents in the blood. As an example, FIG. **5** illustrates the spectrum **500** for different blood constituents in the wavelength range of 2 to 2.45 microns. The glucose absorption spectrum **501** can be unique with its three peaks in this wavelength range. However, other blood constituents such as triacetin **502**, ascorbate **503**, lactate **504**, alanine **505**, urea **506**, and BSA **507** also have spectral features in this wavelength range. To distinguish the glucose **501** from these overlapping spectra, it may be advantageous to have information at multiple wavelengths. In addition, it may be advantageous to use pattern matching algorithms and other software and mathematical methods to identify the blood constituents of interest. In one embodiment, the spectrum may be correlated with a library of known spectra to determine the overlap integrals, and a threshold function may be used to quantify the concentration of different constituents. This is just one way to perform the signal processing, and many other techniques, algorithms, and software may be used and would fall within the scope of this disclosure.

Ketone Bodies Monitoring

Beyond glucose, there are many other blood constituents that may also be of interest for health or disease monitoring. In another embodiment, it may be desirous to monitor the level of ketone bodies in the blood stream. Ketone bodies are three water-soluble compounds that are produced as by-products when fatty acids are broken down for energy in the liver. Two of the three are used as a source of energy in the heart and brain, while the third is a waste product excreted from the body. In particular, the three endogenous ketone bodies are acetone, acetoacetic acid, and beta-hydroxybutyrate or 3-hydroxybutyrate, and the waste product ketone body is acetone.

Ketone bodies may be used for energy, where they are transported from the liver to other tissues. The brain may utilize ketone bodies when sufficient glucose is not available for energy. For instance, this may occur during fasting, strenuous exercise, low carbohydrate, ketogenic diet and in neonates. Unlike most other tissues that have additional energy sources such as fatty acids during periods of low blood glucose, the brain cannot break down fatty acids and relies instead on ketones. In one embodiment, these ketone bodies are detected.

Ketone bodies may also be used for reducing or eliminating symptoms of diseases or disorders characterized by impaired glucose metabolism. For example, diseases associated with reduced neuronal metabolism of glucose include Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease), Huntington's disease and epilepsy. In one embodiment, monitoring of alternate sources of ketone bodies that may be administered orally as a dietary supplement or in a nutritional composition to counteract some of the glucose metabolism impairments is performed. However, if ketone bodies supplements are provided, there is also a need to monitor the ketone level in the blood stream. For instance, if elevated levels of ketone bodies are present in the body, this may lead to ketosis; hyperketonemia is also an elevated level of ketone bodies in the blood. In addition, both acetoacetic acid and beta-hydroxybutyric acid are acidic, and, if levels of these ketone bodies are too high, the pH of the blood may drop, resulting in ketoacidosis.

The general formula for ketones is C_nH_{2n0}. In organic chemistry, a ketone is an organic compound with the structure RC(═O)R', where R and R' can be a variety of carbon-containing substituents. It features a carbonyl group (C═O) bonded to two other carbon atoms. Because the ketones contain the hydrocarbon bonds, there might be expected to be features in the SWIR, similar in structure to those found for glucose.

The infrared spectrum **600** for the ketone 3-hydroxybutyrate is illustrated in FIG. **6**. Just as in glucose, there are significant features in the mid- and long-wave infrared between 6 to 12 microns, but these may be difficult to observe non-invasively. On the other hand, there are some features in the SWIR that may be weaker, but they could potentially be observed non-invasively, perhaps through blood and water.

The optical spectra **700** for ketones as well as some other blood constituents are exemplified in FIG. **7** in the wavelength range of 2100 nm to 2400 nm. In this embodiment, the absorbance for ketones is **701**, while the absorbance for glucose is **702**. However, there are also features in this wavelength range for other blood constituents, such as urea **703**, albumin or blood protein **704**, creatinine **705**, and nitrite **706**. In this wavelength range of 2100 to 2400 nm, the features for ketone **701** seem more spectrally pronounced than even glucose.

Different signal processing techniques can be used to enhance the spectral differences between different constituents. In one embodiment, the first or second derivatives of the spectra may enable better discrimination between substances. The first derivative may help remove any flat offset or background, while the second derivative may help to remove any sloped offset or background. In some instances, the first or second derivative may be applied after curve fitting or smoothing the reflectance, transmittance, or absorbance. For example, FIG. **8**A illustrates the derivative spectra for ketone **801** and glucose **802**, which can be distinguished from the derivative spectra for protein **803**, urea **804** and creatinine **805**. Based on FIG. **8**A, it appears that ketones **801** may have a more pronounced difference than even glucose **802** in the wavelength range between 2100 and 2400 nm. Therefore, ketone bodies should also be capable of being monitored using a non-invasive optical technique in the SWIR, and a different pattern matching library could be used for glucose and ketones.

Hemoglobin A1c Monitoring

Another blood constituent that may be of interest for monitoring of health or diseases is hemoglobin A1c, also known as HbA1c or glycated hemoglobin (glycol-hemoglobin or glycosylated hemoglobin). HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Thus, HbA1c may serve as a marker for average blood glucose levels over the previous months prior to the measurements.

In one embodiment, when a physician suspects that a patient may be diabetic, the measurement of HbA1c may be one of the first tests that are conducted. An HbA1c level less than approximately 6% may be considered normal. On the other hand, an HbA1c level greater than approximately 6.5% may be considered to be diabetic. In diabetes mellitus, higher amounts of HbA1c indicate poorer control of blood glucose levels. Thus, monitoring the HbA1c in diabetic patients may improve treatment. Current techniques for measuring HbA1c require drawing blood, which may be inconvenient and painful. The point-of-care devices use immunoassay or boronate affinity chromatography, as an example. Thus, there is also an unmet need for non-invasive monitoring of HbA1c.

FIG. **2** illustrates the FTIR measurements of HbA1c absorbance **203** over the wavelength range between 1500 and 2400 nm for a concentration of approximately 1 mg/ml. Whereas the absorbance of hemoglobin **201** over this wavelength range is approximately flat, the HbA1c absorbance **203** shows broad features and distinct curvature. Although the HbA1c absorbance **203** does not appear to exhibit as pronounced features as glucose **202**, the non-invasive SWIR measurement should be able to detect HbA1c with appropriate pattern matching algorithms. Moreover, the spectrum for HbA1c may be further enhanced by using first or second derivative data, as seen for ketones in FIG. **8**A. Beyond absorption, reflectance, or transmission spectroscopy, it may also be possible to detect blood constituents such as HbA1c using Raman spectroscopy or surface-enhanced Raman spectroscopy. In general, Raman spectroscopy may require higher optical power levels.

As an illustration, non-invasive measurement of blood constituents such as glucose, ketone bodies, and HbA1c has been discussed thus far. However, other blood constituents can also be measured using similar techniques, and these are

also intended to be covered by this disclosure. In other embodiments, blood constituents such as proteins, albumin, urea, creatinine or nitrites could also be measured. For instance, the same type of SWIR optical techniques might be used, but the pattern matching algorithms and software could use different library features or functions for the different constituents.

In yet another embodiment, the optical techniques described in this disclosure could also be used to measure levels of triglycerides. Triglycerides are bundles of fats that may be found in the blood stream, particularly after ingesting meals. The body manufactures triglycerides from carbohydrates and fatty foods that are eaten. In other words, triglycerides are the body's storage form of fat. Triglycerides are comprised of three fatty acids attached to a glycerol molecule, and measuring the level of triglycerides may be important for diabetics. The triglyceride levels or concentrations in blood may be rated as follows: desirable or normal may be less than 150 mg/dl; borderline high may be 150-199 mg/dl; high may be 200-499 mg/dl; and very high may be 500 mg/dl or greater. FIG. **8**B illustrates one example of the near-infrared absorbance **825** for triglycerides. There are distinct absorbance peaks in the spectrum that should be measurable. The characteristic absorption bands may be assigned as follows: (a) the first overtones of C—H stretching vibrations (1600-1900 nm); (b) the region of second overtones of C—H stretching vibrations (1100-1250 nm); and, (c) two regions (2000-2200 nm and 1350-1500 nm) that comprise bands due to combinations of C—H stretching vibrations and other vibrational modes.

A further example of blood compositions that can be detected or measured using near-infrared light includes cholesterol monitoring. For example, FIG. **8**C shows the near-infrared reflectance spectrum for cholesterol **850** with wavelength in microns (μm). Distinct absorption peaks are observable near 1210 nm (1.21 μm), 1720 nm (1.72 μm), and between 2300-2500 nm (2.3-2.5 μm). Also, there are other features near 1450 nm (1.45 μm) and 2050 nm (2.05 μm). In FIG. **8**D the near-infrared reflectances **875** are displayed versus wavelength (nm) for various blood constituents. The spectrum for cholesterol **876** is overlaid with glucose **877**, albumin **878**, uric acid **879**, and urea **880**. As may be noted from FIG. **8**D, at about 1720 nm and 2300 nm, cholesterol **876** reaches approximate reflectance peaks, while some of the other analytes are in a more gradual mode. Various signal processing methods may be used to identify and quantify the concentration of cholesterol **876** and/or glucose **877**, or some of the other blood constituents.

As illustrated by FIGS. **5** and **7**, one of the issues in measuring a particular blood constituent is the interfering and overlapping signal from other blood constituents. The selection of the constituent of interest may be improved using a number of techniques. For example, a higher light level or intensity may improve the signal-to-noise ratio for the measurement. Second, mathematical modeling and signal processing methodologies may help to reduce the interference, such as multivariate techniques, multiple linear regression, and factor-based algorithms, for example. For instance, a number of mathematical approaches include multiple linear regression, partial least squares, and principal component regression (PCR). Also, as illustrated in FIG. **8**A, various mathematical derivatives, including the first and second derivatives, may help to accentuate differences between spectra. In addition, by using a wider wavelength range and using more sampling wavelengths may improve the ability to discriminate one signal from another. Moreover, it may be advantageous to pulse the light source with a particular pulse width and pulse repetition rate, and then the detection system can measure the pulsed light returned from or transmitted through the tissue. Using a lock-in type technique (e.g., detecting at the same frequency as the pulsed light source and also possibly phase locked to the same signal), the detection system may be able to reject background or spurious signals and increase the signal-to-noise ratio of the measurement. In one particular embodiment, high signal-to-noise ratio may be achieved using a fiber-based super-continuum (SC) light source (described further herein). Other light sources may also be used, including a plurality of laser diodes, super-luminescent laser diodes, or fiber lasers. In one embodiment, an all-fiber-integrated, high-powered SC light source may be elegant for its simplicity. The light may be first generated from a seed laser diode (LD). For example, the seed LD may be a distributed feedback (DFB) laser diode with a wavelength near 1542 nm or 1550 nm, with approximately 0.5-2.0 ns pulsed output, and with a pulse repetition rate between one kilohertz and about 100 MHz or more.

Beyond having a pulse width, the laser output can also have a preferred repetition rate. For pulse repetition rates above around 10 MHz, where multiple pulses fall within a thermal diffusion time, the tissue response may be more related to the energy deposited or the fluence of the laser beam. The separation between pulses or a sub-group of pulses may also be selected so that the tissue sample can reach thermal equilibrium between pulses. Also, the pulse pattern may or may not be periodic. In one embodiment, there may be several pulses used per spot, where the pulse pattern is selected to obtain a desired thermal profile. The laser beam may then be moved to a new spot and then another pulse train delivered to that spot. In one embodiment, there can be several seconds of pre-cooling, the laser can be exposed on the tissue for several seconds, and then there may also be post-cooling. Although particular examples of laser duration and repetition rate are described, other values may also be used consistent with this disclosure. For example, depending on the application and mechanisms, the pulse rate could range all the way from continuous wave to 100's of Megahertz.

The above are just examples of some of the methods of improving the ability to discriminate between different constituents, but other techniques may also be used and are intended to be covered by this disclosure.

In one embodiment, a SWIR camera or infrared camera system may be used to capture the images. The camera may include one or more lenses on the input, which may be adjustable. The focal plane assemblies may be made from mercury cadmium telluride material (HgCdTe), and the detectors may also include thermo-electric coolers. Alternately, the image sensors may be made from indium gallium arsenide (InGaAs), and CMOS transistors may be connected to each pixel of the InGaAs photodiode array. The camera may interface wirelessly or with a cable (e.g., USB, Ethernet cable, or fiber optics cable) to a computer or tablet or smart phone, where the images may be captured and processed. These are a few examples of infrared cameras, but other SWIR or infrared cameras may be used and are intended to be covered by this disclosure.

By use of an active illuminator, a number of advantages may be achieved. First, the variations due to sunlight and time-of-day may be factored out. The effects of the weather, such as clouds and rain, might also be reduced. Also, higher signal-to-noise ratios may be achieved. For example, one way to improve the signal-to-noise ratio would be to use modulation and lock-in techniques. In one embodiment, the

light source may be modulated, and then the detection system would be synchronized with the light source. In a particular embodiment, the techniques from lock-in detection may be used, where narrow band filtering around the modulation frequency may be used to reject noise outside the modulation, frequency. In an alternate embodiment, change detection schemes may be used, where the detection system captures the signal with the light source on and with the light source off. Again, for this system the light source may be modulated. Then, the signal with and without the light source is differenced. This may enable the sun light changes to be subtracted out. In addition, change detection may help to identify objects that change in the field of view. In the following some exemplary detection systems are described.

Interference from Skin

Several proposed non-invasive glucose monitoring techniques rely on transmission, absorption, and/or diffuse reflection through the skin to measure blood constituents or blood analytes in veins, arteries, capillaries or in the tissue itself. However, on top of the interference from other blood constituents or analytes, the skin also introduces significant interference. For example, chemical, structural, and physiological variations occur that may produce relatively large and nonlinear changes in the optical properties of the tissue sample. In one embodiment, the near-infrared reflectance or absorbance spectrum may be a complex combination of the tissue scattering properties that result from the concentration and characteristics of a multiplicity of tissue components including water, fat, protein, collagen, elastin, and/or glucose. Moreover, the optical properties of the skin may also change with environmental factors such as humidity, temperature and pressure. Physiological variation may also cause changes in the tissue measurement over time and may vary based on lifestyle, health, aging, etc. The structure and composition of skin may also vary widely among individuals, between different sites within an individual, and over time on the same individual. Thus, the skin introduces a dynamic interference signal that may have a wide variation due to a number of parameters.

FIG. **9** shows a schematic cross-section of human skin **900**, **901**. The top layer of the skin is epidermis **902**, followed by a layer of dermis **903** and then subcutaneous fat **904** below the dermis. The epidermis **902**, with a thickness of approximately 10-150 microns, may provide a barrier to infection and loss of moisture and other body constituents. The dermis **903** ranges in thickness from approximately 0.5 mm to 4 mm (averages approximately 1.2 mm over most of the body) and may provide the mechanical strength and elasticity of skin.

In the dermis **903**, water may account for approximately 70% of the volume. The next most abundant constituent in the dermis **903** may be collagen **905**, a fibrous protein comprising 70-75% of the dry weight of the dermis **903**. Elastin fibers **906**, also a protein, may also be plentiful in the dermis **903**, although they constitute a smaller portion of the bulk. In addition, the dermis **903** may contain a variety of structures (e.g., sweat glands, hair follicles with adipose rich sebaceous glands **907** near their roots, and blood vessels) and other cellular constituents.

Below the dermis **903** lies the subcutaneous layer **904** comprising mostly adipose tissue. The subcutaneous layer **904** may be by volume approximately 10% water and may be comprised primarily of cells rich in triglycerides or fat. With this complicated structure of the skin **900**, **901**, the concentration of glucose may vary in each layer according to a variety of factors including the water content, the relative sizes of the fluid compartments, the distribution of capillaries, the perfusion of blood, the glucose uptake of cells, the concentration of glucose in blood, and the driving forces (e.g., osmotic pressure) behind diffusion.

To better understand the interference that the skin introduces when attempting to measure glucose, the absorption coefficient for the various skin constituents should be examined. For example, FIG. **10** illustrates **1000** the absorption coefficients for water (including scattering) **1001**, adipose **1002**, collagen **1003** and elastin **1004**. Note that the absorption curves for water **1001** and adipose **1002** are calibrated, whereas the absorption curves for collagen **1003** and elastin **1004** are in arbitrary units. Also shown are vertical lines demarcating the wavelengths near 1210 nm **1005** and 1720 nm **1006**. In general, the water absorption increases with increasing wavelength. With the increasing absorption beyond about 2000 nm, it may be difficult to achieve deeper penetration into biological tissue in the infrared wavelengths beyond approximately 2500 nm.

Although the absorption coefficient may be useful for determining the material in which light of a certain infrared wavelength will be absorbed, to determine the penetration depth of the light of a certain wavelength may also require the addition of scattering loss to the curves. For example, the water curve **1001** includes the scattering loss curve in addition to the water absorption. In particular, the scattering loss can be significantly higher at shorter wavelengths. In one embodiment, near the wavelength of 1720 nm (vertical line **1006** shown in FIG. **10**) the adipose absorption **1002** can still be higher than the water plus scattering loss **1001**. For tissue that contains adipose, collagen and elastin, such as the dermis of the skin, the total absorption can exceed the light energy lost to water absorption and light scattering at 1720 nm. On the other hand, at 1210 nm the adipose absorption **1002** can be considerably lower than the water plus scattering loss **1001**, particularly since the scattering loss can be dominant at these shorter wavelengths.

The interference for glucose lines observed through skin may be illustrated by overlaying the glucose lines over the absorption curves **1000** for the skin constituents. For example, FIG. **2** illustrated that the glucose absorption **202** included features centered around 1587 nm, 1750 nm, 2120 nm, 2270 nm and 2320 nm. On FIG. **10** vertical lines have been drawn at the glucose line wavelengths of 1587 nm **1007**, 1750 nm **1008**, 2120 nm **1009**, 2270 nm **1010** and 2320 nm **1011**. In one embodiment, it may be difficult to detect the glucose lines near 1750 nm **1008**, 2270 nm **1010** and 2320 nm **1011** due to significant spectral interference from other skin constituents. On the other hand, the glucose line near 1587 m **1007** may be more easily detected because it peaks while most of the other skin constituents are sloped downward toward an absorption valley. Moreover, the glucose line near 2120 nm **1009** may also be detectable for similar reasons, although adipose may have conflicting behavior due to local absorption minimum and maximum nearby in wavelength.

Thus, beyond the problem of other blood constituents or analytes having overlapping spectral features (e.g., FIG. **5**), it may be difficult to observe glucose spectral signatures through the skin and its constituents of water, adipose, collagen and elastin. One approach to overcoming this difficulty may be to try to measure the blood constituents in veins that are located at relatively shallow distances below the skin. Veins may be more beneficial for the measurement than arteries, since arteries tend to be located at deeper levels below the skin. Also, in one embodiment it may be advantageous to use a differential measurement to subtract out

some of the interfering absorption lines from the skin. For example, an instrument head may be designed to place one probe above a region of skin over a blood vein, while a second probe may be placed at a region of the skin without a noticeable blood vein below it. Then, by differencing the signals from the two probes, at least part of the skin interference may be cancelled out.

Two representative embodiments for performing such a differential measurement are illustrated in FIG. **11** and FIG. **12**, In one embodiment shown in FIG. **11**, the dorsal of the hand **1100** may be used for measuring blood constituents or analytes. The dorsal of the hand **1100** may have regions that have distinct veins **1101** as well as regions where the veins are not as shallow or pronounced **1102**. By stretching the hand and leaning it backwards, the veins **1101** may be accentuated in some cases. A near-infrared diffuse reflectance measurement may be performed by placing one probe **1103** above the vein-rich region **1101**. To turn this into a differential measurement, a second probe **1104** may be placed above a region without distinct veins **1102**. Then, the outputs from the two probes may be subtracted **1105** to at least partially cancel out the features from the skin. The subtraction may be done preferably in the electrical domain, although it can also be performed in the optical domain or digitally/mathematically using sampled data based on the electrical and/or optical signals. Although one example of using the dorsal of the hand **1100** is shown, many other parts of the hand can be used within the scope of this disclosure. For example, alternate methods may use transmission through the webbing between the thumb and the fingers **1106**, or transmission or diffuse reflection through the tips of the fingers **1107**.

In another embodiment, the dorsal of the foot **1200** may be used instead of the hand. One advantage of such a configuration may be that for self-testing by a user, the foot may be easier to position the instrument using both hands. One probe **1203** may be placed over regions where there are more distinct veins **1201**, and a near-infrared diffuse reflectance measurement may be made. For a differential measurement, a second probe **1204** may be placed over a region with less prominent veins **1202**, and then the two probe signals may be subtracted, either electronically or optically, or may be digitized/sampled and processed mathematically depending on the particular application and implementation. As with the hand, the differential measurements may be intended to compensate for or subtract out (at least in part) the interference from the skin. Since two regions are used in close proximity on the same body part, this may also aid in removing some variability in the skin from environmental effects such as temperature, humidity, or pressure. In addition, it may be advantageous to first treat the skin before the measurement, by perhaps wiping with a cloth or treated cotton ball, applying some sort of cream, or placing an ice cube or chilled bag over the region of interest.

Although two embodiments have been described, many other locations on the body may be used using a single or differential probe within the scope of this disclosure. In yet another embodiment, the wrist may be advantageously used, particularly where a pulse rate is typically monitored. Since the pulse may be easily felt on the wrist, there is underlying the region a distinct blood flow. Other embodiments may use other parts of the body, such as the ear lobes, the tongue, the inner lip, the nails, the eye, or the teeth. Some of these embodiments will be further described below. The ear lobes or the tip of the tongue may be advantageous because they are thinner skin regions, thus permitting transmission rather than diffuse reflection. However, the interference from the skin is still a problem in these embodiments. Other regions such as the inner lip or the bottom of the tongue may be contemplated because distinct veins are observable, but still the interference from the skin may be problematic in these embodiments. The eye may seem as a viable alternative because it is more transparent than skin. However, there are still issues with scattering in the eye. For example, the anterior chamber of the eye (the space between the cornea and the iris) comprises a fluid known as aqueous humor. However, the glucose level in the eye chamber may have a significant temporal lag on changes in the glucose level compared to the blood glucose level.

In some instances, it may be desirable to create multiple locations of focused light. One way to accomplish this may be to slide the assemblies and/or the light source. In yet another embodiment shown in FIG. **13**A, multiple collimated or focused light beams may be created in one assembly **1320**. In this embodiment, optionally a surface cooling apparatus **1324** may be used, where a cooling fluid may be flowed either touching or in close proximity to the skin **1321**. Also, in this particular embodiment a cylindrical assembly may optionally be used, where the cylindrical length may be several millimeters in length and defined by a clamp or mount **1323** placed on or near the leg. The light input **1327** may be received from a light source, which may use a fiber or fiber bundles to couple the light to the lens/mirror assembly **1326**. A lens and/or mirror assembly **1326** may be used to couple the light input **1327** to the lenslet array or window **1325**, either directly or indirectly. The lens and/or mirror assembly **1326** may also be coupled to the clamp or mount assembly **1323**.

In the embodiment of FIG. **13**A, a window and/or lenslet array **1325** is also shown on the cylindrical surface for permitting the light to be incident on the skin **1321** and varicose vein **1322** at multiple spots. The lenslet array **1325** may comprise circular, spherical or cylindrical lenses, depending on the type of spots desired. As before, one advantage of placing the lenslet array **1325** in close proximity to the skin **1321** may be that a high NA lens may be used. Also, the input from the lens and/or mirror assembly to the lenslet array **1325** may be a single large beam, or a plurality of smaller beams. In one embodiment, a plurality of spots may be created by the lenslet array **1325**. Although four spots are shown in FIG. **13**A, any number of spots may be used and are intended to be covered by this disclosure.

Different combinations of these techniques may be employed, and other techniques may also be used and are intended to be covered by this disclosure. For example, in some instances only focused light may be used, in other instances only surface cooling or cryogenic sprays may be used, and in yet other embodiments a combination of the two may be used. Moreover, the clamps, mounts and holders are shown in simple design for illustrative purposes, but human factors engineering may be used to make these more user friendly or ergonomic design. These and other variations are also intended to be covered by this disclosure.

The lens and/or mirror assemblies may comprise one or more lenses, microscope objectives, curved or flat mirrors, lens tipped fibers, or some combination of these elements. As an example, the optics such as used in a camera may be employed in this arrangement, provided that the optics are substantially transparent at the light wavelengths being used. Moreover, reflections and losses through the optics may be reduced by applying anti-reflection coatings, and chromatic dispersion may be reduced by using reflective optics rather than refractive optics. Although a particular method of

focusing the light has been described, other methods may also be used and are intended to be covered by this disclosure.

Because of the complexity of the interference from skin in non-invasive glucose monitoring (e.g., FIG. **10**), other parts of the body without skin above blood vessels or capillaries may be alternative candidates for measuring blood constituents. One embodiment may involve transmission or reflection through human nails. As an example, FIG. **13**B illustrates a typical human nail tissue structure **1300** and the capillary vessels below it. The fingernail **1301** is approximately 1 mm thick, and below this resides a layer of epidermis **1302** with a thickness of approximately 1 mm. The dermis **1304** is also shown, and within particularly the top about 0.5 mm of dermis are a significant number of capillary vessels. To measure the blood constituents, the light exposed on the top of the fingernail must penetrate about 2-2.5 mm or more, and the reflected light (round trip passage) should be sufficiently strong to measure. In one embodiment, the distance required to penetrate could be reduced by drilling a hole in the fingernail **1301**.

In this alternative embodiment using the fingernail, there may still be interference from the nail's spectral features. For example, FIG. **14** illustrates the attenuation coefficient **1400** for seven nail samples that are allowed to stand in an environment with a humidity level of 14%. These coefficients are measured using an FTIR spectrometer over the near-infrared wavelength range of approximately 1 to 2.5 microns. These spectra are believed to correspond to the spectra of keratin contained in the nail plate. The base lines for the different samples are believed to differ because of the influence of scattering. Several of the absorption peaks observed correspond to peaks of keratin absorption, while other features may appear from the underlying epidermis and dermis. It should also be noted that the attenuation coefficients **1400** also vary considerably depending on humidity level or water content as well as temperature and other environmental factors. Moreover, the attenuation coefficient may also change in the presence of nail polish of various sorts.

Similar to skin, the large variations in attenuation coefficient for fingernails also may interfere with the absorption peaks of glucose. As an example, in FIG. **14** below the fingernail spectrum is also shown the glucose spectrum **1401** for two different glucose concentrations. The vertical lines **1402**, **1403**, **1404**, **1405** and **1406** are drawn to illustrate the glucose absorption peaks and where they lie on the fingernail spectra **1400**. As is apparent, the nail has interfering features that may be similar to skin, particularly since both have spectra that vary not only in wavelength but also with environmental factors. In one embodiment, it may be possible to see the glucose peaks **1402** and **1404** through the fingernail, but it may be much more difficult to observe the glucose peaks near **1403**, **1405** and **1406**.

Transmission or Reflection Through Teeth

Yet another embodiment may observe the transmittance or reflectance through teeth to measure blood constituents or analytes. FIG. **15** illustrates an exemplary structure of a tooth **1500**. The tooth **1500** has a top layer called the crown **1501** and below that a root **1502** that reaches well into the gum **1506** and bone **1508** of the mouth. The exterior of the crown **1501** is an enamel layer **1503**, and below the enamel is a layer of dentine **1504** that sits atop a layer of cementum **1507**. Below the dentine **1504** is a pulp region **1505**, which comprises within it blood vessels **1509** and nerves **1510**. If the light can penetrate the enamel **1503** and dentine **1504**, then the blood flow and blood constituents can be measured through the blood vessels in the dental pulp **1505**. While it may be true that the amount of blood flow in the dental pulp **1505** may be less since it comprises capillaries, the smaller blood flow could still be advantageous if there is less interfering spectral features from the tooth.

The transmission, absorption and reflection from teeth has been studied in the near infrared, and, although there are some features, the enamel and dentine appear to be fairly transparent in the near infrared (particularly wavelengths between 1500 and 2500 nm). For example, the absorption or extinction ratio for light transmission has been studied. FIG. **16**A illustrates the attenuation coefficient **1600** for dental enamel **1601** (filled circles) and the absorption coefficient of water **1602** (open circles) versus wavelength. Near-infrared light may penetrate much further without scattering through all the tooth enamel, due to the reduced scattering coefficient in normal enamel. Scattering in enamel may be fairly strong in the visible, but decreases as approximately 1/wavelength^3 (i.e., inverse of the wavelength cubed) with increasing wavelength to a value of only 2-3 cm^{-1} at 1310 nm and 1550 nm in the near infrared. Therefore, enamel may be virtually transparent in the near infrared with optical attenuation 1-2 orders of magnitude less than in the visible range.

As another example, FIG. **16**B illustrates the absorption spectrum **1650** of intact enamel **1651** (dashed line) and dentine **1652** (solid line) in the wavelength range of approximately 1.2 to 2.4 microns. In the near infrared there are two absorption bands around 1.5 and 2 microns. The band with a peak around 1.57 microns may be attributed to the overtone of valent vibration of water present in both enamel and dentine. In this band, the absorption is greater for dentine than for enamel, which may be related to the large water content in this tissue. In the region of 2 microns, dentine may have two absorption bands, and enamel one. The band with a maximum near 2.1 microns may belong to the overtone of vibration of PO hydroxyapatite groups, which is the main substance of both enamel and dentine. Moreover, the band with a peak near 1.96 microns in dentine may correspond to water absorption (dentine may contain substantially higher water than enamel).

In addition to the absorption coefficient, the reflectance from intact teeth and teeth with dental caries (e.g., cavities) has been studied. In one embodiment, FIG. **17** shows the near infrared spectral reflectance **1700** over the wavelength range of approximately 800 nm to 2500 nm from an occlusal (e.g., top/bottom) tooth surface **1704**. The curve with black diamonds **1701** corresponds to the reflectance from a sound, intact tooth section. The curve with asterisks * **1702** corresponds to a tooth section with an enamel lesion. The curve with circles **1703** corresponds to a tooth section with a dentine lesion. Thus, when there is a lesion, more scattering occurs and there may be an increase in the reflected light.

For wavelengths shorter than approximately 1400 nm, the shapes of the spectra remain similar, but the amplitude of the reflection changes with lesions. Between approximately 1.400 nm and 2500 nm, an intact tooth **1701** has low reflectance (e.g., high transmission), and the reflectance appears to be more or less independent of wavelength. On the other hand, in the presence of lesions **1702** and **1703**, there is increased scattering, and the scattering loss may be wavelength dependent. For example, the scattering loss may decrease as 1/(wavelength)^3—so, the scattering loss decreases with longer wavelengths. When there is a lesion in the dentine **1703**, more water can accumulate in the area, so there is also increased water absorption. For example, the dips near 1450 nm and 1900 nm correspond to water absorption, and the reflectance dips are particularly pro-

nounced in the dentine lesion **1703**. One other benefit of the absorption, transmission or reflectance in the near infrared may be that stains and non-calcified plaque are not visible in this wavelength range, enabling better discrimination of defects, cracks, and demineralized areas.

Compared with the interference from skin **1000** in FIG. **10** or fingernails **1400** in FIG. **14**, the teeth appear to introduce much less interference for non-invasive monitoring of blood constituents. The few features in FIG. **16**B or **17** may be calibrated out of the measurement. Also, using an intact tooth **1701** may further minimize any interfering signals. Furthermore, since the tooth comprises relatively hard tissue, higher power from the light sources in the near infrared may be used without damaging the tissue, such as with skin.

Human Interface for Measurement System

A number of different types of measurements may be used to sample the blood in the dental pulp. The basic feature of the measurements should be that the optical properties are measured as a function of wavelength at a plurality of wavelengths. As further described below, the light source may output a plurality of wavelengths, or a continuous spectrum over a range of wavelengths. In a preferred embodiment, the light source may cover some or all of the wavelength range between approximately 1400 nm and 2500 nm. The signal may be received at a receiver, which may also comprise a spectrometer or filters to discriminate between different wavelengths. The signal may also be received at a camera, which may also comprise filters or a spectrometer. In an alternate embodiment, the spectral discrimination using filters or a spectrometer may be placed after the light source rather than at the receiver. The receiver usually comprises one or more detectors (optical-to-electrical conversion element) and electrical circuitry. The receiver may also be coupled to analog to digital converters, particularly if the signal is to be fed to a digital device.

Referring to FIG. **15**, one or more light sources **1511** may be used for illumination. In one embodiment, a transmission measurement may be performed by directing the light source output **1511** to the region near the interface between the gum **1506** and dentine **1504**. In one embodiment, the light may be directed using a light guide or a fiber optic. The light may then propagate through the dental pulp **1505** to the other side, where the light may be incident on one or more detectors or another light guide to transport the signal to a spectrometer, receiver or camera **1512**. In another embodiment, the light source may be directed to one or more locations near the interface between the gum **1506** and dentine **1504** (in one example, could be from the two sides of the tooth). The transmitted light may then be detected in the occlusal surface above the tooth using a spectrometer, receiver, or camera **1512**. In yet another embodiment, a reflectance measurement may be conducted by directing the light source output **1511** to, for example, the occlusal surface of the tooth, and then detecting the reflectance at a spectrometer, receiver or camera **1513**. Although a few embodiments for measuring the blood constituents through a tooth are described, other embodiments and techniques may also be used and are intended to be covered by this disclosure.

The human interface for the non-invasive measurement of blood constituents may be of various forms. In one embodiment, a "clamp" design **1800** may be used cap over one or more teeth, as illustrated in FIG. **18**A. The clamp design may be different for different types of teeth, or it may be flexible enough to fit over different types of teeth. For example, different types of teeth include the molars (toward the back of the mouth), the premolars, the canine, and the incisors (toward the front of the mouth). One embodiment of the clamp-type design is illustrated in FIG. **18**A for a molar tooth **1808**. The C-clamp **1801** may be made of a plastic or rubber material, and it may comprise a light source input **1802** and a detector output **1803** on the front or back of the tooth.

The light source input **1802** may comprise a light source directly, or it may have light guided to it from an external light source. Also, the light source input **1802** may comprise a lens system to collimate or focus the light across the tooth. The detector output **1803** may comprise a detector directly, or it may have a light guide to transport the signal to an external detector element. The light source input **1802** may be coupled electrically or optically through **1804** to a light input **1806**. For example, if the light source is external in **1806**, then the coupling element **1804** may be a light guide, such as a fiber optic. Alternately, if the light source is contained in **1802**, then the coupling element **1804** may be electrical wires connecting to a power supply in **1806**. Similarly, the detector output **1803** may be coupled to a detector output unit **1807** with a coupling element **1805**, which may be one or more electrical wires or a light guide, such as a fiber optic. This is just one example of a clamp over one or more teeth, but other embodiments may also be used and are intended to be covered by this disclosure.

In yet another embodiment, one or more light source ports and sensor ports may be used in a mouth-guard type design. For example, one embodiment of a dental mouth guard **1850** is illustrated in FIG. **18**B. The structure of the mouth guard **1851** may be similar to mouth guards used in sports (e.g., when playing football or boxing) or in dental trays used for applying fluoride treatment, and the mouth guard may be made from plastic or rubber materials, for example. As an example, the mouth guard may have one or more light source input ports **1852**, **1853** and one or more detector output ports **1854**, **1855**. Although six input and output ports are illustrated, any number of ports may be used.

Similar to the clamp design described above, the light source inputs **1852**, **1853** may comprise one or more light sources directly, or they may have light guided to them from an external light source. Also, the light source inputs **1852**, **1853** may comprise lens systems to collimate or focus the light across the teeth. The detector outputs **1854**, **1855** may comprise one or more detectors directly, or they may have one or more light guides to transport the signals to an external detector element. The light source inputs **1852**, **1853** may be coupled electrically or optically through **1856** to a light input **1857**. For example, if the light source is external in **1857**, then the one or more coupling elements **1856** may be one or more light guides, such as a fiber optic. Alternately, if the light sources are contained in **1852**, **1853**, then the coupling element **1856** may be one or more electrical wires connecting to a power supply in **1857**. Similarly, the detector outputs **1854**, **1855** may be coupled to a detector output unit **1859** with one or more coupling elements **1858**, which may be one or more electrical wires or one or more light guides, such as a fiber optic. This is just one example of a mouth guard design covering a plurality of teeth, but other embodiments may also be used and are intended to be covered by this disclosure. For instance, the position of the light source inputs and detector output ports could be exchanged, or some mixture of locations of light source inputs and detector output ports could be used.

Also, if reflectance from the teeth is to be measured, then the light sources and detectors may be on the same side of the tooth. Moreover, it may be advantageous to pulse the light source with a particular pulse width and pulse repetition rate, and then the detection system can measure the

pulsed light returned from or transmitted through the tooth. Using a lock-in type technique (e.g., detecting at the same frequency as the pulsed light source and also possibly phase locked to the same signal), the detection system may be able to reject background or spurious signals and increase the signal-to-noise ratio of the measurement.

Other elements may be added to the human interface designs of FIG. **18** and are also intended to be covered by this disclosure. For instance, in one embodiment it may be desirable to have replaceable inserts that may be disposable. Particularly in a doctor's office or hospital setting, the same instrument may be used with a plurality of patients. Rather than disinfecting the human interface after each use, it may be preferable to have disposable inserts that can be thrown away after each use. In one embodiment, a thin plastic coating material may enclose the clamp design of FIG. **18**A or mouth guard design of FIG. **18**B. The coating material may be inserted before each use, and then after the measurement is exercised the coating material may be peeled off and replaced. Such a design may save the physician or user considerable time, while at the same time provide the business venture with a recurring cost revenue source. Any coating material or other disposable device may be constructed of a material having suitable optical properties that may be considered during processing of the signals used to detect any anomalies in the teeth.

Light Sources for Near Infrared

In general, the near-infrared (NIR) region of the electromagnetic spectrum covers between approximately 0.7 microns (700 nm) to about 2.5 microns (2500 nm). However, it may also be advantageous to use just the short-wave infrared between approximately 1.4 microns (1400 nm) and about 2.5 microns (2500 nm). One reason for preferring the SWIR over the entire NIR may be to operate in the so-called "eye-safe" window, which corresponds to wavelengths longer than about 1400 nm. While the SWIR is used for illustrative purposes, it should be clear that the discussion that follows could also apply to using the NIR wavelength range, or other wavelength bands. There are a number of light sources that may be used in the near infrared. To be more specific, the discussion below will consider light sources operating in the so-called short wave infrared (SWIR), which may cover the wavelength range of approximately 1400 nm to 2500 nm. Other wavelength ranges may also be used for the applications described in this disclosure, so the discussion below is merely provided for exemplary types of light sources. The SWIR wavelength range may be valuable for a number of reasons. First, the SWIR corresponds to a transmission window through water and the atmosphere. For example, **302** in FIG. **3**A and **1602** in FIG. **16**A illustrate the water transmission windows. Also, through the atmosphere, wavelengths in the SWIR have similar transmission windows due to water vapor in the atmosphere. Second, the so-called "eye-safe" wavelengths are wavelengths longer than approximately 1400 nm. Third, the SWIR covers the wavelength range for nonlinear combinations of stretching and bending modes as well as the first overtone of C—H stretching modes. Thus, for example, glucose and ketones among other substances may have unique signatures in the SWIR. Moreover, many solids have distinct spectral signatures in the SWIR, so particular solids may be identified using stand-off detection or remote sensing. For instance, many explosives have unique signatures in the SWIR.

Different light sources may be selected for the SWIR based on the needs of the application. Some of the features for selecting a particular light source include power or intensity, wavelength range or bandwidth, spatial or temporal coherence, spatial beam quality for focusing or transmission over long distance, and pulse width or pulse repetition rate. Depending on the application, lamps, light emitting diodes (LEDs), laser diodes (LD's), tunable LD's, super-luminescent laser diodes (SLDs), fiber lasers or super-continuum sources (SC) may be advantageously used. Also, different fibers may be used for transporting the light, such as fused silica fibers, plastic fibers, mid-infrared fibers (e.g., tellurite, chalcogenides, fluorides, ZBLAN, etc), or a hybrid of these fibers.

Lamps may be used if low power or intensity of light is required in the SWIR, and if an incoherent beam is suitable. In one embodiment, in the SWIR an incandescent lamp that can be used is based on tungsten and halogen, which have an emission wavelength between approximately 500 nm to 2500 nm. For low intensity applications, it may also be possible to use thermal sources, where the SWIR radiation is based on the black body radiation from the hot object. Although the thermal and lamp based sources are broadband and have low intensity fluctuations, it may be difficult to achieve a high signal-to-noise ratio in a non-invasive blood constituent measurement due to the low power levels. Also, the lamp based sources tend to be energy inefficient.

In another embodiment, LED's can be used that have a higher power level in the SWIR wavelength range. LED's also produce an incoherent beam, but the power level can be higher than a lamp and with higher energy efficiency. Also, the LED output may more easily be modulated, and the LED provides the option of continuous wave or pulsed mode of operation. LED's are solid state components that emit a wavelength band that is of moderate width, typically between about 20 nm to 40 nm. There are also so-called super-luminescent LEDs that may even emit over a much wider wavelength range. In another embodiment, a wide band light source may be constructed by combining different LEDs that emit in different wavelength bands, some of which could preferably overlap in spectrum. One advantage of LEDs as well as other solid state components is the compact size that they may be packaged into.

In yet another embodiment, various types of laser diodes may be used in the SWIR wavelength range. Just as LEDs may be higher in power but narrower in wavelength emission than lamps and thermal sources, the LDs may be yet higher in power but yet narrower in wavelength emission than LEDs. Different kinds of LDs may be used, including Fabry-Perot LDs, distributed feedback (DFB) LDs, distributed Bragg reflector (DBR) LDs. Since the LDs have relatively narrow wavelength range (typically under 10 nm), in one embodiment a plurality of LDs may be used that are at different wavelengths in the SWIR. For example, in a preferred embodiment for non-invasive glucose monitoring, it may be advantageous to use LDs having emission spectra near some or all of the glucose spectral peaks (e.g., near 1587 nm, 1750 nm, 2120 nm, 2270 nm, and 2320 nm). The various LDs may be spatially multiplexed, polarization multiplexed, wavelength multiplexed, or a combination of these multiplexing methods. Also, the LDs may be fiber pig-tailed or have one or more lenses on the output to collimate or focus the light Another advantage of LDs is that they may be packaged compactly and may have a spatially coherent beam output. Moreover, tunable LDs that can tune over a range of wavelengths are also available. The tuning may be done by varying the temperature, or electrical current may be used in particular structures, such as distributed Bragg reflector LDs. In another embodiment, external

cavity LDs may be used that have a tuning element, such as a fiber grating or a bulk grating, in the external cavity.

In another embodiment, super-luminescent laser diodes may provide higher power as well as broad bandwidth. An SLD is typically an edge emitting semiconductor light source based on super-luminescence (e.g., this could be amplified spontaneous emission). SLDs combine the higher power and brightness of LDs with the low coherence of conventional LEDs, and the emission band for SLD's may be 5 to 100 nm wide, preferably in the 60 to 100 nm range. Although currently SLDs are commercially available in the wavelength range of approximately 400 nm to 1700 nm, SLDs could and may in the future be made to cover a broader region of the SWIR.

In yet another embodiment, high power LDs for either direct excitation or to pump fiber lasers and SC light sources may be constructed using one or more laser diode bar stacks. As an example, FIG. **19** shows an example of the block diagram **1900** or building blocks for constructing the high power LDs. In this embodiment, one or more diode bar stacks **1901** may be used, where the diode bar stack may be an array of several single emitter LDs. Since the fast axis (e.g., vertical direction) may be nearly diffraction limited while the slow-axis (e.g., horizontal axis) may be far from diffraction limited, different collimators **1902** may be used for the two axes.

Then, the brightness may be increased by spatially combining the beams from multiple stacks **1903**, The combiner may include spatial interleaving, it may include wavelength multiplexing, or it may involve a combination of the two. Different spatial interleaving schemes may be used, such as using an array of prisms or mirrors with spacers to bend one array of beams into the beam path of the other. In another embodiment, segmented mirrors with alternate high-reflection and anti-reflection coatings may be used. Moreover, the brightness may be increased by polarization beam combining **1904** the two orthogonal polarizations, such as by using a polarization beam splitter. In one embodiment, the output may then be focused or coupled into a large diameter core fiber. As an example, typical dimensions for the large diameter core fiber range from approximately 100 microns in diameter to 400 microns or more. Alternatively or in addition, a custom beam shaping module **1905** may be used, depending on the particular application. For example, the output of the high power LD may be used directly **1906**, or it may be fiber coupled **1907** to combine, integrate, or transport the high power LD energy. These high power LDs may grow in importance because the LD powers can rapidly scale up. For example, instead of the power being limited by the power available from a single emitter, the power may increase in multiples depending on the number of diodes multiplexed and the size of the large diameter fiber. Although FIG. **19** is shown as one embodiment, some or all of the elements may be used in a high power LD, or additional elements may also be used.

SWIR Super-Continuum Lasers

Each of the light sources described above have particular strengths, but they also may have limitations. For example, there is typically a trade-off between wavelength range and power output. Also, sources such as lamps, thermal sources, and LEDs produce incoherent beams that may be difficult to focus to a small area and may have difficulty propagating for long distances. An alternative source that may overcome some of these limitations is an SC light source. Some of the advantages of the SC source may include high power and intensity, wide bandwidth, spatially coherent beam that can propagate nearly transform limited over long distances, and easy compatibility with fiber delivery.

Supercontinuum lasers may combine the broadband attributes of lamps with the spatial coherence and high brightness of lasers. By exploiting a modulational instability initiated supercontinuum (SC) mechanism, an all-fiber-integrated SC laser with no moving parts may be built using commercial-off-the-shelf (COTS) components. Moreover, the fiber laser architecture may be a platform where SC in the visible, near-infrared/SWIR, or mid-JR can be generated by appropriate selection of the amplifier technology and the SC generation fiber. But until now, SC lasers were used primarily in laboratory settings since typically large, table-top, mode-locked lasers were used to pump nonlinear media such as optical fibers to generate SC light. However, those large pump lasers may now be replaced with diode lasers and fiber amplifiers that gained maturity in the telecommunications industry.

In one embodiment, an all-fiber-integrated, high-powered SC light source **2000** may be elegant for its simplicity (FIG. **20**). The light may be first generated from a seed laser diode **2001**. For example, the seed LD **2001** may be a distributed feedback laser diode with a wavelength near 1542 or 1550 nm, with approximately 0.5-2.0 ns pulsed output, and with a pulse repetition rate between a kilohertz to about 100 MHz or more. The output from the seed laser diode may then be amplified in a multiple-stage fiber amplifier **2002** comprising one or more gain fiber segments. In one embodiment, the first stage pre-amplifier **2003** may be designed for optimal noise performance. For example, the pre-amplifier **2003** may be a standard erbium-doped fiber amplifier or an erbium/ytterbium doped cladding pumped fiber amplifier. Between amplifier stages **2003** and **2006**, it may be advantageous to use band-pass filters **2004** to block amplified spontaneous emission and isolators **2005** to prevent spurious reflections. Then, the power amplifier stage **2006** may use a cladding-pumped fiber amplifier that may be optimized to minimize nonlinear distortion. The power amplifier fiber **2006** may also be an erbium-doped fiber amplifier, if only low or moderate power levels are to be generated.

The SC generation **2007** may occur in the relatively short lengths of fiber that follow the pump laser. In one exemplary embodiment, the SC fiber length may range from a few millimeters to 100 m or more. In one embodiment, the SC generation may occur in a first fiber **2008** where the modulational-instability initiated pulse break-up primarily occurs, followed by a second fiber **2009** where the SC generation and spectral broadening primarily occurs.

In one embodiment, one or two meters of standard single-mode fiber (SMF) after the power amplifier stage may be followed by several meters of SC generation fiber. For this example, in the SMF the peak power may be several kilowatts and the pump light may fall in the anomalous group-velocity dispersion regime—often called the soliton regime. For high peak powers in the dispersion regime, the nanosecond pulses may be unstable due to a phenomenon known as modulational instability, which is basically parametric amplification in which the fiber nonlinearity helps to phase match the pulses. As a consequence, the nanosecond pump pulses may be broken into many shorter pulses as the modulational instability tries to form soliton pulses from the quasi-continuous-wave background. Although the laser diode and amplification process starts with approximately nanosecond-long pulses, modulational instability in the short length of SMF fiber may form approximately 0.5 ps to several-picosecond-long pulses with high intensity. Thus, the few meters of SMF fiber may result in an output similar

to that produced by mode-locked lasers, except in a much simpler and cost-effective manner.

The short pulses created through modulational instability may then be coupled into a nonlinear fiber for SC generation. The nonlinear mechanisms leading to broadband SC may include four-wave mixing or self-phase modulation along with the optical Raman effect. Since the Raman effect is self-phase-matched and shifts light to longer wavelengths by emission of optical photons, the SC may spread to longer wavelengths very efficiently. The short-wavelength edge may arise from four-wave mixing, and often times the short wavelength edge may be limited by increasing group-velocity dispersion in the fiber. In many instances, if the particular fiber used has sufficient peak power and SC fiber length, the SC generation process may fill the long-wavelength edge up to the transmission window.

Mature fiber amplifiers for the power amplifier stage **2006** include ytterbium-doped fibers (near 1060 nm), erbium-doped fibers (near 1550 nm), erbium/ytterbium-doped fibers (near 1550 nm), or thulium-doped fibers (near 2000 nm). In various embodiments, candidates for SC fiber **2009** include fused silica fibers (for generating SC between 0.8-2.7 μm), mid-IR fibers such as fluorides, chalcogenides, or tellurites (for generating SC out to 4.5 μm or longer), photonic crystal fibers (for generating SC between 0.4 and 1.7 μm), or combinations of these fibers. Therefore, by selecting the appropriate fiber-amplifier doping for **2006** and nonlinear fiber **2009**, SC may be generated in the visible, near-IR/SWIR, or mid-IR wavelength region.

The configuration **2000** of FIG. **20** is just one particular example, and other configurations can be used and are intended to be covered by this disclosure. For example, further gain stages may be used, and different types of lossy elements or fiber taps may be used between the amplifier stages. In another embodiment, the SC generation may occur partially in the amplifier fiber and in the pig-tails from the pump combiner or other elements. In yet another embodiment, polarization maintaining fibers may be used, and a polarizer may also be used to enhance the polarization contrast between amplifier stages. Also, not discussed in detail are many accessories that may accompany this set-up, such as driver electronics, pump laser diodes, safety shut-offs, and thermal management and packaging.

One example of an SC laser that operates in the SWIR used in one embodiment is illustrated in FIG. **21**. This SWIR SC source **2100** produces an output of up to approximately SW over a spectral range of about 1.5 to 2.4 microns, and this particular laser is made out of polarization maintaining components. The seed laser **2101** is a distributed feedback (DFB) laser operating near 1542 nm producing approximately 0.5 nanosecond (ns) pulses at an about 8 MHz repetition rate. The pre-amplifier **2102** is forward pumped and uses about 2 m length of erbium/ytterbium cladding pumped fiber **2103** (often also called dual-core fiber) with an inner core diameter of 12 microns and outer core diameter of 130 microns. The pre-amplifier gain fiber **2103** is pumped using a 10 W 940 nm laser diode **2105** that is coupled in using a fiber combiner **2104**.

In this particular SW unit, the mid-stage between amplifier stages **2102** and **2106** comprises an isolator **2107**, a band-pass filter **2108**, a polarizer **2109** and a fiber tap **2110**. The power amplifier **2106** uses a 4 m length of the 12/130 micron erbium/ytterbium doped fiber **2111** that is counter-propagating pumped using one or more 30 W 940 nm laser diodes **2112** coupled in through a combiner **2113**. An approximately 1-2 meter length of the combiner pig-tail helps to initiate the SC process, and then a length of PM-1550 fiber **2115** (polarization maintaining, single-mode, fused silica fiber optimized for 1550 nm) is spliced **2114** to the combiner output.

If an output fiber of about 10 m in length is used, then the resulting output spectrum **2200** is shown in FIG. **22**. The details of the output spectrum **2200** depend on the peak power into the fiber, the fiber length, and properties of the fiber such as length and core size, as well as the zero dispersion wavelength and the dispersion properties. For example, if a shorter length of fiber is used, then the spectrum actually reaches to longer wavelengths (e.g., a 2 m length of SC fiber broadens the spectrum to ~2500 nm). Also, if extra-dry fibers are used with less O—H content, then the wavelength edge may also reach to a longer wavelength. To generate more spectrum toward the shorter wavelengths, the pump wavelength (in this case .about.1542 nm) should be close to the zero dispersion wavelength in the fiber. For example, by using a dispersion shifted fiber or so-called non-zero dispersion shifted fiber, the short wavelength edge may shift to shorter wavelengths.

Although one particular example of a 5 W SWIR-SC has been described, different components, different fibers, and different configurations may also be used consistent with this disclosure. For instance, another embodiment of the similar configuration **2100** in FIG. **21** may be used to generate high powered SC between approximately 1060 and 1800 nm. For this embodiment, the seed laser **2101** may be a 1064 nm distributed feedback (DFB) laser diode, the pre-amplifier gain fiber **2103** may be a ytterbium-doped fiber amplifier with 10/125 microns dimensions, and the pump laser **2105** may be a 10 W 915 nm laser diode. In the mid-stage, a mode field adapter may be included in addition to the isolator **2107**, band pass filter **2108**, polarizer **2109** and tap **2110**. The gain fiber **2111** in the power amplifier may be a 20 m length of ytterbium-doped fiber with 25/400 microns dimension for example. The pump **2112** for the power amplifier may be up to six pump diodes providing 30 W each near 915 nm, for example. For this much pump power, the output power in the SC may be as high as 50 W or more.

In another embodiment, it may be desirous to generate high power SWIR SC over 1.4-1.8 microns and separately 2-2.5 microns (the window between 1.8 and 2 microns may be less important due to the strong water and atmospheric absorption). For example, the top SC source of FIG. **23** can lead to bandwidths ranging from about 1400 nm to 1800 nm or broader, while the lower SC source of FIG. **23** can lead to bandwidths ranging from about 1900 nm to 2500 nm or broader. Since these wavelength ranges are shorter than about 2500 nm, the SC fiber can be based on fused silica fiber, Exemplary SC fibers include standard single-mode fiber SMF, high-nonlinearity fiber, high-NA fiber, dispersion shifted fiber, dispersion compensating fiber, and photonic crystal fibers. Non-fused-silica fibers can also be used for SC generation, including chalcogenides, fluorides, ZBLAN, tellurites, and germanium oxide fibers.

In one embodiment, the top of FIG. **23** illustrates a block diagram for an SC source **2300** capable of generating light between approximately 1400 and 1800 nm or broader. As an example, a pump fiber laser similar to FIG. **21** can be used as the input to a SC fiber **2309**. The seed laser diode **2301** can comprise a DFB laser that generates, for example, several milliwatts of power around 1542 or 1553 nm. The fiber pre-amplifier **2302** can comprise an erbium-doped fiber amplifier or an erbium/ytterbium doped double clad fiber. In this example a mid-stage amplifier **2303** can be used, which can comprise an erbium/ytterbium doped double-clad fiber.

A bandpass filter **2305** and isolator **2306** may be used between the pre-amplifier **2302** and mid-stage amplifier **2303**. The power amplifier stage **2304** can comprise a larger core size erbium/ytterbium doped double-clad fiber, and another bandpass filter **2307** and isolator **2308** can be used before the power amplifier **2304**. The output of the power amplifier can be coupled to the SC fiber **2309** to generate the SC output **2310**. This is just one exemplary configuration for an SC source, and other configurations or elements may be used consistent with this disclosure.

In yet another embodiment, the bottom of FIG. **23** illustrates a block diagram for an SC source **2350** capable of generating light between approximately 1900 and 2500 nm or broader. As an example, the seed laser diode **2351** can comprise a DFB or DBR laser that generates, for example, several milliwatts of power around 1542 or 1553 nm. The fiber pre-amplifier **2352** can comprise an erbium-doped fiber amplifier or an erbium/ytterbium doped double-clad fiber. In this example a mid-stage amplifier **2353** can be used, which can comprise an erbium/ytterbium doped double-clad fiber. A bandpass filter **2355** and isolator **2356** may be used between the pre-amplifier **2352** and mid-stage amplifier **2353**. The power amplifier stage **2354** can comprise a thulium doped double-clad fiber, and another isolator **2357** can be used before the power amplifier **2354**. Note that the output of the mid-stage amplifier **2353** can be approximately near 1550 nm, while the thulium-doped fiber amplifier **2354** can amplify wavelengths longer than approximately 1900 nm and out to about 2100 nm. Therefore, for this configuration wavelength shifting may be required between **2353** and **2354**. In one embodiment, the wavelength shifting can be accomplished using a length of standard single-mode fiber **2358**, which can have a length between approximately 5 and 50 meters, for example. The output of the power amplifier **2354** can be coupled to the SC fiber **2359** to generate the SC output **2360**. This is just one exemplary configuration for an SC source, and other configurations or elements can be used consistent with this disclosure. For example, the various amplifier stages can comprise different amplifier types, such as erbium doped fibers, ytterbium doped fibers, erbium/ytterbium co-doped fibers and thulium doped fibers. One advantage of the SC lasers illustrated in FIGS. **20-23** are that they may use all-fiber components, so that the SC laser can be all-fiber, monolithically integrated with no moving parts. The all-integrated configuration can consequently be robust and reliable.

FIGS. **20-23** are examples of SC light sources that may be advantageously used for SWIR light generation in various medical diagnostic and therapeutic applications. However, many other versions of the SC light sources may also be made that are intended to also be covered by this disclosure. For example, the SC generation fiber could be pumped by a mode-locked laser, a gain-switched semiconductor laser, an optically pumped semiconductor laser, a solid state laser, other fiber lasers, or a combination of these types of lasers. Also, rather than using a fiber for SC generation, either a liquid or a gas cell might be used as the nonlinear medium in which the spectrum is to be broadened.

Even within the all-fiber versions illustrated such as in FIG. **21**, different configurations could be used consistent with the disclosure. In an alternate embodiment, it may be desirous to have a lower cost version of the SWIR SC laser of FIG. **21**. One way to lower the cost could be to use a single stage of optical amplification, rather than two stages, which may be feasible if lower output power is required or the gain fiber is optimized. For example, the pre-amplifier stage **2102** might be removed, along with at least some of the mid-stage elements. In yet another embodiment, the gain fiber could be double passed to emulate a two stage amplifier. In this example, the pre-amplifier stage **2102** might be removed, and perhaps also some of the mid-stage elements. A mirror or fiber grating reflector could be placed after the power amplifier stage **2106** that may preferentially reflect light near the wavelength of the seed laser **2101**. If the mirror or fiber grating reflector can transmit the pump light near 940 nm, then this could also be used instead of the pump combiner **2113** to bring in the pump light **2112**. The SC fiber **2115** could be placed between the seed laser **2101** and the power amplifier stage **2106** (SC is only generated after the second pass through the amplifier, since the power level may be sufficiently high at that time). In addition, an output coupler may be placed between the seed laser diode **2101** and the SC fiber, which now may be in front of the power amplifier **2106**. In a particular embodiment, the output coupler could be a power coupler or divider, a dichroic coupler (e.g., passing seed laser wavelength but outputting the SC wavelengths), or a wavelength division multiplexer coupler. This is just one further example, but a myriad of other combinations of components and architectures could also be used for SC light sources to generate SWIR light that are intended to be covered by this disclosure.

Wireless Link to the Cloud

The non-invasive blood constituent or analytes measurement device may also benefit from communicating the data output to the "cloud" (e.g., data servers and processors in the web remotely connected) via wired and/or wireless communication strategies. The non-invasive devices may be part of a series of biosensors applied to the patient, and collectively these devices form what might be called a body area network or a personal area network. The biosensors and non-invasive devices may communicate to a smart phone, tablet, personal data assistant, computer, and/or other microprocessor-based device, which may in turn wirelessly or over wire and/or fiber optically transmit some or all of the signal or processed data to the internet or cloud. The cloud or internet may in turn send the data to doctors or health care providers as well as the patients themselves. Thus, it may be possible to have a panoramic, high-definition, relatively comprehensive view of a patient that doctors can use to assess and manage disease, and that patients can use to help maintain their health and direct their own care.

In a particular embodiment **2400**, the physiological measurement device or non-invasive blood constituent measurement device **2401** may comprise a transmitter **2403** to communicate over a first communication link **2404** in the body area network or personal area network to a receiver in a smart phone, tablet cell phone, PDA, or computer **2405**. For the measurement device **2401**, it may also be advantageous to have a processor **2402** to process some of the physiological data, since with processing the amount of data to transmit may be less (hence, more energy efficient). The first communication link **2404** may operate through the use of one of many wireless technologies such as Bluetooth, Zigbee, WiFi, IrDA (infrared data association), wireless USB, or Z-wave, to name a few. Alternatively, the communication link **2404** may occur in the wireless medical band between 2360 and 2390 MHz, which the FCC allocated for medical body area network devices, or in other designated medical device or WMTS bands. These are examples of devices that can be used in the body area network and surroundings, but other devices could also be used and are included in the scope of this disclosure.

The personal device **2405** may store, process, display, and transmit some of the data from the measurement device

2401. The device **2405** may comprise a receiver, transmitter, display, voice control and speakers, and one or more control buttons or knobs and a touch screen. Examples of the device **2405** include smart phones such as the Apple iPhones® or phones operating on the Android or Microsoft systems. In one embodiment, the device **2405** may have an application, software program, or firmware to receive and process the data from the measurement device **2401**. The device **2405** may then transmit some or all of the data or the processed data over a second communication link **2406** to the internet or "cloud" **2407**. The second communication link **2406** may advantageously comprise at least one segment of a wireless transmission link, which may operate using WiFi or the cellular network. The second communication link **2406** may additionally comprise lengths of fiber optic and/or communication over copper wires or cables.

The internet or cloud **2407** may add value to the measurement device **2401** by providing services that augment the physiological data collected. In a particular embodiment, some of the functions performed by the cloud include: (a) receive at least a fraction of the data from the device **2405**; (b) buffer or store the data received; (c) process the data using software stored on the cloud; (d) store the resulting processed data; and (e) transmit some or all of the data either upon request or based on an alarm. As an example, the data or processed data may be transmitted **2408** back to the originator (e.g., patient or user), it may be transmitted **2409** to a health care provider or doctor, or it may be transmitted **2410** to other designated recipients.

The cloud **2407** may provide a number of value-add services. For example, the cloud application may store and process the physiological data for future reference or during a visit with the healthcare provider. If a patient has some sort of medical mishap or emergency, the physician can obtain the history of the physiological parameters over a specified period of time. In another embodiment, if the physiological parameters fall out of acceptable range, alarms may be delivered to the user **2408**, the healthcare provider **2409**, or other designated recipients **2410**. These are just some of the features that may be offered, but many others may be possible and are intended to be covered by this disclosure. As an example, the device **2405** may also have a GPS sensor, so the cloud **2407** may be able to provide time, data and position along with the physiological parameters. Thus, if there is a medical emergency, the cloud **2407** could provide the location of the patient to the healthcare provider **2409** or other designated recipients **2410**. Moreover, the digitized data in the cloud **2407** may help to move toward what is often called "personalized medicine." Based on the physiological parameter data history, medication or medical therapies may be prescribed that are customized to the particular patient.

Beyond the above benefits, the cloud application **2407** and application on the device **2405** may also have financial value for companies developing measurement devices **2401** such as a non-invasive blood constituent monitor. In the case of glucose monitors, the companies make the majority of their revenue on the measurement strips. However, with a non-invasive monitor, there is no need for strips, so there is less of an opportunity for recurring costs (e.g., the razor/razor blade model does not work for non-invasive devices). On the other hand, people may be willing to pay a periodic fee for the value-add services provided on the cloud **2407**. Diabetic patients, for example, would probably be willing to pay a periodic fee for monitoring their glucose levels, storing the history of the glucose levels, and having alarm warnings when the glucose level falls out of range. Similarly, patients taking ketone bodies supplement for treatment of disorders characterized by impaired glucose metabolism (e.g., Alzheimer's, Parkinson's, Huntington's or ALS) may need to monitor their ketone bodies level. These patients would also probably be willing to pay a periodic fee for the value-add services provided on the cloud **2407**. Thus, by leveraging the advances in wireless connectivity and the widespread use of handheld devices such as smart phones that can wirelessly connect to the cloud, businesses can build a recurring cost business model even using non-invasive measurement devices.

In addition, it may be advantageous to use pattern matching algorithms and other software and mathematical methods to identify the blood constituents of interest. In one embodiment, the spectrum may be correlated with a library of known spectra to determine the overlap integrals, and a threshold function may be used to quantify the concentration of different constituents. This is just one way to perform the signal processing, and many other techniques, algorithms, and software may be used and would fall within the scope of this disclosure.

Described herein are just some examples of the beneficial use of near-infrared or SWIR lasers for non-invasive monitoring of glucose, ketones, HbA1c and other blood constituents. However, many other medical procedures can use the near-infrared or SWIR light consistent with this disclosure and are intended to be covered by the disclosure.

In another specific embodiment, experiments have been performed for stand-off detection of solid targets with diffuse reflection spectroscopy using a fiber-based super-continuum source (further described herein). In particular, the diffuse reflection spectrum of solid samples such as explosives (TNT, RDX, PETN), fertilizers (ammonium nitrate, urea), and paints (automotive and military grade) have been measured at stand-off distances of 5 m. Although the measurements were done at 5 m, calculations show that the distance could be anywhere from a few meters to over 150 m. These are specific samples that have been tested, but more generally other materials (particularly comprising hydro-carbons) could also be tested and identified using similar methods. The experimental set-up **2500** for the reflection-spectroscopy-based stand-off detection system is shown in FIG. **25**, while details of the SC source **2501** are described in this disclosure in FIGS. **20**,**21**, and **23**. First, the diverging SC output is collimated to a 1 cm diameter beam using a 25 mm focal length, 90 degrees off-axis, gold coated, parabolic mirror **2502**. To reduce the effects of chromatic aberration, refractive optics are avoided in the setup. All focusing and collimation is done using metallic mirrors that have almost constant reflectivity and focal length over the entire SC output spectrum. The sample **2504** is kept at a distance of 5 m from the collimating mirror **2502**, which corresponds to a total round trip path length of 10 m before reaching the collection optics **2505**. A 12 cm diameter silver coated concave mirror **2505** with a 75 cm focal length is kept 20 cm to the side of the collimation mirror **2502**. The mirror **2505** is used to collect a fraction of the diffusely reflected light from the sample, and focus it into the input slit of a monochromator **2506**. Thus, the beam is incident normally on the sample **2504**, but detected at a reflection angle of tan-1(0.2/5) or about 2.3 degrees. Appropriate long wavelength pass filters mounted in a motorized rotating filter wheel are placed in the beam path before the input slit **2506** to avoid contribution from higher wavelength orders from, the grating (**300** grooves/mm, 2 μm blaze). The output slit width is set to 2 mm corresponding to a spectral resolution of 10.8 nm, and the light is detected by a 2 mm×2 mm liquid

nitrogen cooled (77K) indium antimonide (InSb) detector **2507**. The detected output is amplified using a trans-impedance pre-amplifier **2507** with a gain of about 105V/A and connected to a lock-in amplifier **2508** setup for high sensitivity detection. The chopper frequency is 400 Hz, and the lock-in time constant is set to 100 ms corresponding to a noise bandwidth of about 1 Hz. These are exemplary elements and parameter values, but other or different optical elements may be used consistent with this disclosure.

Process Analytical Technology (PAT)

One definition of process analytical technology, PAT, is "a system for designing, analyzing and controlling manufacturing through timely evaluations (i.e., during processing) of significant quality and performance attributes of raw and in-process materials and processes, with the goal of ensuring final product quality." Near-infrared or SWIR spectroscopy may have applications in the PAT of the pharmaceutical industry by providing, for example, quantitative analysis of multiple components in a sample and in pack quantification of drugs in formulation, as well as quality of a drug and quality control of complex excipients used in formulation. The PAT process may benefit from near-infrared or SWIR spectroscopy for some steps, such as: raw material identification, active pharmaceutical ingredient applications, drying, granulation, blend uniformity and content uniformity. Some of the strengths of near-infrared or SWIR spectroscopy include: radiation has good penetration properties, and, thus, minimal sample preparation may be required; measurement results may be obtained rapidly, and simultaneous measurements may be obtained for several parameters; non-destructive methods with little or no chemical waste; and organic chemicals that comprise most pharmaceutical products have unique spectra in the near-infrared and SWIR ranges, for example.

One goal of the manufacturing process and PAT may be the concept of a "smart" manufacturing process, which may be a system or manufacturing operation responding to analytical data generated in real-time. Such a system may also have an in-built "artificial intelligence" as decisions may be made whether to continue a manufacturing operation. For example, with respect to the raw materials, integration of the quality measurement into smart manufacturing processes could be used to improve manufacturing operations by ensuring that the correct materials of the appropriate quality are used in the manufacture. Similarly, a smart blender would be under software control and would respond to the real-time spectral data collected.

FIG. **26** illustrates what might be an eventual flow-chart **2600** of a smart manufacturing process. The manufacturing process **2601** may have as input the process feed **2602** and result in a process output **2603**. A process controller **2604** may at least partially control the manufacturing process **2601**, and the controller **2604** may receive inputs from the closed loop control (process parameters) **2605** as well as the on-line monitoring of process parameters **2606**. The feedback loops in the process could refine the manufacturing process **2601** and improve the quality of the process output **2603**. These are particular embodiments of the use of near-infrared or SWIR spectroscopy in the PAT of the pharmaceutical industry, but other variations, combinations, and methods may also be used and are intended to be covered by this disclosure.

The discussion thus far has included use of near-infrared or SWIR spectroscopy in applications such as identification of counterfeit drugs, detection of illicit drugs, and pharmaceutical process control. Although drugs and pharmaceuticals are one example, many other fields and applications may also benefit from the use of near infrared or SWIR spectroscopy, and these may also be implemented without departing from the scope of this disclosure. As just another example, near-infrared or SWIR spectroscopy may also be used as an analytic tool for food quality and safety control. Applications in food safety and quality assessment include contaminant detection, defect identification, constituent analysis, and quality evaluation. The techniques described in this disclosure are particularly valuable when non-destructive testing is desired at stand-off or remote distances.

Although the present disclosure has been described in several embodiments, a myriad of changes, variations, alterations, transformations, and modifications may be suggested to one skilled in the art, and it is intended that the present disclosure encompass such changes, variations, alterations, transformations, and modifications as falling within the spirit and scope of the appended claims.

While exemplary embodiments are described above, it is not intended that these embodiments describe all possible forms of the disclosure. Rather, the words used in the specification are words of description rather than limitation, and it is understood that various changes may be made without departing from the spirit and scope of the disclosure. Additionally, the features of various implementing embodiments may be combined to form further embodiments of the disclosure. While various embodiments may have been described as providing advantages or being preferred over other embodiments with respect to one or more desired characteristics, as one skilled in the art is aware, one or more characteristics may be compromised to achieve desired system attributes, which depend on the specific application and implementation. These attributes include, but are not limited to: cost, strength, durability, life cycle cost, marketability, appearance, packaging, size, serviceability, weight, manufacturability, ease of assembly, etc. The embodiments described herein that are described as less desirable than other embodiments or prior art implementations with respect to one or more characteristics are not outside the scope of the disclosure and may be desirable for particular applications.

What is claimed is:

1. A system for measuring one or more physiological parameters and for use with a smart phone or tablet, the system comprising:

a wearable device adapted to be placed on a wrist or an ear of a user, including a light source comprising a plurality of semiconductor sources that are light emitting diodes, each of the light emitting diodes configured to generate an output optical light having one or more optical wavelengths;

the wearable device comprising one or more lenses configured to receive a portion of at least one of the output optical lights and to direct a lens output light to tissue;

the wearable device further comprising a detection system configured to receive at least a portion of the lens output light reflected from the tissue and to generate an output signal having a signal-to-noise ratio, wherein the detection system is configured to be synchronized to the light source;

wherein the detection system comprises a plurality of spatially separated detectors, and wherein at least one analog to digital converter is coupled to at least one of the spatially separated detectors;

wherein a detector output from the at least one of the plurality of spatially separated detectors is coupled to an amplifier having a gain configured to improve detection sensitivity;

the smart phone or tablet comprising a wireless receiver, a wireless transmitter, a display, a speaker, a voice input module, one or more buttons or knobs, a microprocessor and a touch screen, the smart phone or tablet configured to receive and process at least a portion of the output signal, wherein the smart phone or tablet is configured to store and display the processed output signal, and wherein at least a portion of the processed output signal is configured to be transmitted over a wireless transmission link;

a cloud configured to receive over the wireless transmission link an output status comprising the at least a portion of the processed output signal, to process the received output status to generate processed data, and to store the processed data;

wherein the output signal is indicative of one or more of the physiological parameters, and the cloud is configured to store a history of at least a portion of the one or more physiological parameters over a specified period of time;

the wearable device configured to increase the signal-to-noise ratio by increasing light intensity of at least one of the plurality of semiconductor sources from an initial light intensity and by increasing a pulse rate of at least one of the plurality of semiconductor sources from an initial pulse rate; and

the detection system further configured to:

generate a first signal responsive to light received while the light emitting diodes are off,

generate a second signal responsive to light received while at least one of the light emitting diodes is on, and

increase the signal-to-noise ratio by comparing the first signal and the second signal.

2. The system of claim **1**, wherein the wearable device is configured to use artificial intelligence in making decisions associated with at least a portion of the output signal.

3. The system of claim **2**, wherein the wearable device is at least in part configured to identify an object, and to compare a property of at least some of the output signal to a threshold.

4. The system of claim **3**, wherein the wearable device is configured to perform pattern identification or classification based on at least a part of the output signal.

5. The system of claim **4**, wherein at least one of the spatially separated detectors is located at a first distance from at least one of the light emitting diodes and at least another of the spatially separated detectors is located at a second distance from the at least one of the light emitting diodes, and the at least one of the spatially separated detectors is configured to generate a third signal responsive to light from the at least one light emitting diode and the at least another of the spatially separated detectors is configured to generate a fourth signal responsive to the light from the at least one of the light emitting diodes; and

wherein at least one of the spatially separated detectors is located at a third distance from a first one of the light emitting diodes and at a fourth distance from a second one of the light emitting diodes, and is configured to generate a fifth signal responsive to light from the first light emitting diode and a sixth signal responsive to light from the second light emitting diode, and wherein the first distance is different from the second distance, and the third distance is different from the fourth distance.

6. The system of claim **5**, wherein the wearable device further comprises a reflective surface positioned to reflect at least a portion of the lens output light reflected from the tissue.

7. A system for measuring one or more physiological parameters and for use with a smart phone or tablet, the system comprising:

a wearable device adapted to be placed on a wrist or an ear of a user, and including a light source comprising a plurality of semiconductor sources, each of the semiconductor sources configured to generate an output light having one or more optical wavelengths;

the wearable device comprising one or more lenses configured to receive a portion of at least one of the output lights and to deliver a lens output light to tissue;

the wearable device further comprising a detection system configured to receive at least a portion of the lens output light reflected from the tissue and to generate an output signal having a signal-to-noise ratio, wherein the detection system is configured to be synchronized to the light source;

wherein the detection system comprises a plurality of spatially separated detectors, and wherein at least one analog to digital converter is coupled to at least one of the spatially separated detectors;

the smart phone or tablet comprising a wireless receiver, a wireless transmitter, a display, a speaker, a voice input module, one or more buttons or knobs, a microprocessor and a touch screen, the smart phone or tablet configured to receive and process at least a portion of the output signal, wherein the smart phone or tablet is configured to store and display the processed output signal, and wherein at least a portion of the processed output signal is configured to be transmitted over a wireless transmission link;

a cloud configured to receive over the wireless transmission link an output status comprising the at least a portion of the processed output signal, to process the received output status to generate processed data, and to store the processed data;

wherein the output signal is indicative of one or more of the physiological parameters;

the wearable device configured to increase the signal-to-noise ratio by increasing light intensity of at least one of the semiconductor sources from an initial light intensity and by increasing a pulse rate of at least one of the semiconductor sources from an initial pulse rate; and

the detection system further configured to:

generate a first signal responsive to light received while the semiconductor sources are off,

generate a second signal responsive to light received while at least one of the semiconductor sources is on, and

increase the signal-to-noise ratio by comparing the first signal and the second signal.

8. The system of claim **7**, wherein the wearable device is at least in part configured to identify an object, and a property of at least some of the output signal is compared by at least one of the wearable device, the smart phone or tablet to a threshold.

9. The system of claim **8**, wherein a detector output from at least one of the plurality of spatially separated detectors is coupled to an amplifier having a gain configured to improve detection sensitivity.

10. The system of claim **9**, wherein the wearable device is configured to use artificial intelligence to process at least a portion of the output signal.

11. The system of claim **10**, wherein the artificial intelligence comprises pattern identification or classification.

12. The system of claim **10**, wherein the wearable device is configured to perform pattern identification or classification based on at least a part of the output signal.

13. The system of claim **12**, wherein at least one of the spatially separated detectors is located at a first distance from at least one of the light emitting diodes and at least another of the spatially separated detectors is located at a second distance from the at least one of the light emitting diodes, and the at least one of the spatially separated detectors is configured to generate a third signal responsive to light from the at least one light emitting diode and the at least another of the spatially separated detectors is configured to generate a fourth signal responsive to the light from the at least one of the light emitting diodes; and

wherein at least one of the spatially separated detectors is located at a third distance from a first one of the light emitting diodes and at a fourth distance from a second one of the light emitting diodes, and is configured to generate a fifth signal responsive to light from the first light emitting diode and a sixth signal responsive to light from the second light emitting diode, and wherein the first distance is different from the second distance, and the third distance is different from the fourth distance.

14. The system of claim **13**, wherein the wearable device further comprises a reflective surface positioned to reflect at least a portion of the lens output light reflected from the tissue.

15. A system for measuring one or more physiological parameters and for use with a smart phone or tablet, the system comprising:

a wearable device adapted to be placed on a wrist or an ear of a user, including a light source comprising a plurality of semiconductor sources that are light emitting diodes, each of the light emitting diodes configured to generate an output optical light having one or more optical wavelengths;

the wearable device comprising one or more lenses configured to receive a portion of at least some of the output optical light and to deliver a lens output light to tissue;

the wearable device further comprising a detection system configured to receive at least a portion of the lens output light reflected from the tissue and to generate an output signal having a signal-to-noise ratio, wherein the detection system is configured to be synchronized to the light source;

wherein the detection system comprises a plurality of spatially separated detectors, and wherein at least one analog to digital converter is coupled to at least one of the spatially separated detectors;

the smart phone or tablet comprising a wireless receiver, a wireless transmitter, a display, a microphone, a speaker, one or more buttons or knobs, a microprocessor and a touch screen, the smart phone or tablet configured to receive and process at least a portion of the output signal, wherein the smart phone or tablet is configured to store and display the processed output signal, and wherein at least a portion of the processed output signal is configured to be transmitted over a wireless transmission link;

a cloud configured to receive over the wireless transmission link an output status comprising the at least a portion of the processed output signal, to process the received output status to generate processed data, and to store the processed data;

wherein the output signal is indicative of one or more of the physiological parameters;

the wearable device configured to increase the signal-to-noise ratio by increasing light intensity of at least one of the plurality of semiconductor sources from an initial light intensity; and

the detection system further configured to:

generate a first signal responsive to light received while the light emitting diodes are off,

generate a second signal responsive to light received while at least one of the light emitting diodes is on, and

increase the signal-to-noise ratio by comparing the first signal and the second signal.

16. The system of claim **15**, wherein the wearable device is at least in part configured to detect an object, and a property of at least some of the output signal is compared to a threshold.

17. The system of claim **15**, wherein a detector output from at least one of the plurality of spatially separated detectors is coupled to an amplifier having a gain configured to be adjusted to improve detection sensitivity.

18. The system of claim **15**, wherein the wearable device is configured to use artificial intelligence in making decisions associated with at least a portion of the output signal.

19. The system of claim **18** wherein the artificial intelligence comprises a pattern matching algorithm.

20. The system of claim **18** wherein the artificial intelligence comprises spectral fingerprinting.

21. The system of claim **15**, wherein the wearable device is configured to perform pattern identification or classification based on at least a part of the output signal.

22. The system of claim **21**, wherein the pattern identification or classification comprises a pattern matching algorithm or spectral fingerprinting.

23. The system of claim **15**, wherein the wearable device further comprises a reflective surface positioned to reflect at least a portion of light reflected from the tissue.

* * * * *